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Start by doing what is necessary, then what is possible, and suddenly you are doing 
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 St. Francis Of Assisi 
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ABSTRACT 
Ovarian cancer is the 5th most common malignancy in European women, but it 
occupies 1st place in the mortality statistics for gynecological malignancies. In 
Finland, approximately 500 women are diagnosed yearly, and over 200 women die 
of the disease each year. There is a need for research in this field to better understand 
the pathogenesis of the disease, as well as to develop treatments. 
In this dissertation, the early pathogenesis of epithelial ovarian cancer (EOC) was 
investigated by comparing the genome-wide gene expression levels in BRCA1/2 -
mutation-positive risk-reducing salpingo-oophorectomy (RRSO) samples to those in 
healthy controls. The study revealed differentially expressed genes by microarray 
analysis, from which selected genes were validated by quantitative real time 
polymerase chain reaction (qRT-PCR), demonstrating comparable expression 
patterns between BRCA1/2-mutation-positive RRSO and high-grade serous ovarian 
cancer (HGSC) samples.  
In addition, in light of recent vivid research in the field of targeted therapy, 
specifically that of Poly(ADP)Ribose Polymerase (PARP) inhibitors in EOC, PARP 
expression was investigated. A PARP pharmacodynamic assay revealed an 
association between high PARP activity and platinum sensitivity and longer 
progression-free survival (PFS), which is a novel finding. Furthermore, neoadjuvant 
chemotherapy (NACT) seemed to be associated with low PARP activity. PARP 
immunohistochemistry (IHC) staining and enzyme-linked immunosorbent assay 
(ELISA) pharmacodynamic assay PARP activity measurements were not associated, 
and the PARP pharmacodynamic assay may reflect more biologically significant 
PARP relative to PARP IHC.  
Third, exploring chemoresistance in EOC was undertaken, yielding a novel result 
showing the association of differential expression of ROR2 and GREB1 with 
treatment response in HGSC. In detail, the Wnt5a/ROR2 pathway was found to be 
potentially actionable in the possible modulation of chemoresistance in EOC. A 
combination of ROR antagonists and chemotherapeutic agents may be an 
investigation-worthy option in the future, as silencing ROR1 and ROR2 restores the 
chemosensitivity of carboplatin-resistant ovarian cancer cells. 
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TIIVISTELMÄ 
Munasarjasyöpä on viidenneksi yleisin gynekologinen syöpä eurooppalaisessa 
väestössä, mutta gynekologisten syöpäkuolemien tilastoissa se on ensimmäisellä 
paikalla. Suomessa noin 500 naista vuodessa saa munasarjasyöpädiagnoosin, siihen 
liittyviä kuolemia on kuitenkin yli 200. Tämän vuoksi munasarjasyövän varhaisen 
patogeneesin selvittely ja hoitoihin liittyvä tutkimus on tärkeässä roolissa. 
Väitöstutkimuksessa selvitettiin epiteliaalisen munasarjasyövän varhaista 
kehitystä vertailemalla BRCA 1/2 -mutaationkantajien morfologisesti normaaleja 
munasarja- ja munatorvinäytteitä hyvänlaatuisen kohtuperäisen syyn vuoksi 
poistettuihin munasarja- ja munatorvinäytteisiin mikrosirumenetelmällä. Tässä 
tutkimuksessa havaitut BRCA1/2-mutaationäytteissä merkitsevästi erilailla 
ilmentyneet geenit saattavat olla merkityksellisiä munasarjasyövän varhaisessa 
kehityksessä. 
Lisäksi tutkittiin PARP:n aktiivisuutta ELISA-menetelmällä ja sen ilmentymistä 
immunohistokemiallisella (IHC) menetelmällä high-grade munasarjasyöpäpotilaiden 
kohortissa. PARP-estäjät ovat ns. uusi räätälöidyn hoidon lääkeryhmä. Tässä 
tutkimuksessa todettiin, että PARP-aktiivisuus on yhteydessä platinaherkkyyteen ja 
pidempään tautivapaaseen aikaan. Lisäksi neoadjuvanttihoidon todettiin olevan 
yhteydessä matalaan PARP-aktiivisuuteen. ELISA-menetelmällä mitattu PARP-
aktiivisuus ja IHC-värjäyksillä tutkittu PARP ilmentymä eivät korreloineet 
keskenään; PARP on mahdollisesti paremmin osoitettavissa tuorenäytteistä 
aktiivisuustutkimuksena verrattuna parafiiniblokeista väräyksillä saatuihin tuloksiin. 
Väitöstutkimuksessa tarkasteltiin lisäksi myös platinavasteeseen liittyviä tekijöitä 
samassa high-grade munasarjasyöpäpotilaskohortissa. Tutkimuksessa havaittiin 
yhteys ROR2- ja GREB1- ilmentymän ja platinaherkkyyden välillä. Lisäksi 
Wnt5a/ROR2 signalointireitti vaikutti mahdolliselta muokkauksen kohteelta 
lääkeresistenssin modulaatiossa. Aiempien tutkimusten perusteella ROR1 ja ROR2 
reseptorien hiljentäminen platinaresistenteillä munasarjasyöpäsoluilla palauttaa 
kemosensitiivisyyden näissä soluissa ja näin ollen tulevaisuudessa ROR-antagonistin 
ja solusalpaajan yhdistelmä voisi olla lupaava vaihtoehto jatkotutkimuksia ajatellen.  
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1 INTRODUCTION 
Ovarian cancer is an aggressive disease that is often diagnosed at a late stage and has 
a poor prognosis. The standard treatment consists of surgery and chemotherapy; 
many patients, however, relapse after completing primary treatment and eventually 
become resistant to chemotherapy (Rojas et al., 2016). 
The early pathogenesis of ovarian cancer has been extensively investigated using 
modern molecular biology techniques. These efforts have produced an 
understanding that is now widely accepted, namely, that high-grade serous ovarian 
cancer (HGSC) in fact arises from the Fallopian tube (Kurman and Shih, 2010). The 
Fallopian tube theory has benefitted greatly from data extracted from BRCA 
mutation carriers’ prophylactic salpingo-oophorectomy samples. Trailblazing work 
investigating the origin of HGSC has demonstrated that serous tubal intraepithelial 
carcinoma (STIC) is the precursor for HGSC (Prat, 2012). To emphasize, HGSC is 
currently viewed as an entity of three related diseases – high-grade epithelial 
Fallopian tube cancer, high-grade epithelial ovarian cancer and primary peritoneal 
cancer (Singh et al., 2017).  
The challenge in ovarian cancer remains to be late diagnosis leading to poor 
prognosis. In this regard, molecular subtyping and detailed profiling might aid in 
earlier and more accurate diagnosis and perhaps screening. The work exploring 
Fallopian tubes and prophylactic salpingectomies has already provided an 
opportunity for prevention in high-risk patients. 
Currently, the standard treatment for ovarian cancer entails surgery combined 
with 6 cycles of platinum-based chemotherapy in further combination with anti-
angiogenetic therapy in high-risk patients (Reuss et al., 2019). Ovarian cancer (OC) 
is chemoresponsive, but not a chemocurable disease (Bast, 2011). Despite initially 
responding to treatment, most women diagnosed with HGSC develop recurrent 
disease and chemotherapy resistance (Pignata et al., 2017). The understanding of 
chemoresistance mechanisms has not yielded clinically usable alternatives, and EOC 
with platinum resistance is associated with poor overall survival (Ethier et al., 2017).  
New treatment modalities such as targeted treatments are made possible by the 
exploration of underlying tumor biology. In 2000, researchers Hanahan and 
 22 
Weinberg put forward a groundbreaking theory named hallmarks of cancer, in which 
the normal capacities and molecular mechanisms of a cell are capitalized upon and 
modified by cancer cells in order to acquire survival properties and other modalities 
to enhance spread and avoid normal protective mechanisms (Hanahan and 
Weinberg, 2000). These in turn can be exploited by means of targeted therapies 
(Hanahan and Weinberg, 2011). In the setting of ovarian cancer, understanding of 
the BRCA mutation and its effect on DNA repair, specifically the lack of a repair 
mechanism called homologous recombination (HR), has made possible the 
development of targeted inhibition of PARP.  
PARP inhibitors have changed the therapy landscape for ovarian cancer, and 
most recent research demonstrates marked benefits in terms of primary treatment 
of BRCA-mutated ovarian cancer (Suh et al., 2018; Moore et al., 2018). However, 
more research is needed with respect to PARP inhibition and its possible predictive 
markers in order to identify all OC patients benefiting from PARP inhibitors (Mirza 
and Matulonis, 2017). The use of PARP inhibitors is now being expanded beyond 
tumors with HR deficiency to HR-competent tumors. These include tumors in 
which HR has been impaired synthetically by the use of other agents administered 
in combination with PARP inhibitors (del Rivero and Kohn, 2017).  
The aim of this study was to explore the early pathogenesis of ovarian cancer and 
aspects of PARP inhibition and chemoresistance in clinical samples of HGSC 
patients and healthy BRCA mutation carriers (with no ovarian or breast malignancy). 
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2 REVIEW OF THE LITERATURE 
2.1 Ovarian cancer 
2.1.1 Epidemiology of ovarian cancer 
Most ovarian cancers are of epithelial origin (90%), and only 10% are nonepithelial, 
originating from sex cord cells or from germinal cells (Webb and Jordan, 2017). 
Seventy percent of epithelial ovarian neoplasms are HGSC (Prat, 2012). The focus 
of this dissertation is primarily on HGSC.  
Ovarian cancer is the deadliest gynecological malignancy among women 
worldwide, being the 7th leading cancer diagnosis and 8th leading cause of cancer 
mortality (Siegel et al., 2015). The incidence varies in different regions, with 
incidence being highest in Europe and North America and lowest in Thailand 
(Coburn et al., 2017).  The prevalence of different subtypes, such as serous and 
endometrioid also varies, serous OC being more prevalent in Europe, and 
endometrioid OC in Asia. The incidence of OC is highest in Caucasian women, 
being highest in Northern Europe and the incidence rates have remained quite stable 
during the last 40 years (Coburn et al., 2017). In Finland, approximately 450 women 
are diagnosed yearly, but more than 250 women die of the disease each year 
(https://cancerregistry.fi). 
The typical age at which diagnosis is received is 55 to 64, although the disease 
affects women in all age groups (Clarke-Pearson, 2009). The average lifetime risk of 
ovarian cancer is 1.37% in the general female population (Pearce et al., 2015). 
. 
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2.1.2 Risk and protective factors of ovarian cancer 
Ovarian cancer has some generally accepted risk factors and in this chapter risk 
factors for OC are discussed, focusing also on the subtypes (especially HGSC) in 
some cases. The most prominent and well-known is the theory of lifetime number 
of ovulatory cycles associated with OC (i.e., incessant ovulation theory, in which the 
age at ovulation is an index of a woman’s ovarian cancer risk) (Fathalla, 1971). Other 
suggested mechanisms include stimulation by hormonal exposures (including 
estrogens, insulin, androgens and IGF-1 as well as endometriosis, inflammation and 
hormone replacement therapy (HRT). 
In more detail, it is well established that OC development involves pro-
angiogenic factor-regulated angiogenesis, mainly mediated by vascular endothelial 
growth factor (VEGF) (Skirnisdottir et al., 2016). Notably, estradiol has a positive 
effect on VEGF expression in EOC, probably through the activation of the ER 
receptor, which further accentuates the role of hormonal influence on the 
development of OC (Valladares et al., 2017). VEGF’s role in OC development will 
be viewed in more detail in Chapter 2.3.3.1. 
Chronic inflammation has also been suggested as a risk factor for OC (Ness and 
Cottreau, 1999; Risch and Howe, 1995), and a recent meta-analysis found that pelvic 
inflammatory disease (PID) might indeed be considered as a risk factor, although the 
analysis concluded that more prospective trials addressing the issue are needed 
(Zhou et al., 2017). In a study published in 2017, recurrent PID was found to carry 
two-fold risk for borderline ovarian tumors (Rasmussen et al., 2017). Interestingly, 
another study demonstrated higher risk of HGSC in association with PID (HR 1.47, 
95% CI 1.04-2.07) (Stewart et al., 2018). The underlying hypothesis relates OC 
development to inflammation and repair (e.g., ovulation), hypothesizing that chronic 
inflammation might either directly influence the ovarian surface or, alternatively, 
influence the premalignant lesions in the Fallopian tubes (Kisielewski et al., 2013). 
Endometriosis is another established OC risk factor, specifically of the 
endometrioid and clear cell subtype (Ruderman and Pavone, 2017). In a meta-
analysis, the prevalence of ovarian cancer (endometrioid and clear cell type) among 
endometriosis patients was 2.0-17.0% (Heidemann et al., 2014).  
In addition, both current and recent use of HRT in menopause are related to 
serous and endometrioid OC, but not mucinous or clear cell subtypes (Edmonds 
and Dewhurst, 2007). It is noteworthy, however, that HRT has been associated with 
a limited increase in overall cancer risk, and this increase in the risk of female 
reproductive organ cancers appears to be almost neutralized by a decreased risk of 
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gastrointestinal cancers; this finding has been especially evident in patients treated 
with estrogen alone (Simin et al., 2017). 
While there are no strong associations of OC with tobacco use, there is a direct 
link for tobacco use in (borderline) mucinous cancers and a limited impact on 
overall OC mortality (Praestegaard et al., 2017). In addition, height and BMI are 
associated with the risk of OC, although the risk is specifically associated with non-
HGSC, whereas prevalence of HGSC is unaffected by higher BMI (Dixon et al., 
2016; La Vecchia, 2017). In a recent meta-analysis, it was concluded that high 
consumption of total, saturated and trans-fats increases OC risk and that different 
histological subtypes have different susceptibilities to dietary fat (Qiu et al., 2016). 
Increased alcohol consumption has been associated with OC risk (Yan-Hong et al., 
2015; D. Wu et al., 2018); but interestingly, guideline-concordant consumption does 
not increase the risk, and it has been suggested that red wine consumption might 
even reduce the risk (Cook et al., 2016). 
To summarize, there are some lifestyle associations with the risk of OC, but the 
strongest associations are found with ovarian functions, i.e., the menstrual cycle. The 
genetic risk factors are explored in detail in a different chapter (see 2.2.3). It is 
important to emphasize that OC, and especially HGSC, is not significantly affected 
by lifestyle choices unlike some other cancers, i.e. in case of lung cancer the 
association with smoking.  
There are known protective factors that have long been associated with OC: oral 
contraceptives have been demonstrated to reduce ovarian cancer risk in several 
studies (Iversen et al., 2017; Wu et al., 2017). Additionally, the levonorgestrel-
releasing intrauterine system (LNG-IUS) has been demonstrated to reduce the risk 
of both invasive (mainly serous, but also mucinous and endometrioid subtypes) and 
borderline ovarian tumors (Soini et al., 2016). Breastfeeding has also been found to 
be inversely associated with the risk of OC (Li et al., 2014). More specifically, long-
term breastfeeding duration (more than 6 months) has demonstrated a 
stronger protective effect, as well as full-term pregnancy (Li et al., 2014). In that 
regard, full-term pregnancy has been demonstrated to be more strongly inversely 
associated with type I than type II tumors (type I: relative risk (RR) 0.47 [95% 
confidence interval (CI): 0.33-0.69]; type II, RR: 0.81 [0.61-1.06]) (Fortner et al., 
2015). Type I and II tumors and their differences are discussed in more detail in 
Chapter 2.1.4 of this dissertation. 
Importantly, there is widely recognized and well-established evidence 
demonstrated in multiple studies that sterilization prevents OC. Specifically, 
Hankinson et al. observed in 1993 that OC risk among women who had a tubal 
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ligation was 77% lower compared to that of women with no tubal procedure 
(Hankinson et al., 1993). Since then, multiple analyses with longer follow-up have 
supported these original findings (Rice et al., 2014; Birmann et al., 2016). In addition, 
it was observed in the studies referenced above (and others not mentioned here) that 
hysterectomy is a protective factor for OC.  
Seventy percent of all ovarian neoplasms are HGSC (Prat, 2012). Current 
understanding is that the origin of HGSC is in the distal Fallopian tube (Karnezis et 
al., 2017). Interestingly, in a population-based cohort study, data on women with 
previous surgery on benign indications (sterilization, salpingectomy, hysterectomy, 
and bilateral salpingo-oophorectomy [BSO], hysterectomy; n = 251,465) were 
compared with data on an unexposed population (n = 5,449,119) between 1973 and 
2009. The results indicated that among women with previous salpingectomy, there 
was a significantly lower risk for OC (HR = 0.65, 95% CI = 0.52 to 0.81) as well as 
among women with previous hysterectomy (HR = 0.79, 95% CI = 0.70 to 0.88), 
sterilization (HR = 0.72, 95% CI = 0.64 to 0.81), and hysterectomy with BSO (HR 
= 0.06, 95% CI = 0.03 to 0.12). A 50% decrease in OC risk was associated with BSO 
relative to the unilateral procedure (HR = 0.35, 95% CI = 0.17 to 0.73, and 0.71, 
95% CI = 0.56 to 0.91, respectively) (Falconer et al., 2015).  
To summarize, it has been well established that removal of the Fallopian tubes 
reduces OC risk (Falconer et al., 2015). These observations have strengthened the 
STIC theory (discussed in detail in chapter 2.4 of this dissertation) of the 
development of ovarian cancer and provide a means to prevent this deadly disease. 
An overview of the risk and protective factors associated with OC is provided in 
Table 1. 
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Table 1.  Risk and protective factors associated with ovarian cancer. 
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2.1.3 Symptoms of ovarian cancer 
Ovarian cancer is often diagnosed at a late stage because the symptoms of this 
disease are nonspecific and vague. Women may present with symptoms such as 
abdominal bloating, discomfort and pressure symptoms (nausea, colicky abdominal 
pain) (Edmonds and Dewhurst, 2007). Pelvic pressure symptoms such as frequent 
urination, pressure in the pelvic region, constipation or diarrhea may be present. At 
the late stage, symptoms can include pelvic resistance, ascites, lymphadenopathy, and 
pleural effusion (Edmonds and Dewhurst, 2007). Malignant ascites is a specific 
feature of EOC and should lead to prompt examination, regardless of the presence 
or absence of accompanying adnexal mass, since it is strongly associated with poor 
prognosis (Huang et al., 2013). 
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2.1.4 Diagnostics of ovarian cancer 
Basic investigation consists of pelvic examination, transvaginal ultrasound (TVU) 
and cancer antigen 125 (CA 125) (Skates et al., 2017). Adnexal solid or cystic masses 
with ascites prompt a suspicion for OC, especially when cysts have solid or papillary 
properties and are bilateral (Menon, 2004). If findings are suspicious for OC, the 
patient should be promptly referred to a gynecologic oncologist (Doubeni et al., 
2016).  
The tumor marker for OC, CA 125, was first discovered in the blood of patients 
with specific types of cancers or some benign conditions (Bast et al., 
1998). However, due to its limited specificity and sensitivity, CA 125 alone isn’t 
viewed as an ideal biomarker for OC (Bottoni and Scatena, 2015). Specifically, the 
sensitivity and positive predictive value have been found to be 64.29% and 53.57% 
for stage I-II cancer patients and 91.43% and 88.57% for stage III-
IV cancer patients, respectively (Zheng et al., 2018). It has been well established that 
simultaneous testing with CA 125 and TVU produces high false-positive rates (RR, 
1.01; 95% CI, 0.96-1.06), inducing unnecessary surgeries to identify one true-positive 
(Buys et al., 2011). Combined detection of CA 125 with HE4 improves the 
sensitivity and specificity of OC diagnosis and also has clinical significance that can 
later guide treatment planning in a better way compared to that with CA 125 alone 
(Zhao and Hu, 2016; Goff et al., 2017). Evidence also suggests that HE4 seems to 
better predict recurrence than CA 125 (Scaletta et al., 2017). 
Based on patient history, clinical features and tumor markers, several risk-
calculating models have been developed (Skates et al., 1995). In the 1990s, the risk 
of malignancy index (RMI) was developed and later modified. The RMI takes into 
account the patient’s age, ultrasound score, menopausal status, a clinical impression 
score and serum CA 125 level (RMI 2 = U × M × serum CA 125) (Jacobs et al., 
1990; Tingulstad et al., 1996). An RMI cut-off level of 200 had a sensitivity of 85% 
and specificity of 97% in discriminating pelvic masses in the initial study; since then, 
a similar sensitivity and specificity have been reported (Niemi et al., 2017; Yanaranop 
et al., 2017). Additional prediction algorithms have been developed in pursuit of even 
more precise preoperative investigation - ROMA is a risk of malignancy index that 
is also used in OC, and it incorporates HE4 value in addition to CA 125 (Wei et al., 
2016). It is considered an additional tool in the diagnosis of OC.  
In suspicion of OC, patient should be referred to a specialized center for 
evaluation, where more advanced preoperative diagnostics, CT, MRI, PET/CT, 
PET/MRI and ascites cytology are used according to and catering to a specific 
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clinical situation and possibilities (Javadi et al., 2016; Khiewvan et al., 2017). Cytology 
washings are especially important in the diagnostic phase, since malignant ascites is 
a prominent feature in OC. In detail, ascites arises as a plasma exudate, and its 
formation is a result of an imbalance between the efflux and influx of fluid from the 
peritoneal cavity (Nagy et al., 1993). Many factors are attributed to this, such as 
increased microvascular permeability, vascular endothelial growth factors and the 
blockade of lymphatic drainage (Milliken et al., 2002). In terms of malignant ascites 
formation, the most prominent factor is VEGF, which specifically modulates 
peritoneal permeability by downregulating adhesion proteins via tumor-
derived VEGF (Bekes et al., 2016). It has thus been hypothesized that early 
dysregulation of vascular permeability leading to ascites may be associated with 
advanced OC with aggressive tumor biology, prompting a search for VEGF-based 
biomarkers (Liang et al., 2013). Summa summarum, ascites is distinctly associated with 
malignant ovarian and peritoneal diseases, and cytological samples from ascites can 
greatly contribute to preoperative evaluation. 
The staging of ovarian cancer is surgical, and preoperatively, only efforts to 
predict the stage and thus possible prognosis are made. Definitive staging is surgical 
and is discussed in more detail in Chapter 2.2.1.  
2.1.5 Screening of ovarian cancer 
Currently, there are no clearly defined anatomical steps in early tumor progression 
that would allow for the screening of precancerous lesions, unlike cervical or 
colorectal cancer (Crum et al., 2013). However, the theory of OC arising from the 
tubal epithelium has led to attempts to screen with intrauterine probe samples and 
tubal lavage washings (Menon et al., 2014; van der Steen et al., 2017). These methods, 
however, are not currently in clinical use. In addition, there has been an effort to 
clarify the value of yearly screening in terms of reducing OC death rates. In a recent 
RCT where patients were annually screened multimodally (ultrasound, CA 125) 
versus no screening, the analysis demonstrated that death rates from OC were 
reduced by screening (p=0.021), with an overall average mortality reduction of 20% 
(Jacobs et al., 2016). The study highlighted that a rising level of CA 125 rather than 
an elevated concentration above cutoff level, is an important and sensitive marker 
for early cancer detection. This result is indeed very encouraging considering the 
high mortality rates of OC; however, as the researchers themselves conclude, further 
exploration of this subject is needed, including assessment of cost-effectiveness. 
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2.2 Histopathological classification of epithelial ovarian cancer 
Ovarian neoplasms can be divided into three major groups: benign, borderline and 
malignant. These include stromal, germ cell and epithelial tumors depending on the 
cell of origin of the neoplasm. Stromal and germ cell tumors differ histologically 
from epithelial tumors and are relatively rare (10% collectively) (Boussios et al., 
2017). 
Borderline ovarian tumors (BOT) are epithelial neoplasms. They are 
characterized by upregulated cellular proliferation without destructive stromal 
invasion (Silverberg et al., 2004). Similar to invasive carcinomas, there are six 
histologic subtypes based on the epithelial cell type, including serous and mucinous, 
endometrioid, clear cell, seromucinous, and borderline Brenner tumor (Seidman et 
al., 2004). Histologically, BOT is characterized by hierarchically branching papillae 
and pseudopapillae with paucicellular, edematous, or hyalinized fibrous stroma, 
enlined with epithelial proliferations that are architecturally complex (Hauptmann et 
al., 2017). Borderline ovarian tumors have been associated with microinvasion, 
lymph node involvement and noninvasive and invasive peritoneal implants (Seidman 
and Kurman, 2000). They are not, however, a precancerous state of HGSC (although 
they are considered a precancerous state of low-grade tumors). 
EOC is a heterogeneous disease with specific epidemiological, phenotypical and 
molecular subtypes, including high-grade serous carcinoma (HGSC), low-grade 
serous, endometrioid, mucinous and clear cell carcinoma (Prat, 2012). Serous 
carcinomas are 70% of all EOC, with HGSC accounting for 70% of all ovarian 
malignancies (Kaku et al., 2003). Endometrioid and clear cell subtypes are the next 
largest groups, and ovarian carcinosarcomas are also classified as epithelial cancers 
with sarcomatous differentiation (Dubeau, 2008). 
Serous carcinomas are characterized by solid, papillary glandular and transitional 
patterns, and thus the histological diagnosis is straightforward, helped by the typical 
morphologic features of serous carcinoma such as glands that are slit-like rather than 
smooth/round, with prominent cellular budding and bizarre nuclei (Ramalingam, 
2016). Endometrioid carcinomas are associated with squamous differentiation, 
endometriosis and adenofibromatous background (Malpica et al., 2004). Historically, 
immunohistochemistry was not used for diagnosis of either HGSC or low-grade 
serous carcinoma (LGSC) (Seidman et al., 2004). There are some overlapping 
characteristics, and on the other hand, some distinct immunophenotypic features 
exist as well (Ramalingam, 2016). Both express paired box gene 8 (PAX8), WT1, 
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estrogen receptor (ER) and progesterone receptor (PR) expression (Kaldawy et al., 
2016). 
Historically, ovarian cancer has been graded I-III, but currently, low- vs high-
grade classification is used as it represents the aggressiveness of the disease more 
effectively (Crum et al., 2013). The incidence details of different subtypes of EOC 
are listed in Table 2.  
Table 2.  Epithelial ovarian cancer subtypes. 

 %
	#$#!&$ >7C
!(#$#!&$ <C
& !&$ :C
 !%#! 87C
# 87C
# !$#!$ 9C
Currently, immunoprofiling is used in addition to standard histopathological 
diagnostics described above, especially to differentiate between HGSC and LGSC. 
The current grading system (high and low grade) in combination with 
immunoprofiling provided by IHC methods for different markers such as p53, ER 
and PR, WT1, p16 and ARID1A have significantly enhanced diagnostic accuracy 
and interobserver accuracy (Köbel et al., 2014). Due to this significant change in 
diagnostics in 2014, results of older and newer studies are challenging to compare. 
The accuracy of OC subtype documentation has improved markedly, and up to 20% 
of subtype estimates may be falsely documented in studies undertaken before 2014. 
It is particularly important to note this when interpreting results from studies using 
older datasets. 
2.3 Standard treatment of ovarian cancer 
The golden standard of epithelial ovarian cancer treatment is primary debulking 
surgery (PDS) combined with 6 cycles of platinum-based combination 
chemotherapy (Tate et al., 2017). In stages IIIB-IV, bevacizumab is added at a dose 
of 7.5 - 15 mg/kg for suboptimally debulked patients according to national 
guidelines (Gadducci et al., 2019). With cytoreductive surgery and combination 
chemotherapy being used increasingly, 5-year survival has improved from 37% in 
1974–1976 to 46% in 1999–2005 (Bast, 2011).  
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2.3.1 Surgery in the primary treatment setting 
Surgical treatment is the most important cornerstone of treatment in all stages of 
OC, aimed to ensure optimal cytoreduction and confirm the diagnosis with 
appropriate staging according to FIGO (du Bois et al., 2009). OC staging has two 
purposes: to provide standard terminology allowing a comparison of patient 
outcomes between centers and assignment of patients and their tumors to prognostic 
groups requiring specific treatments (Prat, 2015). Currently, during surgery, the 
extent of the disease is described, and tumor tissue samples are analyzed in order to 
provide the details for adequate staging. Extent of disease is considered the most 
important predictor of recurrence and survival (Maxwell and Mutch, 2017). OC 
staging is currently based on 2014 FIGO recommendations as presented in Table 3 
(Prat, 2015). 
In the surgical management of OC in the primary setting, primary debulking 
surgery (PDS) is performed. In preoperative assessment, operability and the 
possibility of radical surgery are assessed by a multidisciplinary team including an 
experienced surgeon, pathologist and radiologist. The aim is to perform radical 
surgery and remove all visible disease (R0, i.e., no residual tumor). By definition, an 
R1 result is achieved with 0-10 mm of residual tumor, and the R2 result means 10 
mm or more of residual tumor is present. In addition to removal of the cancerous 
tissue, pelvic and para-aortic lymphadenectomies (LNDs) are performed; details of 
LND are discussed below.  
In apparent stage I-II, staging is performed. An important part of PDS and 
staging is LND. It is imperative to perform LND to ensure accurate staging and thus 
make decisions regarding adjuvant therapy (Mikami, 2014). LND’s importance stems 
from the knowledge that even in a very early stage of OC development, lymphatic 
spread can already occur. Thus, in approximately 20% of cases, LND leads to 
upstaging in these early stages, as involvement of the paraaortic lymph nodes is 
present even without the involvement of the pelvic lymph nodes (Young et al., 1983; 
Burghardt et al., 1991; Shimizu, 2004). However, according to a study published in 
2017, in low-grade disease, upstaging due to lymph node involvement alone occurred 
in only 2.4% of patients, raising questions about the value of lymphadenectomy in 
those cases (Minig et al., 2017). This, however, is only thought to be the case in low-
grade and not in high-grade tumors. 
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Table 3.  2014 FIGO ovarian, Fallopian tube, and peritoneal cancer staging system and 
corresponding TNM. Copyright (2014), with permission from Elsevier (Prat, 2015). 
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In stages III-IV, PDS is also an aim. In stages IIIC-IV, assessment is made regarding 
whether the patient benefits from PDS or should undergo neoadjuvant treatment 
(NACT) in case the tumor is unresectable. For details of NACT, please see chapter 
2.3.2.2 of this dissertation. It is important to convey that if R0 or R1 is not achievable, 
the patient does not benefit from surgery in terms of survival (du Bois et al., 2009). 
The maximum diameter of the postoperative residual tumor after cytoreductive 
surgery is considered to be the strongest independent clinical prognostic factor 
(Eisenkop et al., 1998). According to a meta-analysis published in 2002, a 5.5% 
increase in survival time (median) was associated with a 10% increase in maximal 
tumor resection. In detail, patients with  25% maximal tumor resection had a 
survival time (median) of 22.7 months, and patients with more than 75% maximal 
tumor resection had a survival time of 33.9 months. Thus, survival increased 50% 
depending on surgical outcome (Bristow et al., 2002). More recently, these results 
have been re-evaluated, and it is currently believed that surgical tumor reduction to 
0 mm is the most important prognostic factor of survival (Chang et al., 2013; Tate 
et al., 2017; Cordeiro Vidal et al., 2017; du Bois et al., 2009). 
To describe radical surgery, it includes a longitudinal abdominal incision 
extending from symphysis to sternum in order to allow a detailed exploration of the 
abdomen, in which special attention needs to be paid to the domes of the diaphragm, 
the entire small and large intestine and the peritoneum (Di Saia et al., 2018). At 
minimum, the following surgical procedures are performed: BSO, total 
extraperitoneal hysterectomy, cytology washings and multiple peritoneal biopsies, 
infragastric omentectomy as far as the splenic hilum, and systemic pelvic and para-
aortic LND up to the level of the renal vessels bilaterally (Sehouli, 2014). Any 
metastatic structures are removed. In the HGSC setting, appendectomy is not 
necessary, as it is recommended for only mucinous tumors.  
The relevance of LND in stage III disease has been of great interest, since it has 
been under dispute whether or not R0 debulked patients benefit from additional 
lymphadenectomies. This is an important matter, considering additional morbidity 
and mortality that might accompany more extensive surgery. In a well-designed study 
from 2006, removal of lymph nodes in patients with residual disease near 10 mm 
was evaluated, and according to the outcome, LND for patients with complete or 
near-complete resection of abdominal disease appears to be justified (Aletti et al., 
2006). According to the prospective randomized LION study by the German 
Association Of Gynecological Oncology (AGO, Arbeitsgruppe der 
Gynäkologischer Onkologie), it appears that in patients with advanced OC for 
whom complete cytoreduction was achieved, additional systematic LND of clinically 
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negative lymph nodes did not provide additional benefit and should thus be omitted 
(Harter et al., 2019).  
Ultraradical (extensive) cytoreductive surgery in ovarian cancer treatment has 
been proposed for patients with widespread disease (Ang et al., 2011). Specifically, 
patients with upper abdominal disease affecting the diaphragm, liver, spleen and 
omentum or widespread disease affecting the bowel will need much more radical 
surgery than the standard procedure described above in order to achieve complete 
or optimal cytoreduction (Ang et al., 2011). This ultraradical procedure often 
includes bowel resection, splenectomy, liver resection or mobilization and 
diaphragmatic stripping. The range of surgical techniques demanded to be able to 
perform these procedures is broad and use of the techniques is decided depending 
on the particular involvement of different organs. Mobilization of the liver in order 
to achieve peritonectomy in the upper abdomen is especially challenging (Sehouli, 
2014).  
In the setting of ultraradical OC surgery, supportive care demands are more 
extensive (Eisenkop and Spirtos, 2001). However, even though complete 
cytoreduction is the objective of PDS, tumor load remains an independent poor 
prognostic factor reflecting a more aggressive disease (Martinez et al., 2016).  
In conclusion, it must be emphasized that surgical effort with a good outcome 
carried out skillfully is beneficial for the patient, as the 5-year survival rate of R0 
disease regardless of the stage is up to 60% (May et al., 2017; Wimberger et al., 2007).  
2.3.2 Adjuvant chemotherapy in first-line treatment 
By definition, adjuvant therapy is additional treatment given after primary treatment 
in order to prevent recurrence and may include chemotherapy, radiation therapy, 
hormone therapy, targeted therapy, or biological therapy (Hayat, 1984). If there is 
disease is left behind postsurgery, further treatment is not adjuvant by definition.  
The combination of paclitaxel and carboplatin is the standard combination of 
first-line chemotherapy for EOC stages IB-IV (Sehouli, 2014), and in stages IIIB-
IV, according to national guidelines, bevacizumab is added (Gadducci et al., 2019). 
As introduced above, the decision to administer chemotherapy is made according to 
FIGO stage, which is crucial in contemplating the choice of options. Additionally, 
grading of the tumor is integrated in the assessment. Because there is no survival 
benefit, stage I A low-grade tumors do not require chemotherapy, but postsurgery 
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combination chemotherapy is recommended for high-grade stage 1A and for all 
other stages (IB-IV) (Trimbos et al., 2003).  
Combination chemotherapy has improved the prognosis of ovarian cancer 
patients dramatically. The first-line treatment is platinum-based, a combination of 
platinum and taxane. The benefit of this approach was first established in the 1990s 
in the GOG 111 study, where patients with stage II-IV OC were randomized to 
receive paclitaxel-cisplatin vs cyclophosphamide-cisplatin, and in the paclitaxel-
cisplatin arm, the response rate was 73% compared to 60% in the cisplatin-
cyclophosphamide arm. PFS and OS were significantly longer with paclitaxel-
cisplatin: 12.9 vs 17.9 months and 37.5 vs 24.4 months, respectively (McGuire et al., 
1996). Following studies looking into combination chemotherapy, the superiority of 
one compound over others was investigated, as well as the role of topotecan, 
pegylated liposomal doxorubicin and gemcitabine combined with carboplatin. 
However, their efficacy did not differ from that of carboplatin and paclitaxel 
(Bookman et al., 2009). In comparison to platinum compounds, the superiority of 
carboplatin over cisplatin was demonstrated not in terms of treatment effect, 
because both are effective, but in terms of side effects, as carboplatin has fewer 
adverse effects (Greimel et al., 2006). In the SCOTROC trial, the effectiveness of 
docetaxel and carboplatin was demonstrated; the overall response rate for the study 
was 66%, and the median PFS was 16.6 months (95% CI 13.3–19.1), being 
comparable to the effectiveness of paclitaxel and carboplatin (Vasey et al., 2001). In 
addition, to further determine if there is any added benefit to adding a third 
chemocompound to the regimen, the OCTOPUS trial briefly mentioned above was 
conducted, and it demonstrated that compared to standard treatment, the addition 
of a third cytotoxic agent provided no benefit in PFS or OS, regardless of the surgical 
result (Bookman et al., 2009). Currently, the standard is 6 cycles of paclitaxel at 175 
mg/m2 combined with carboplatin AUC (area under the curve) 5, providing the 
patient can tolerate this dosage (Marth et al., 2017). The recommended duration of 
the combination chemotherapy is six cycles. 
Dose-dense therapy has also been tested with both agents. Compared with 
paclitaxel administered every 3 weeks, weekly paclitaxel did not prolong progression-
free survival among patients with ovarian cancer (Chan et al., 2016). Dose-dense 
paclitaxel in combination with carboplatin was compared to a standard regimen in a 
large study including 600 patients, and this demonstrated a significant survival 
benefit: the median PFS was 28 months in the dose-dense arm vs 17.2 months in 
the standard regimen arm (Katsumata et al., 2009). Since it involves higher toxicity, 
and because the promising results of the Japanese study have not been repeated in 
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trials in Europe, the dose-dense treatment regimen is not currently considered a first-
line option (Clamp AR et al., 2017).  
Another investigated treatment option is intraperitoneal chemotherapy (IP). In 
2006, GOG-172 was published, where paclitaxel-cisplatin was compared to iv 
paclitaxel and IP cisplatin on day 2 and IP paclitaxel on day 6 in the setting of 
advanced OC with an R0 or R1 surgical result. The treatment was administered in 3-
week cycles, with 6 cycles in total. As a result, the 4-year survival was 65.6 months 
in the IP arm vs 49.7 months in the standard treatment arm (Armstrong et al., 2006). 
However, the adverse effects were also significant, and the quality of life of the 
patients in the investigative arm was poorer. Another study also demonstrated a 
survival benefit (28 months in the experimental arm vs 22 months in the standard 
treatment arm), but significant toxicity was also encountered, and IP chemotherapy 
is thus not currently part of the routine management of OC (Markman et al., 2001). 
Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) is a single 
treatment of intraoperative chemotherapy administered intraoperatively (Di Saia et 
al., 2018). This modality might add benefit in several ways: when the chemotherapy 
is given intraoperatively, drug exposure is better without the effect of postoperative 
adhesions; the surgeon can oversee optimal distribution of the drug; and 
hyperthermia increases DNA-crosslinking and tumor penetration, maximizing the 
effect of the drug administered (Cowan et al., 2017). Results of a prospective 
randomized controlled trial (RCT) were recently published (van Driel et al., 2018). 
In this study, 245 patients with stage III OC who were receiving neoadjuvant 
chemotherapy were randomized to HIPEC and standard treatment. The HR for the 
HIPEC group was 0.66, the 95% CI was 0.50-0.87 and the median recurrence-free 
survival was 10.7 months in the standard treatment group and 14.2 months in the 
HIPEC group. Other RCTs examining this approach, especially with regard to 
treatment toxicity, are awaited. 
2.3.2.1 Bevacizumab in first-line treatment 
Angiogenesis provides an important means for targeted therapy in EOC. Tumor 
nodules cannot increase to >1 mm without developing their own blood supply (Bast, 
2011). OCs produce multiple angiogenesis-stimulating factors, such as VEGF, 
bFGF and IL-8 (Bast et al., 2009). Studies indicating that increased levels of VEGF 
in OC were associated with increased resistance to chemotherapy and a poorer 
prognosis have provided the molecular rationale for the use of antiangiogenic 
therapy (Siddiqui et al., 2011; Rojas et al., 2016). 
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In first-line treatment, the results from GOG-218 and ICON7 have 
demonstrated improved outcome when bevacizumab is administered in 
combination with standard chemotherapy and when continued after finalizing the 
initial treatment as maintenance. In GOG-218, 1873 patients with stage III-IV OC 
were recruited, and the primary endpoint was PFS. The main result demonstrated 
that the use of bevacizumab during and after carboplatin and paclitaxel 
chemotherapy (cycles 2-22) prolonged the median PFS by 3.8 months in patients 
with advanced epithelial ovarian cancer (10.3 months in the standard treatment arm 
and 14.1 months in the experimental bevacizumab arm) (Burger et al., 2011). 
ICON 7 recruited 1520 patients with OC; 70% had stage IIIC or IV ovarian 
cancer. As a result, PFS at 42 months was 22.4 months without bevacizumab versus 
24.1 months with bevacizumab, and significantly, in patients with high risk for 
progression, the bevacizumab benefit was a greater PFS at 42 months (18.1 months 
vs 14.5 months with standard therapy alone), with respective median overall survival 
of 36.6 and 28.8 months (Perren et al., 2011). The final report of ICON 7 showed 
the treatment benefit in terms of OS not in the overall analysis but only in poor-
prognosis patients in stage IIIC and IV (Oza et al., 2015).  
Thus, a Cochrane Systematic review stated that for patients with a high risk of 
progression, treatment with VEGF-inhibitors and chemotherapy improved PFS and 
OS (Wang et al., 2018). However, VEGF-inhibitor use also increased the incidence 
of common adverse events, and there was no survival benefit in the pure 
maintenance setting (Wang et al., 2018).  
2.3.2.2 Neoadjuvant chemotherapy 
NACT is used when successful PDS is considered unachievable, usually in stages 
IIIC or IV. It consists of 2-4 cycles of platinum-based chemotherapy prior to interval 
debulking surgery (IDS) (Wright et al., 2016). There is an ongoing debate about PDS 
vs NACT-IDS, and to date, the absolute superiority of either option has yet not been 
demonstrated (Angeles et al., 2018). 
In a trial addressing the issue, 670 patients with stage IIIC-IV EOC were 
recruited. The HR for death (intention-to-treat analysis) in the NACT group 
followed by IDS, compared with the group assigned to PDS followed by standard 
chemotherapy, was 0.98 (90% CI, 0.84 to 1.13), and the HR for progressive disease 
was 1.01 (90% CI, 0.89 to 1.15). The complete resection of all macroscopic disease 
(at primary or interval surgery) was the strongest independent variable predicting OS 
(Vergote et al., 2010). In terms of complications, the patients in the IDS group fared 
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better: postoperative death (defined as death <28 days after surgery) occurred in 
2.5% of patients in the PDS group and in 0.7% of patients in the IDS group. Grade 
3 or 4 hemorrhage occurred in 7.4% of patients after PDS and in 4.1% after IDS, 
with infection in 8.1% and 1.7%, respectively. However, quality of life assessments 
did not differ at any point of the study. 
The CHORUS trial was an RCT comparing NACT + IDS to PDS and standard 
chemotherapy. The results of this study were concordant with those of previously 
published RCT investigations. According to the CHORUS trial, the median OS was 
22.6 months in the PDS group vs 24.1 months in the NACT group. However, in the 
PDS group, grade 3 or 4 postoperative adverse events and deaths were detected at a 
higher rate compared to that in the NACT group (24% vs 14%, respectively) (Kehoe 
et al., 2015). 
A Cochrane Systematic review stated in 2012 that the use of NACT in women 
with stage IIIC/IV OC is an alternative to PDS, especially in the case of bulky 
disease (Morrison et al., 2012). PDS is however the standard in stage IIIA and IIIB 
(Morrison et al., 2012). According to a more recent Cochrane Systematic review, in 
terms of the survival rates of women with advanced OC, there is no conclusive 
evidence for IDS superiority. The benefit of IDS has only been demonstrated in case 
the surgery was not as extensive of primarily not performed by gynecological 
oncologist (Tangjitgamol et al., 2016).  
Although the noninferiority of NACT has thus currently been accepted (Qin et 
al., 2018), more well-designed prospective RCTs and the reliable data they provide 
are needed. NACT and its effect on survival remain a target for active research. 
Currently, a trial investigating NACT and IDS vs PDS and standard chemotherapy 
(TRUST) is recruiting. There are many unanswered questions regarding the 
superiority or inferiority of NACT, and the possible induction of chemoresistance 
and difficulty of assessing the residual tumor during IDS remain the focus of the 
discussion, hopefully answered in the future by data provided from RCTs and basic 
research. 
Targeted therapies, specifically bevacizumab, have been investigated in this 
setting as well: NACT+ bevacizumab following IDS has been proposed and may 
prove to be an acceptable strategy in the future, although further RCT data are still 
needed (Komiyama et al., 2018). 
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2.3.3 Treatment of recurrent ovarian cancer 
As stated earlier, OC is a chemoresponsive, but almost never chemocurable disease 
(Bast, 2011). Most women diagnosed with HGSC develop recurrent disease and 
eventually also chemotherapy resistance, despite initially responding to treatment 
(Cornelison et al., 2017). Chemoresistance is defined by the timing of the recurrence: 
sensitive disease is defined by recurrence >12 months after completion of platinum-
based first-line therapy and resistant disease by recurrence 6 months after 
completion of platinum-based first-line therapy (Di Saia et al., 2018). Partially 
sensitive is by definition a recurrence 6–12 months after completion of platinum-
based first-line therapy (Mutch and Prat, 2014). The chemoresistance cycle is further 
characterized by recurrent relapses with shortening time intervals between relapses 
until the disease becomes untreatable, i.e., chemoresistant. Definitions to describe 
the events of treatment response have evolved over the course of time, and currently, 
a definition using the platinum-free interval (PFI) to categorize patients as having 
platinum-sensitive/resistant disease has been replaced by the therapy-
free interval (TFI), which can be subgrouped into TFIp (PFI), TFInp (non-PFI) and 
TFIb (biological agent-free interval) (Wilson et al., 2017). 
In platinum-sensitive recurrent disease, several chemotherapeutic agents have 
proven beneficial, and choosing the best option involves taking into account prior 
systemic therapy, BRCA status, tumor histology, the PFI and previous treatment 
with bevacizumab (Pignata et al., 2017). In platinum-sensitive disease, the 
CALYPSO trial has demonstrated that carboplatin and liposomal doxorubicin 
(CPLD) is associated with less toxicity and improved PFS compared with carboplatin 
and paclitaxel using standard doses (11.3 months in the experimental arm vs 9.4 
months in the carboplatin and paclitaxel arm) (Pujade-Lauraine et al., 2010). 
Additionally, according to the OCEANS trial, bevacizumab with carboplatin and 
gemcitabine did not increase PFS when compared with standard treatment alone in 
patients with recurrent disease (12.4 vs 8.4 months, respectively), although no OS 
difference has been observed (Aghajanian et al., 2012). The GOG-213 trial assigned 
patients to a standard carboplatin and paclitaxel regimen vs carboplatin and paclitaxel 
plus bevacizumab. The study also had a surgical arm, the results of which are still 
awaited. The primary endpoint was OS. Median OS in the chemotherapy 
plus bevacizumab group was 42.2 vs 37.3 months in the chemotherapy group, the 
difference was non-significant statistically. Adverse effects (grade 3 or worse adverse 
event) were more prominent in the chemotherapy plus bevacizumab group (96% vs 
86%) than in the chemotherapy group (Coleman et al., 2017). 
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The treatment of recurrent platinum-resistant/platinum-refractory EOC with 
sequential single-agent salvage chemotherapy is superior to multiagent 
chemotherapy because of its less significant toxicity since multiagent treatment has 
no survival benefit in this setting (Oronsky et al., 2017). The administration of 
paclitaxel either weekly or three -weekly was assessed in an RCT, in which 55 patients 
were enrolled. For weekly vs three-weekly paclitaxel, the objective response rates 
were 27% and 16%, the median PFS were 7 and 4.5 months, and the median OS l 
were 15.5 and 12.5 months, respectively (Osman et al., 2016). Importantly, the 
treatments significantly improved the quality of life of the patients.  
To evaluate the effectiveness of combining bevacizumab with chemotherapy, the 
AURELIA trial was initiated as the first randomized phase III trial, and it was 
observed that adding bevacizumab to chemotherapy significantly improved PFS 
without any new safety concerns (Pujade-Lauraine et al., 2014).  
To conclude, recurrent disease, especially platinum-resistant recurrent EOC, 
poses a significant treatment challenge with modest survival benefits when compared 
to primary treatment.  
2.3.4 Mechanisms of resistance to chemotherapy 
As a characteristic of EOC, most women become resistant to chemotherapy at some 
point in the disease. Cancer cells are able to actively expel the chemotherapeutic 
agent via transport proteins, resulting in treatment resistance. A form of 
chemotherapy resistance is multiple drug resistance (MDR), which is diagnosed 
when cancer cells become resistant to not only the primary chemotherapeutic agent 
(platinum in the case of OC) but also to the next treatment lines (Ozben, 2006). This 
effectively prevents further treatment and dramatically worsens the prognosis 
(Januchowski et al., 2013). 
When considering the background of treatment response, resistance to treatment 
is divided into the categories of intrinsic or acquired resistance, although 
distinguishing these mechanisms can be difficult (Cornelison et al., 2017). In intrinsic 
resistance cancer cells have innate ability to persist through the first exposure to 
treatment (Abdullah and Chow, 2013). Specifically, cancer cells may have 
mechanisms in place prior to treatment (de novo) to avoid response, for instance 
through limited drug uptake, detoxification of drugs or enhancing the efflux of drugs 
(Gottesman, 2002). Some of the mechanisms involved include modified aldehyde 
dehydrogenase (ALDH) activity and B-cell lymphoma-2 (BCL2)-related 
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chemoresistance (Abdullah and Chow, 2013). Tumor microenvironment has 
recently been studied extensively and specifically in OC, and tumor cells ensure via 
properties of intrinsic mechanisms (cytokine and bioactive lipid expression) that 
cancer-associated, mesenchymal stem cells and tumor-associated macrophages 
regulate chemoresistance as well as tumor growth, angiogenesis and dissemination 
(Thibault et al., 2014).  
Acquired resistance is the result of exposure to treatment and subsequent 
evolution of cancer cells to an unaffected and persistent state (Cornelison et al., 
2017). Acquired chemoresistance is based on the idea that most cells are sensitive to 
the chemotherapeutic drug, but then develop resistance through spontaneous 
mutations at variable rates, as proposed by the Goldie-Coldman hypothesis (Dembo, 
1984). Acquired chemoresistance is facilitated by different mechanisms including 
genetic and epigenetic alternations of crucial genes (David W Chan and YS Ngan, 
2012). Most anti-cancer drugs impair DNA synthesis, damage DNA in the nucleus 
or break down the mitotic spindles in the cells (David W Chan and YS Ngan, 2012). 
As a result, DNA mutations, deletions, amplifications, translocations occur, and 
when changes happen to crucial genes, such as TP53, RB1 and KRAS, cancer cells 
become aggressive and chemoresistant (Jardin et al., 2009; Sankala et al., 2011; Wang 
et al., 2010). Several other genes such as Krüppellike factor 6 (KLF6), AGGF1 and 
MFAP4, have been proposed to be associated with chemoresistance in OC and also 
as markers for treatment response (Zhao et al., 2019; Chen et al., 2018). MicroRNAs 
have also been found to regulate crucial gene expression in the development of drug 
resistance (L. Zhang et al., 2016). In cell line models, evidence of miRNA-21 
regulating cisplatin resistance by negatively targeting the PTEN/PI3K/Akt signaling 
pathway in OC has emerged (Yu et al., 2017). Another study demonstrated that miR-
34a has a suppressive effect on OC cells via directly binding and downregulating 
HDAC1 expression (Lv et al., 2018).  
The clonal origin and mutational adaptations associated 
with recurrent disease are however, poorly understood (Castellarin et al., 2013), 
partly because the genomic characteristics of HGSC samples collected at initial 
surgery have been extensively studied, but also because the molecular features of 
recurrent disease are less well-explored due to the challenges of sample collection 
posttreatment (Christie and Bowtell, 2017). The tumor suppressors RB1, NF1, 
RAD51B and PTEN are commonly inactivated in HGSC by gene breakage and that 
contributes to acquired chemotherapy resistance (Rojas et al., 2016). CCNE1 
amplification commonly has been found in primary resistant and refractory disease 
and indicates HR proficiency (Patch et al., 2015). However, as of yet, these 
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characteristics are not utilized in clinical decision-making. In terms of broader 
analysis, both known and novel pathways are commonly mutated, and it is thought 
that recurrent disease arises from multiple clones that are also present in 
the primary tumor with negligible accumulation of new mutations during standard 
treatment (Castellarin et al., 2013). In a recent study, however, it was demonstrated 
that after a single line of platinum, there was huge variability between primary and 
recurrent tumors, underlining the need for HGSC biopsies collected at relapse to 
tailor treatment options to the underlying genetic profile (Lambrechts et al., 2016). 
Interestingly, all primary platinum-sensitive HGSCs remained HR-deficient in this 
study, suggesting that although platinum treatment does change a tumor’s properties, 
it likely remains responsive to PARPi treatment. In addition, it is noteworthy that 
even a single line of platinum therapy contributes to chromosomal instability, leading 
to acquired resistance (Lambrechts et al., 2016). 
2.4 BRCA 1 /2 mutations 
The BRCA1 gene was cloned in 1994, and it is located in human chromosome 
17q21 (Miki et al., 1994). The BRCA1 is a multifunctional protein and is known to 
interact with different protein partners in various cellular compartments and it plays 
essential roles in diverse cellular pathways such as DNA damage repair, apoptosis, 
cell cycle arrest, transcriptional activation, genetic instability and tumorigenesis 
(Deng and Scott, 2000). BRCA2 is a large gene comprising 10,254 nucleotides and 
26 coding exons (Perets et al., 2013) and is located in 13q13.1, which is the long (q) 
arm of chromosome 13 at position 13.1. BRCA2 suppresses genome instability by 
being centrally involved in two processes: DNA lesion repair by HR and nascent 
strand protection from degradation at stalled replication forks (Prakash et al., 2015). 
In different models, BRCA2 has been evaluated and it has been demonstrated that 
it prevents chromosomal aberrations upon replication stalling to maintain genomic 
integrity, and through this likely suppresses tumorigenesis (Schlacher et al., 2011).  
BRCA genes have an essential role in suppressing genome instability: they behave 
as caretakers and thus act as chromosome structure preserves (Venkitaraman, 2002). 
The best-known function of both BRCA1 and BRCA2 is in the DNA repair 
pathway. In DNA, different lesions are constantly caused by UV light and metabolic 
processes as well as other factors. Among these different types of lesions, double
strandbreaks (DSBs) are repaired by several mechanisms but preferably by HR 
repair, which is the cell's most errorfree repair mechanism. (Moynahan et al., 1999; 
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Bouwman and Jonkers, 2012; Severson et al., 2015). Cells without functional BRCA1 
and BRCA2 are deficient in HR and are forced to use alternative mechanisms to 
repair DSBs. These highly errorprone nonhomologousendjoining (NHEJ) 
mechanisms, which result in genomic instability, further worsen the cell’s state and 
ability to repair lesions (Severson et al., 2015). Ultimately, this results in genomic 
instability that is so significant that the cell is predisposed to cancer formation.  
2.4.1 Hereditary ovarian cancer  
In terms of hereditary breast and ovarian cancer syndrome, in 20% of HGSC cases, 
the disease is due to hereditary or somatic mutations in BRCA1 and BRCA2 
(Edmonds and Dewhurst, 2007). The lifetime risk of breast cancer in BRCA 1/2 
mutation carriers is 41% to 90% (Kuchenbaecker et al., 2017;  Ford et al., 1998). 
Approximately 65-85% of ovarian tumors with hereditary susceptibility (20% of all 
cases) have a BRCA gene germline mutation; nevertheless, some other suppressor 
genes and oncogenes have also been associated with hereditary OCs (Toss et al., 
2015). These include mismatch repair (MMR) gene mutations in Lynch syndrome 
that is associated with clear cell and endometrioid subtypes (and not associated with 
BRCA mutations), the tumor suppressor gene TP53 in Li-Fraumeni syndrome, and 
several other genes involved in the DSB repair system, such as CHEK2, RAD51, 
BRIP1, and PALB2 (Nakonechny and Gilks, 2016; Walsh et al., 2011). In addition, 
BRCA 1/2 mutations predispose to several other cancers, most prominently to 
pancreatic (Matsubayashi et al., 2017) and prostate cancers (Ibrahim et al., 2018). An 
overview of the genes involved is depicted in Figure 1. 
In ovarian cancer, 40% of BRCA1 mutation carriers are diagnosed with the 
disease by age 70, and 18% of BRCA2 mutation carriers face risk (Kuchenbaecker 
et al., 2017; Venkitaraman, 2002). Ovarian screening does not improve outcomes, so 
BRCA mutation carriers are recommended to undergo prophylactic risk-reducing 
salpingo-oophorectomy (RRSO) around the age of 40, followed by hormone 
replacement therapy in the case of negative breast cancer history (Hartmann and 
Lindor, 2016). Any specimens from prophylactic surgery should be carefully 
examined for occult malignancy, which do occur and have provided additional 
confidence in the current counseling for RRSO for high risk women (Lee et al., 
2017). The genetic testing in order to identify patients with inherited predisposition 
to cancer should be performed only after careful counseling, especially in case the 
testing panels for genes include those that may identify confusing variants of 
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uncertain significance or unsuspected disease predisposition (Society of Gynecologic 
Oncology, 2017). New methods for triaging patients for genetic testing are needed, 
as the selection criteria that is currently used, fails to detect up to half of mutation 
carriers (Nilsson et al., 2018). 
Figure 1.  Inherited ovarian cancer, proportions of genes with primary ovarian, Fallopian tube or 
peritoneal cancers with germline mutations. Adapted from PMC (Walsh et al., 2011) 
 
 
Currently, the most effective method for preventing OC is without a doubt 
primary surgical prevention through RRSO (Tschernichovsky and Goodman, 2017), 
especially among the high-risk patient population, such as BRCA1 and BRCA2 
mutation carriers (Temkin et al., 2017). Thus, as a guideline, currently RRSO is 
recommended for both BRCA1 and BRCA2 carriers between the ages of 35 and 40 
years who have completed their childbearing (Hartmann and Lindor, 2016; 
Edmonds and Dewhurst, 2007; Walker et al., 2015). In BRCA2 mutation carriers, 
surgery might also be considered at a later age (up to 45 years), since the onset of 
cancer is 8 to 10 years later than that of BRCA1 carriers (Marchetti et al., 2014), and 
the risk of developing OC before the age of 50 years is 1% (Hartmann and Lindor, 
2016). Not insignificantly, the cost-effectiveness of RRSO in BRCA1/BRCA2 
carriers older than 35 years is also well established (Walker et al., 2015). In other 
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moderate-risk gene mutation carriers and those with polygenic risk, RRSO needs be 
considered at 50 years of age (Yamauchi and Takei, 2018). The optimal threshold for 
RRSO remains the subject of ongoing research and discussion, aimed to ultimately 
enable introduction of a targeted primary prevention approach that would 
significantly impact the future burden of OC (Manchanda and Menon, 2017). 
Further details of RRSO and BRCAness are detailed in Chapters 2.5 and 2.6. 
2.5 RRSO and the origin of HGSC 
It has been historically thought that the polarized cuboidal epithelial monolayer that 
is in continuity with the rest of the peritoneal mesothelium and covers the ovaries is 
the origin of EOC (Edmonds and Dewhurst, 2007). This theory has been challenged, 
and it is the present understanding that in fact OC arises from the tubal epithelium 
(Dubeau, 2008; Nishida et al., 2016; Piek et al., 2001) in the case of HGSC (Kurman 
and Shih, 2010). More distinctly, high-grade serous ovarian cancer refers to the 
HGSC arising from the ovary, Fallopian tube, or peritoneum (Kim et al., 2018).  
Figure 2.  Development of high grade epithelial ovarian cancer arising from fimbriae. Adapted from 
Gloss and Samimi (Gloss and Samimi, 2014). 
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Extensive and groundbreaking work exploring the origin of HGSC has 
demonstrated that STIC lesions are suspected to be the precursor for most HGSCs 
of the pelvis (Prat, 2012). This is based on an observation that there is a clonal 
relationship between STIC and established HGSCs sharing TP53 mutations as well 
as integrated molecular analyses (Lee et al., 2007; Eckert et al., 2016; Ducie et al., 
2017). The data have been retrieved from material derived from BRCA mutation 
carriers undergoing RRSO. In these, from 57% up to 100% of prophylactic surgeries 
in both the BRCA1 and BRCA2 mutation carrier populations reveal the involvement 
of the Fallopian tube, especially at the fimbriated end (Callahan et al., 2007; Finch et 
al., 2006).  
Thus, STIC is an intraepithelial malignancy with potential for spread, and it 
directly precedes invasive serous carcinoma. It is composed of secretory cells having 
significant atypia, such as loss of nuclear polarity, increased nuclear to cytoplasmic 
ratio and prominent nucleoli (Crum, 2009). In another work, intermediate lesions– 
or “tubal intraepithelial lesions in transition” (TILTs) – in which p53-aberrant 
epithelium displays a higher degree of proliferative activity however falling short of 
malignancy, have also been described (Jarboe et al., 2008). The association studies 
referred to above have been followed by genetic model studies demonstrating that 
early alterations in BRCA, p53, and PTEN indeed lead to intraepithelial precursor 
lesions (Perets et al., 2013).  
According to current understanding, implants are shed on the peritoneal surface 
epithelium from these lesions that arise from the distant Fallopian tube, giving rise 
to HGSC. Depending on where the tumorous cells start to proliferate, the disease is 
classified as high-grade serous ovarian cancer (HGSOC), high-grade tubal carcinoma 
or high-grade peritoneal carcinoma. Because of their origin and properties, they are 
essentially one disease with a similar course and prognosis (Kim et al., 2018). Several 
works have been published that support this theory, reviewed by Singh and 
colleagues (Singh et al., 2017).  
2.5.1 Characterization of low grade and high grade tumors 
In EOC, tumors are divided in two subtypes: type I tumors comprise low-grade 
serous, low-grade endometrioid, clear cell and mucinous carcinomas, and Brenner 
tumors and are characterized by specific mutations, including KRAS, BRAF, 
ERBB2, CTNNB1, PTEN, PIK3CA, ARID1A, and PPP2R1A (Shih and Kurman, 
2004; Kurman and Shih, 2011; Wiegand et al., 2010). Type II tumors include high-
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grade serous, high-grade endometrioid (not illustrated in the figure), malignant mixed 
mesodermal tumors (carcinosarcomas), and undifferentiated carcinomas, which are 
characterized by aggressiveness, presentation in advanced stage, and a very high 
frequency of TP53 mutations (Shih and Kurman, 2004). Type II tumors rarely harbor 
the mutations detected in type I tumors (Kurman and Shih, 2011). This subtype 
division is illustrated in Figure 3.  
 
Figure 3.  Expanded dualistic model of ovarian carcinogenesis. Ovarian carcinomas derive from 
endometrial tissue, Fallopian tube tissue, germ cells, and transitional epithelium. Type I 
carcinomas comprise endometrioid, clear cell, LG serous, and mucinous carcinomas. 
Type II carcinomas are largely composed of HG serous carcinoma, carcinosarcoma, and 
undifferentiated carcinoma. Transitional cell indicates metaplastic transitional epithelium at 
the tuboperitoneal junction. Adapted from Kurman and Shih (Kurman and Shih, 2016). 
 
LG-low grade
HG – High grade 
SET – solid, pseudoendometroid, transitional carcinoma 
 
 
 
Furthermore, type II tumors have molecular alterations that perturb the expression 
of BRCA either by mutation or by promoter methylation and the defining 
characteristic of these tumors is genetic instability (Kurman and Shih, 
2011). New molecular genetic data, especially those data derived from next-
generation sequencing (NGS), further underline the heterogeneity of OC and 
identify actionable mutations in terms of possible targeted treatments (Binder et al., 
2015). 
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Figure 4.  The revised dualistic model in the pathogenesis of EOC. Type I carcinomas comprise low-
grade serous, clear cell, endometrioid, and mucinous carcinomas. Seromucinous 
carcinomas and malignant Brenner tumors are rare and not shown. Type II carcinomas 
are largely composed of high-grade serous carcinomas. Carcinosarcoma and 
undifferentiated carcinoma are relatively uncommon and not illustrated. The molecular 
pathway alterations that characterize each tumor subtype are shown color-coded beside 
the subtype. Some pathway abnormalities are shared by different tumor types and are 
shown in two-color coding. Adapted from Kurman and Shih (Kurman and Shih, 2016).  
 
 
ARID1A, AT-rich interaction domain 1A 
BRAF, B-Raf proto-oncogene, serine/threonine kinase 
CCNE1, cyclin E1 
ERRB2, estrogen-related receptor 	2 
HR DDR, homologous recombination-mediated DNA damage repair 
KRAS, Kirsten rat sarcoma viral oncogene homolog 
MEK, mitogen-activated protein (MAP) extracellular signal-related kinase (ERK) kinase 
MMR, DNA mismatch repair 
NF1, nuclear factor 1 
PI3K, phosphatidylinositol 3-kinase 
PTEN, phosphatase and tensin homolog 
Rb, retinoblastoma protein 
An important feature of HGSC is that it has the tendency to spread from primary 
tumor cells to nearby organs such as bowel, peritoneum, uterus, mesentery and 
omentum (Weidle et al., 2016). HGSC also spreads through blood and lymph vessels. 
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To conclude, HGSC is currently viewed as an entity of three diseases – high-
grade epithelial Fallopian tube cancer, high-grade epithelial ovarian cancer and 
primary peritoneal cancer (Singh et al., 2017). Molecular subtyping and constantly 
widening understanding of the underlying mechanisms of this disease entity have led 
to improvements in treatment strategies.  
2.6 Molecular subtyping of EOC 
Although division of EOC into either type I or type II is currently based on histology 
and tumor grade, the development of molecular analyses will possibly provide a more 
accurate basis for tumor classification (Rojas et al., 2016). Using microarray 
technique, the gene expression profiling has separated four molecular subtypes 
of HGSC, each correlating with survival data and has specific biological 
characteristics: C1 (mesenchymal), C2 (immunoreactive), C4 (differentiated), and C5 
(proliferative) (Patch et al., 2015; Leong et al., 2015).  
Clustering analysis and extensive search in the existing literature have thus 
outlined four gene clusters that correspond to distinct biological processes, including 
cell division, tumor invasion, mitochondrial system and glycoprotein synthesis, the 
last of which is speculated to be highly predictive of OS among OC patients (H. 
Zhang et al., 2016). Tumor expression profiling with techniques such as sequencing, 
microarray, and proteomic methods have provided analysis at the DNA, RNA and 
protein levels, however, the challenge of determination of clinically significant 
alterations is significant (Binder et al., 2015). Currently molecular subtyping is not 
used in routine clinical praxis, due to its suboptimal repeatability. 
The coding genes from 316 HGSCs have been sequenced by The Cancer 
Genome Atlas (TCGA) Research Network and 96% of the genes had somatic 
mutations of p53, BRCA1 or BRCA2 mutations (germline or somatic) were found 
in 20% (H. Zhang et al., 2016). RB1, NF1, FAT3, CSMD3, GABRA6 and CDK12 
were also recurrently mutated in 5% of HGSCs (Zhang et al., 2014). Overall, 50% 
of HGSCs exhibit HR defects, including tumors with epigenetic silencing, the 
BRCA1 and BRCA2 inactivating mutations, EMSY amplification or mutation, 
PTEN deletion or mutation, RAD51C hypermethylation, ATM or ATR mutation, 
and Fanconi anemia genes mutation (Bast, 2011). These genomic scar signatures are 
an important feature to consider, since they pose the possibility for targeted 
treatment as well as for response-related issues in platinum treatment 
(Konstantinopoulos et al., 2015). A genomic scar is defined as a genomic aberration 
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with a known origin, and in the setting of OC and HR, a genomic scar includes 
telomeric allelic imbalance (TAI) and loss of heterozygosity (LOH), which are 
thought to be biomarkers for homologous recombination deficiency (HRD) 
(Watkins et al., 2014). In 2018, Macintyre et al. explored copy-number signatures and 
found a relation to treatment response (Macintyre et al., 2018). HR deficiency and 
mutational signatures have also been investigated in terms of treatment response to 
PARP inhibitors beyond BRCA mutations and according to a recently published 
study, may be useful in PARP inhibitor- related decision-making, since HR 
deficiency signature is associated with good response to PARP inhibitors (Gulhan et 
al., 2019). The details of HRD are further discussed in Chapter 2.7 and 2.8. The data 
from TCGA are visualized in Figure 5. 
Figure 5.  Molecular subtyping of EOC: associated genes. Approximately 50% of HGSCs have 
alterations in HR repair genes. HR-deficient tumors on the right are associated with 
FA/BRCA pathway alterations. PTEN deletion and EMSY amplification are possibly HR-
deficient. HR-proficient tumors (cyclin E1) are associated with inferior outcome and poor 
response to platinum-based chemotherapy. Remaining tumors may be HR deficient via 
miRNA upregulation or other unknown mechanism. Adapted from (Konstantinopoulos et 
al., 2015). 
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2.7 DNA damage repair and BRCAness 
Lesions in genomic DNA are induced by both environmental and internal factors 
(Ciccia and Elledge, 2010), and failure to repair them will induce genomic instability 
and ultimately tumorigenesis (Li and Yu, 2015). Different DNA lesions include 
DNA strand breaks (double or single), chemically modified nucleobases, and 
intrastrand DNA cross-links (Geacintov and Broyde, 2017).  Genomic stability is 
ensured by the DNA damage response system that recognizes and repairs DNA 
lesions, thus suppressing tumorigenesis (Jackson and Bartek, 2009; Li and Yu, 2015).  
In more detail, alterations in the DNA can be divided into crosslinks, base 
modifications, single-strand breaks (SSBs) and double strand breaks (DSBs) (Caruso 
et al., 2017). DNA can be repaired by at least five different mechanisms, two of 
which are responsible for DSB repair: homologous recombination (HR) and 
nonhomologous end joining (NHEJ) (Davar et al., 2012). By ensuring efficient and 
precise repair of DSB, the BRCA1 and BRCA2 proteins are central to the role of 
maintaining genomic stability (Ledermann et al., 2016). Cells with intact BRCA are 
able to survive by repairing DSBs, but BRCA-mutated cells undergo apoptosis 
because of the inability to repair damage (Morris and Chan, 2015). By definition, 
alteration in two genes (either by a mutation or a medical compound) initiates 
a synthetically lethal interaction, essentially because the perturbation of either gene 
alone is survivable, but the perturbation of both genes simultaneously results in the 
loss of viability (Bhattacharjee and Nandi, 2017). The synthetic lethality and the 
underlying genetic interactions have been identified and mechanistically 
characterized, which greatly enhances the possibilities of exploiting synthetic 
lethality in cancer treatment (O’Neil et al., 2017).  
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Figure 6.  DNA damage response pathways – drug targets. Cell cycle targets are shown with 
rationale for targeting these pathways. PARP, ATR, ATM and DNA-PK are SSB and DSB 
repair targets that are being evaluated in clinical trials. Adapted from O’Connor (O’Connor, 
2015). 
 
 
 
There is considerable progress made in the understanding of BRCA1 and BRCA2 
gene functions and the loss-of-function mutations, making cells vulnerable to 
targeted therapy (Lord and Ashworth, 2016). "BRCAness" is the functional state and 
therapeutic sensitivity that is often referred to in this state, and it is most commonly 
associated with OC, but also some breast cancer types (Li et al., 2017). The 
'BRCAness' properties are essentially the characteristics that some sporadic 
malignancies share with those occurring in either BRCA1- or BRCA2-mutation 
carriers, such as response to standard therapy (Turner et al., 2004). Prior 
investigations have shown that a BRCA-like phenotype can be present in 
approximately 50% of cases of HGSC, most likely reflecting HRD status (Tan et al., 
2008; M. Zhang et al., 2016).  
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2.8 PARP inhibition 
The first clinically approved drugs developed to exploit synthetic lethality are the 
PARP inhibitors (PARPi), a cancer therapy targeting poly(ADP-ribose) polymerase 
(Lord and Ashworth, 2017). Poly(ADP-ribosyl)ation (PARylation) is an integral  part 
of the DNA damage response system and it has multiple roles in several molecular 
and cellular processes (Taylor and Eskander, 2018). In addition to DNA 
damage detection and repair, it also has a role in mitotic apparatus function, 
chromatin modification, cell death pathways, transcription, and insulator function 
(Schiewer et al., 2012). Genome maintenance, aging, carcinogenesis, inflammation, 
and neuronal function are some of the physiological and pathological outcomes that  
critically depend on these processes (Kim et al., 2005).  
In terms of the DNA damage response and OC, PARylation regulates both DSB 
and SSB repair and cell cycle checkpoint activation (Schiewer et al., 2018). DNA 
damage-induced PAR is recognized by many DNA damage response factors. PAR 
mediates the recruitment of DNA damage response factors to the lesions and this 
initiates DNA damage response pathway activation (Pascal, 2018). After activation 
of different DNA damage response pathways, the PAR is degraded by PARG and 
other mechanisms (DNA damage-induced phosphorylation and ubiquitination 
events) ensure that DNA repair factors are selectively retained at DNA lesions to 
complete repair (Li and Yu, 2015). Cells with BRCA1 or BRCA2 dysfunction are 
profoundly sensitized to the inhibition of PARP enzymatic activity that leads to 
chromosomal instability, cell cycle arrest and eventually, apoptosis (Farmer et al., 
2005). DSBs repair is mediated by two main pathways, NHEJ and HR, and three 
main pathways are used to repair SSBs: nucleotide excision repair, base excision 
repair (BER), and mismatch repair (Hengel et al., 2017). PARP1 is involved in several 
pathways such as NHEJ, HR, and BER (Li and Yu, 2015). 
As described above, BRCA1 or BRCA2 loss results in defective HR repair of 
DCBs and repair therefore relies on potentially mutagenic mechanisms such as 
NHEJ (Taylor and Eskander, 2018). These explorations have introduced the 
synthetic lethality approach to targeting BRCA-mutated cancers, with PARP 
inhibition as a well-researched example as described above (Lord and Ashworth, 
2013). To further illustrate, a normal cell survives PARP inhibition because it is able 
to use other repair mechanisms for the damage that has occurred. However, in 
BRCA-mutated cells (or otherwise HR deficient), the ability to repair SSBs via BER 
is lost if PARP1 is inhibited, resulting in cell death (synthetic lethality). An illustration 
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of DNA damage and its repair in normal cells and BRCA-mutated cells is provided 
in Figure 7.  
 
Figure 7.  DNA damage repair in normal cell and HRD cell demonstrating the PARP inhibition 
mechanism in normal and BRCA-mutated cell. Adapted from Mäenpää (Mäenpää, J, 
2018).  
 A - normal cell, B- BRCA-mutated cell, C – PARP inhibition in normal cell, D – PARP 
 Inhibition in BRCA-mutated cell 
 
 
 
 
PARP inhibitors have been a much-awaited breakthrough in the treatment of OC. 
The first PARPi  approved for cancer treatment was olaparib in 2014 (Dréan et al., 
2016). Currently, olaparib, rucaparib and niraparib have also been approved in the 
US and/or Europe for the treatment of BRCA-mutated OC. There are many 
ongoing RCTs exploring different combinations of PARPi with chemotherapeutics 
or molecular-targeted agents (Ohmoto and Yachida, 2017). Interestingly, it has also 
been hypothesized that in patients with BRCA1/2 mutation carrier OC (PBMCOC), 
exposure to PARPi may compromise benefit to subsequent chemotherapy with 
platinum-based regimens, possibly through the acquisition of secondary BRCA1/2 
mutations (Barber et al., 2013). However, Ang et al. found in 2013 that heavily 
pretreated PARPi-resistant PBMCOC retains the potential to respond to subsequent 
chemotherapy, and no secondary BRCA1/2 mutations were found (Ang et al., 2013). 
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Excitingly, recently PARP inhibition has shown its importance in first-line 
treatment according to the SOLO1 trial, in which women with newly diagnosed 
advanced OC and a BRCA1/2 mutation showed substantial benefit in PFS with 
olaparib maintenance in frontline therapy. In detail, after a median follow-up of 41 
months, olaparib lowered the risk of disease progression or death by 70% compared 
to placebo (Kaplan–Meier estimate of the rate of freedom from disease progression 
and from death at 3 years, 60% vs 27%; HR for disease progression or death, 0.30; 
CI 95% 0.23 to 0.41; P<0.001) (Moore et al., 2018).  
In the treatment of recurrent disease, the much anticipated results from three 
phase III trials (NOVA, SOLO2 and ARIEL3) demonstrated remarkable survival 
benefit (improvement in PFS) when PARP inhibitors were given as maintenance 
therapy to patients with complete or partial response after platinum-based therapy 
for platinum-sensitive OC (Mirza et al., 2018; Pujade-Lauraine et al., 2017; Coleman 
et al., 2017). An overview of these trials is detailed in Table 4.   
The results of first-line treatment discussed in the beginning of the chapter and 
in the treatment of recurrent disease depicted above are indeed very encouraging. 
Very recently, new research has indicated that in cell lines and mouse models, PARP 
inhibitors have immunomodulational properties regardless of BRCAness, which 
might explain their success in BRCA- and HR-negative EOC patients (Shen et al., 
2019). Future challenges in terms of PARPi include improvement in our ability to 
identify ideal candidates for PARPi as well as identification and targeting the 
mechanisms of drug resistance, and finding novel approaches for combinational 
therapies (Taylor and Eskander, 2018). 
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Table 4.  NOVA, SOLO2 and ARIEL3 trials. 
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2.9 HGSC and research prospects 
Although chemotherapy and surgery are the standard treatment for ovarian cancer, 
with results benefiting up to 70% of patients depending on stage and the success of 
surgery, the disease of the majority of patients with advanced HGSC remains 
incurable with current options. Basic research is needed to identify underlying 
molecular mechanisms in patients developing chemoresistant disease, but resistance 
to new targeted treatments (PARP) is an emerging issue (Jiang et al., 2019). PARP 
affects many functions in a cell, and although extensive work has been published, 
there are still areas that need to be explored. The signaling pathways affecting 
treatment response are an important target of research in the HGSC setting, with 
possible implications for emerging new treatment modalities such as gene therapies, 
immunomodulation and combinational targeted therapies.  
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3 AIMS OF THE STUDY 
The aim of this dissertation was to seek insight into early development processes in 
HGSC, to find possible biomarkers for targeted therapies and to identify biomarkers 
related to the development of chemoresistance in HGSC. The specific aims for the 
studies were as follows: 
1. To identify early pathogenetic events in HGSC development using 
microarray technology providing high-throughput screening of genome-
wide gene expression in prospectively collected RRSO specimens derived 
from BRCA1/2 mutation carriers.  
2. To investigate PARP activity measurement and PARP protein expression by 
IHC in HGSC and their correlation to platinum sensitivity and clinical 
outcome. Also, the aim was to assess correlation between the two 
measurement modalities. 
3. To identify candidate genes and their respective molecular pathways 
involved in the pathogenesis and chemoresistance of HGSC. 
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4 PATIENTS, MATERIALS AND METHODS 
All gene and protein names and symbols that appear in this dissertation follow the 
nomenclature guidelines of the HUGO Gene Nomenclature Committee (Povey et 
al., 2001; Wain et al., 2002).  
4.1 Study subjects and tissue samples 
4.1.1 BRCA cohort (I) 
Nine BRCA1/2 mutation carriers undergoing RRSO and five control patients with 
no known BRCA1/2 mutation undergoing BSO for benign indications were the 
prospective study cohort and control group, respectively. All tissue samples were 
taken from macroscopically healthy-looking ovary and distal Fallopian tube. 
BRCA1/2 mutation carriers at the time of RRSO surgery were clinically 
characterized as follows: mean age was 55 years; seven out of nine (78%) patients 
out of the study group had been diagnosed with breast cancer. The control cohort 
patients’ mean age at the time of surgery was 47 years and they had no history 
(personal or family) of any gynecological malignancy. 
From each BRCA1/2 mutation carrier, both distal Fallopian tube and ovarian 
samples were collected. A total of eighteen mutation-positive samples were obtained. 
In addition, six adnexal control samples were used. For morphological and 
histopathological findings, the samples were analyzed by an experienced pathologist 
at the Tampere University Hospital (TAUH) Department of Pathology. In addition, 
fresh tumor samples from three HGSC patients operated on in TAUH during the 
study period were obtained and used as additional controls in the study I. 
In detail, 5 x 5 x 5 mm-sized tissue samples of distal Fallopian tube and ovarian 
surface were collected intraoperatively and immediately snap-frozen with liquid 
nitrogen and stored at -70 °C.   
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4.1.2 EOC cohort (II, III) 
In this prospective study for the assessment of PARP activity in HGSC, one hundred 
consecutive women providing informed consent and scheduled either for PDS or 
IDS for suspected or histologically verified OC were recruited at Tampere University 
Hospital in 2011-2013. Perioperatively, two fresh samples sized approximately 5 x 5 
x 5 mm were collected from macroscopically evaluated tumor tissue from each 
enrolled patient. The samples were taken in the operation room and were 
immediately snap-frozen with liquid nitrogen and stored at -70 °C. In the case of 
IDS, fresh tumor samples were collected from the macroscopically visible residual 
tumor as assessed by an experienced gynecological oncologist. 
The final histopathological diagnosis was made by experienced pathologists as 
part of routine diagnostics at the Department of Pathology in Tampere University 
Hospital. Finally, only samples from patients with histologically verified primary 
EOC were included in the study cohort for further analyses of PARP concentration, 
resulting in a final study cohort of 57 women. From the one hundred originally 
recruited patients only patients with final diagnosis of ovarian cancer were included 
and the patients with other diagnoses were excluded. 
For the microarray analysis of study III, a subgroup of 12 HGSC patients was 
chosen from the prospective cohort based on the level of PARP activity. Six patients 
with the lowest and six patients with the highest PARP levels were included in the 
microarray analyses.  
For all cohorts, clinical and pathological data were collected from the patient 
records (including age at diagnosis, date of primary or interval surgery, FIGO stage, 
grade and histological tumor type). Stage was confirmed by a thorough review of the 
operative and pathology reports by a multidisciplinary team consisting of 
gynecological oncologists, pathologists and oncologists. 
Data regarding chemotherapy were obtained: number of treatment cycles, 
platinum sensitivity defined as no recurrence within 12 months after the completion 
of first-line platinum-based chemotherapy, and use of neoadjuvant chemotherapy. 
For survival analyses, follow-up data were collected from medical records by 
documenting the time of recurrence or the last follow-up visit or death.  
The characteristics of the study patients were as follows: mean age of the patients 
was 66 years (SD 9.3). Most of the samples were high-grade (70%) and had serous 
(84%) histology. The median follow-up time was 31 months (range 2-50 months). 
The characteristics of OC patients included in studies II and III are described in 
Table 5.  
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Table 5.  Characteristics of the study patients in study II and III. 
 
Study patients' characteristics n=53 (II) n=12 (III) 
Age at surgery, yrs.  66  65 
Median follow-up, months (range) 31 (2-50) 31 (2-50) 
Response to platinum therapy3, n (%)   
         Sensitive 38 (71,5) 6 (50) 
              Resistant 15 (28.5) 6 (50) 
FIGO1 stage, n (%)   
       Stage 1-2 5 (9.5) 0 (0) 
       Stage 3-4 48 (90.5) 12 (100) 
Histology, n (%)   
      Serous, HGSC 46 (87) 12 (100) 
      Endometroid 4 (7.5) 0 
       Papillary 2 (4) 0 
      Transitional cell 1 (1.5) 0 
Grade, n (%)   
       Low Grade 10 (19) 0 
       High Grade 43 (81) 12 (100) 
Neoadjuvant therapy, n (%) 19 (36) 5 (42) 
Recurrence, n (%) 36 (68) 10 (83) 
Death, n (%) 22 (42) 5 (42) 
 
Sensitivity defined as relapse or event-free interval > 12 months after completion of platinum based 
1st line therapy.  
NACT - neoadjuvant therapy 
FIGO - International Federation of Gynecology and Obstetrics 
4.2 Methods 
4.2.1 RNA extraction (I-III) 
For extraction of RNA, approx. 30 mg of fresh frozen ovarian cancer tissue was 
used. Extraction was performed with TRIzol reagent (Invitrogen, Carlsbad, CA, 
USA) according to the manufacturer’s protocol. The quality and integrity of the 
RNA were assessed using Fragment Analyzer parallel capillary electrophoresis 
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(Advanced Analytical Technologies, Ankeny, IA, USA) prior to microarray analysis. 
Only samples with high-quality RNA with RIN values above 8 were used for 
analyses. Samples with an RNA concentration minimum of 100 ng/pl were used for 
gene expression analysis. 
4.2.2 Microarray (I; III) 
For study I, to generate purified sense-strand cDNA (with incorporated 2´-
deoxyuridine, 5´-triphosphate, dUTP), the Ambion WT Expression Kit (Thermo 
Fischer Scientific, Waltham, MA, USA) was used. For single-stranded cDNA 
synthesis (sscDNA), 15 pg of cRNA was taken, and DNA was labeled by terminal 
deoxynucleotidyl transferase (TdT) with the Affymetrix® proprietary DNA Labeling 
Reagent. This agent was then covalently linked to biotin using the Affymetrix 
GeneChip WT Terminal Labeling Kit (Affymetrix, Santa Clara, CA). Subsequently, 
5.5 μg of sscDNA was fragmented and hybridized to the GeneChip array 
(Affymetrix Human Gene 1.0 ST Array) in cartridge format during a 17-h incubation 
at 45 °C. After hybridization, the array was washed and stained with streptavidin 
phycoerythrin conjugate using an automated protocol on a GeneChip® Fluidics 
Station 450, followed by scanning on a GeneChip® Scanner (Affymetrix Human 
Gene 1.0 ST Array). 
For study III, the Agilent gene expression microarray kit (Agilent Technologies, 
Santa Clara, CA, USA) was used for RNA extraction as described above and then 
labeled and hybridized according to the manufacturer's instruction. RNA was labeled 
with Cy3 fluorochrome and thereafter co-hybridized for 21 h in Agilent 4X44K 
human gene expression array slides, using Xpress Ref TM Human Universal 
Reference Total RNA (SuperArray Bioscience Corporation, Frederick, MD, USA) 
labeled with Cy5 as a control. The slides were scanned on an Agilent C scanner. The 
raw data obtained were then extracted using Agilent Feature Extraction software ver. 
11.0.1.1 and quantile normalized. 
4.2.3 Quantitative Real-Time PCR (qRT-PCR) (I, III) 
The validation of microarray data in both studies was performed by qRT-PCR as 
previously described (Balacescu et al., 2014).  
For study I, six genes were chosen for qRT-PCR validation based on fold change, 
signal intensity, rank in the list of differentially expressed genes and possible presence 
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in gene ontology categories. The chosen genes were KLF4, PLK, SIK1, TDP2, AQP9 
and EGR3. A total of 385 ng of RNA was reverse-transcribed using the DyNAmo 
cDNA Syndissertation Kit (Thermo Fisher Scientific, Waltham, MA, USA) 
according to the manufacturer’s instructions. The primer and probe sequences are 
as follows:  
 
 
KLF4 fwd.  CCATCTTTCTCCACGTTCG 
KLF4 rev  AGTCGCTTCATGTGGGAGAG 
PLK3 fwd.  CAGCACCTGAAGACAGCTCA 
PLK3 rev  AGAGCACAAAGGGCTGACTC 
SIK1 fwd. GGGACCTCAAGACCGAGAA 
SIK1 rev GAGGCTCTCCTGACTTGTAGAAA 
TDP2 fwd. TCGAGGGGTGTGTTCCTACT 
TDP2 rev TGGGGGAATAACTTCCTGTAGA 
AQP9 fwd. GCAACCGTCTTTGGCATTTA 
AQP9 rev TTTTCTCCCACGATCAGCA 
EGR3 fwd. CAATCTGTACCCCGAGGAGA 
EGR3 rev  CAGACCGATGTCCATTACATTC 
 
For study III, qRT-PCR validation was based on fold change, q-value, signal intensity 
and literature data. The 14 putatively differentially expressed genes were ROR2, 
GREB1, CAST, ATP6V1D, TOP1MT, TMOD1, MYCN, DLK1, PLEKHG4B, 
B4GALNT4, SLC35F3, PTCH2, TNNC1, and BNC1. mRNA of the chosen genes 
was reverse-transcribed using random hexamer primers and MultiScribe reverse 
transcriptase (Thermo Fischer Scientific, Waltham, MA, USA). Thereafter, Maxima 
SYBR Green/ROX qPCR Master Mix (Thermo Fischer Scientific, Waltham, MA, 
USA) on a BioRad CFX96 ™ Real-Time PCR Detection System (BioRad 
Laboratories, Hercules, CA, USA) was used for qRT-PCR. Each sample was run in 
duplicate. Furthermore, expression values were normalized against the TATA-
binding protein (TBP), which is a traditional housekeeping gene often used for 
normalization purposes because of its stability (Gao et al., 2019; Macabelli et al., 
2014). The primer sequences for the validated genes are detailed below: 
 
 
 
GREB1 fwd.  5’ATGGGAAATTCTTACGCTGGAC 
GREB1 rev  5’CACTCGGCTACCACCTTCT 
ROR2 fwd.  5’GTGCGGTGGCTAAAGAATGAT 
ROR2 rev  5’ATTCGCAGTCGTGAACCATATT 
CAST fwd. 5’CAAGCCGGGTGACAAGAAAAA 
CAST rev 5’CCCGATGGTTTATCCGGTTTAG 
ATP6V1D fwd. 5’AGCAGGTGTTACTTTGCCAGT 
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ATP6V1D rev 5’AGTTCCACCAGTAGTTCCACT 
TOP1MT fwd. 5’ACGAAGACGGGGTGAAGTG 
TOP1MT rev 5’CCGGAAAACCTCCTTTGTTGTG 
TMOD1 fwd. 5’ATGTCGTACAGACGAGAACTAGA 
TMOD1 rev 5’CAGTGCATTATCAGGGTCCAG 
MYCN fwd. 5’ACCCGGACGAAGATGACTTCT 
MYCN rev 5’CAGCTCGTTCTCAAGCAGCAT 
DLK1 fwd. 5’CTTTCGGCCACAGCACCTAT 
DLK1 rev 5’TGTCATCCTCGCAGAATCCAT 
PLEKHG4B fwd. 5’AAGCGGTTGGAGTTGGATGAC 
PLEKHG4B rev 5’CACGATCTGGAGCAGTAGGTG 
B4GALNT4 fwd. 5’GCTGCCACTGAACTTCACC 
B4GALNT4 rev 5’TGCGCGTATGAGGGAACAG 
SLC35F3 fwd. 5’GTGAAGCAGCGATACAGGGAA 
SLC35F3 rev 5’GCAGAACAACACGGAGACATC 
PTCH2 fwd. 5’GCTTCGTGCTTACTTCCAGGG 
PTCH2 rev 5’CATGCGGAGACCTAATGCCA 
TNNC1 fwd. 5’TGGTTCGGTGCATGAAGGAC 
TNNC1 rev 5’GTCGATGTAGCCATCAGCATT 
BNC1 fwd. 5’GCTGCAAGATCCCCTACGAAG 
BNC1 rev 5’ACGAAGAAGTGTACGAAGGGTT 
TBP fwd.  5’GAATATAATCCCAAGCGGTTTG 
TBP rev  5’ACTTCACATCACAGCTCCCC 
 
4.2.4 PARP concentration by ELISA pharmacodynamic assay (II) 
The PARP (poly(ADP-ribose)) concentration was measured using the HT PARP in 
vivo Pharmacodynamic Assay II by Trevigen (Gaithersburg, MD, USA) according 
to the manufacturer’s instructions and as described in detail in the original 
publication. Briefly, approx. 10 mg of frozen tumor tissue was homogenized and 
subsequently sonicated (Sonics, Vibra-Cell, Newtown, CT, USA). Sodium dodecyl 
sulfate (SDS) was added to the lysates to a final concentration of 1.0%, and samples 
were incubated at 100 °C for 5 min. Supernatants were collected, and equal amounts 
(approx. 3 pg) of protein lysates were analyzed in duplicate with an ELISA assay; 
PARP concentrations were quantified based on chemiluminescent signal 
measurement (Luminoskan Ascent, Thermo Fisher Scientific, MA, USA). 
Commercial protein lysate controls were included in the assay.  
4.2.5 Immunohistochemistry (II) 
In study II, PARP-1 protein expression was evaluated by immunohistochemistry 
(IHC). For this, the Department of Pathology at Tampere University Hospital 
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provided representative archival ovarian cancer samples. A standard microtome was 
used to cut the tumor sample blocks into 3-4 pm-thick sections. Subsequently, the 
slides were deparaffinized and rehydrated (in graded ethanol). Pretreatment was 
performed with a PT-Module (Lab Vision, Fremont, CA) at 98 °C for 15 min in 0.05 
M TrisHCl buffer, pH 9.0, containing 0.001 M EDTA, as described in the original 
publication. The primary PARP-1 antibody (anti-PARP-1, Cat# sc-8007; Santa Cruz 
Biotechnology, Dallas, TX) was used at a dilution of 1:5,000. Visualization of PARP-
1 was carried out with a PowerVision+ polymer kit (Leica Biosystems Newcastle 
Ltd., Newcastle, UK), and diaminobenzidine was used as a chromogen 
(DABImmPact, Vectorlabs, Burlingame, CA). Counterstaining with hematoxylin 
(Mayer’s hematoxylin, Oy FFChemicals Ab, Haukipudas, Finland) was performed, 
and slides were then dehydrated, cleared and mounted. Autostainer 480 (Lab Vision, 
Los Angeles, CA, USA) was used for staining protocols. Placenta was used for a 
positive tissue control. In each staining batch, positive and negative (primary 
antibody omitted) controls were included. An Olympus System Microscope BX43 
was used to analyze the samples; staining was assessed by two independent 
researchers. The researchers were blinded with regard to the clinico-pathological 
information of the patients and PARP concentration determined by ELISA 
pharmacodynamic assay. Semiquantitative scoring was used for PARP-1 nuclear 
staining intensity: low (negative or weak nuclear staining), intermediate (more 
pronounced or focally more intensive nuclear staining compared to the low staining 
pattern) or strong (intensive uniform nuclear staining). 
4.2.6 Western blotting (III) 
In study III, protein assessment was performed as follows: frozen tumor pieces were 
thawed, washed twice with cold PBS and incubated in lysis buffer containing 50 mM 
Tris-HCl pH 7.5, 10% glycerol, 150 mM NaCl, 1 mM EDTA, 1% Triton-x-100, 50 
mM NaF supplemented with protease and phosphatase inhibitor cocktails (Bimake, 
Houston, TX, USA). Prior to SDS-PAGE gel electrophoresis and Western blotting, 
the lysates were mixed with 4X Laemmli loading buffer. The details of the primary 
antibodies are shown below in Table 6: 
 
 
 
 
 67 
Table 6.  Primary antibodies in Western blotting. 
 
Akt S473  (#4060) 
pMEK1/2 S217/221  (#9121) 
NF-
B p65  (#6956) 
pPI3K p85 Y458/p55 Y199  (#4228) 
PI3K p85  (#13666) 
Rac-1  (#4651) 
pSTAT3 Y705  (#9145) 
STAT3  (#9139) 
Wnt5a/b  (#2530) (Cell Signaling Technology, Danvers, MA, USA) 
Akt  (#sc-5298) 
Bcl-2  (#sc-7382) 
MEK1/2  (#sc-6250) 
	-tubulin  (#sc-166729) (Santa Cruz, Dallas, TX, USA) 
ROR1 6D4  (Dr. Riddel lab) 
ROR2  (#565550) (BD Biosciences, San Jose, CA, USA) 
 
IRDye® 800CW donkey anti-mouse IgG or IRDye® 680RD donkey anti-rabbit IgG 
(LI-COR, Lincoln, NE, USA) was used as the secondary antibody. Odyssey and 
LiCor software were used for scanning and quantifying the blots. The -tubulin 
expression level was used to normalize protein expression levels in the Western blot 
assays. 
4.2.7 Cell culture (III) 
For cell line experiments, cells were purchased from Merck & Company Inc. 
(Kenilworth, NJ, USA), and the A2780 and A2780cis cell lines were cultured 
according to the manufacturer’s recommendations. Medium containing 1 μM 
cisplatin (Selleckchem, Munich, Germany) was used to maintain the A2780 line. The 
cisplatin EC50 responses of A2780 and A2780cis cells were validated by incubating 
cells with increasing concentrations of cisplatin for 3 days. CellTiterGlo (CTG) 
Assay (Promega, San Luis Obispo, CA, USA) was used to investigate cell viability. 
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Subsequently, TRI Reagent® (Molecular Research Center Inc. Cincinnati, OH, 
USA) was used to collect RNA from A2780 and A2780cis according to the 
manufacturer’s protocol, and qRT-PCR was performed as described in the original 
publication and section 4.2.3 of this dissertation. The expression of ROR2 and 
GREB1 was normalized against TBP, and each cell line was run in 4 replicates. 
4.2.8 Statistical analysis (I-III) 
In studies I and III, qRT-PCR data were analyzed using the Student’s t-test and 
Mann-Whitney U test where appropriate, and Kaplan-Meier and Cox regression 
analyses were used to estimate the survival rates from the date of surgery (PDS) or 
from the date of the first dose of NACT until the date of the event of interest. For 
PFS, the event of interest was a recurrence or death, whichever occurred first. 
Patients alive at the last follow-up without a recurrence were censored at the last 
follow-up date. Statistical analysis was performed using GraphPad Prism 6 software 
for Windows (GraphPad Software Inc., La Jolla, CA, USA) for study III and version 
22 of IBM SPSS statistics software (IBM Inc., Armonk, NY, USA) for studies I and 
II. In all studies, a p-value less than 0.05 was considered significant. For gene 
expression and survival data, the Oncomine 
(https://www.oncomine.org/resource/login.html) and Kaplan-Meier plotter 
(http://kmplot.com/analysis/index.php?p=service&cancer=ovar) databases were 
searched. 
4.2.8.1 Bioinformatics (I) 
GO Slim ontology was used for Gene Ontology (GO) enrichment analysis (Davey 
et al. 2011). GO human annotation files (ver. 6/11/2013) and experimentally 
validated interactions (EXP, IDA and IPI) were also used. To test the significance 
of the enrichment, Bonferroni correction testing was implemented. The significance 
level threshold was set at 0.05. In MATLAB® (R2012b), GO analysis was performed 
using the Bioinformatics Toolbox® functions to handle the GO structure. 
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4.2.8.2 Microarray data analysis (I, III) 
In study I, remapped gene annotations from the Brainarray Custom CDF files 
(HuGene10stv1_Hs_ENSG, v.14.1.0) (Gentleman et al., 2004) were used for 
GeneChip® signal intensity processing with robust multiarray analysis. Simpleaffy, 
limma, BioMart, and qvalue packages of the Bioconductor project (Storey and 
Tibshirani, 2003; Gentleman et al., 2004; Smyth, 2004; Durinck et al., 2005; Wilson 
and Miller, 2005) were used for analysis that was implemented in R (the R project 
for Statistical Computing). Differential expression significance was assessed using 
the empirical Bayes moderated paired t-statistics followed by p-value adjustment 
with the FDR (false discovery rate) approach (Smyth, 2004). Before statistical testing, 
arrays were quality weighted (Ritchie et al., 2006). Differentially expressed genes were 
considered to be genes with FDR-corrected P-values  0.05. Hierarchical clustering 
(HC) and principal component analysis (PCA) were used for data visualization in 
MATLAB® (R2012b). The raw gene expression data have been uploaded into the 
GEO website (http://www.ncbi.nlm.nih.gov/geo/). 
In study III, implementation in R using the packages limma and preprocess Core 
of Bioconductor project (Gentleman et al., 2004b; Bolstad et al., 2003; Smyth, 2004) 
was performed for the statistical analysis of mRNA microarray data. The probes with 
the highest average expression were chosen, and the data were quantile-normalized 
(Bolstad et al., 2003). Differential expression was identified between patients who 
had low PARP value/platinum resistance and patients who had high 
PARP/platinum sensitivity using the limma approach (Smyth, 2004). The empirical 
Bayes moderated t-test was used to obtain P-values. To determine differential 
mRNA expression, a fold-change cutoff of 2 was used. Principal component analysis 
and hierarchical clustering were used to interpret the results (Mardia et al., 1992). 
4.3 Ethical aspects (I-III) 
In conducting the studies, the Declaration of Helsinki was followed. The protocols 
of studies I-III were approved by the Pirkanmaa Hospital District Ethics Committee. 
All study and control patients provided informed consent to express their willingness 
to participate in the study. Prior to consenting, patients had received a written patient 
information leaflet, and they had sufficient time to read it and an opportunity to ask 
additional questions regarding the study. The patients were informed in accordance 
with TENK guidelines (http://www.tenk.fi/fi/tenkin-ohjeistot) that at any point of 
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time they can withdraw their consent. Patients were also informed that participation 
in the study does not affect the treatment of their medical condition, nor would study 
participation subject the patients to any additional intervention. 
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5 RESULTS 
5.1 Differentially expressed genes in samples from RRSO (I) 
5.1.1 Expression array 
A total of 454 transcripts were identified from 22,733 genes (all ovarian and 
Fallopian tube samples were pooled together) as differentially expressed in samples 
from BRCA1/2 mutation carriers relative to controls. Two hundred ninety-nine 
genes were downregulated, and 155 genes were upregulated; the 20 most down- and 
upregulated genes are presented in Table 7. In addition, when only BRCA1/2-
mutation-positive Fallopian tube samples were compared with controls, 148 
transcripts were expressed differentially. Of these, 34 genes were upregulated, and 
114 were downregulated.  
Unsupervised clustering was used to analyze global gene expression patterns. This 
analysis separated ovarian and Fallopian tube samples from each other as expected 
and, furthermore, controls from BRCA mutation carriers. Interestingly, BRCA1/2-
mutation-positive samples mostly grouped together regardless of personal history of 
breast cancer. The results of unsupervised clustering are visualized in Figure 8.  
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Table 7.  The 20 Most Up- and Downregulated Genes in BRCA1/2 Ovarian and Fallopian Tube 
RRSO* Samples. 
 
Gene name Gene description Fold 
change 
P-
value 
Gene 
name 
Gene description Fold 
change 
P-value 
U4 U4 small nuclear RNA  3,21 0,011 MIR22HG MIR22 host gene -3,55 0,005 
NIPAL3 NIPA-like domain 
containing 3 family 
members 
2,65 0,027 KLF4 Kruppel-like factor 4 -3,6 0,0004 
AQP9 Aquaporin 9  2,22 0,046 HBEGF Heparin-binding EGF-
like growth factor 
-3,72 0,003 
PLAG1 Pleiomorphic adenoma 
gene 1 
2,1 0,028 ATP1B3 ATPase, Na+/K+ 
transporting, beta 3 
polypeptide 
-3,83 0,003 
RPS26P3 Ribosomal protein S26 
pseudogene 3 
2,09 0,046 MT1A Metallothionein 1A -3,84 0,005 
C5orf54 Chromosome 5 open 
reading frame 54 
2,08 0,014 ZNF331 Zinc finger protein 33 -3,86 0,005 
SLC9A11 Solute carrier family 9, 
member 11 
1,99 0,035 SLC2A3 Solute carrier family 2 -3,89 0,001 
CCL28 Chemokine (C-C motif) 
ligand 28 
1,85 0,008 NR4A1 A member of nuclear 
receptor family, 
involved in cell death 
-3,98 0,005 
KRT8 Keratin 8 1,84 0,049 MT1M Metallothionein 1M -4,02 0,013 
ZNF772 Zinc finger protein 772 1,77 0,007 CYR61 Cysteine-rich, 
angiogenic inducer, 61 
-4,09 0,039 
ZNF232 Zinc finger protein 232 1,73 0,005 CSRNP1 Cysteine-serine-rich 
nuclear protein 1 
-4,09 0,001 
GALM Galactose mutarotase 1,71 0,031 ZFP36 Zinc finger protein 36 -4,14 0,003 
SCARNA15 Small Cajal body-
specific RNA 1 
1,69 0,046 NR4A2 NR4A2 nuclear 
receptor subfamily 4, 
group A, member 2 
-4,5 0,012 
WDR5B WD repeat domain 5B 1,66 0,01 SOCS3 Suppressor of cytokine 
signaling 3  
-4,58 0,0004 
P2RY13 Purinergic receptor 
P2Y, G-protein 
coupled, 13 
1,66 0,015 ADAMTS4 ADAM 
metallopeptidase with 
thrombospondin type 1 
motif 
-4,85 0,0008 
THNSL2 Threonine synthase-like 
2 (S. Cerevisiae)  
1,65 0,0104 CXCL2 Chemokine (C-X-C 
motif) ligand 2 
-4,87 0,003 
DPY19L2P Dpy-19-like 2 
pseudogene 2 (C. 
elegans) 
1,65 0,015 SIK1 Salt-inducible kinase1  -4,93 0,001 
Y_RNA Y RNA 1,63 0,046 NR4A3 Nuclear receptor 
subfamily 4, group A, 
member 3 
-5 0,003 
DENND2D DENN/MADD, a 
signaling protein that 
has multiple functions 
1,62 0,041 EGR3 Early growth response 
3 
-5,43 0,003 
MCTP2 Multiple C2 domains, 
transmembrane 2 
1,57 0,046 FOSB FBJ murine 
osteosarcoma viral 
oncogene homolog B 
-7,31 0,002 
*RRSO, Risk-reducing salpingo-oophorectomy 
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Figure 8.  Scatterplot showing location of samples (control, BRCA1 and BRCA2 ovarian and 
Fallopian tube) along the first two principal components (PC1 and PC2). Squares: ovarian 
samples; dots: Fallopian tube samples. Black: control samples, bright and dark red: 
samples from BRCA1 mutation carriers with or without a personal history of breast cancer, 
respectively.  Cyan and blue color: samples from BRCA2 mutation carriers with or without 
a personal history of breast cancer, respectively. 
 
5.1.2 qRT-PCR 
KLF4, PLK, SIK1, TDP2, AQP9 and EGR3, the six differentially expressed genes in 
the microarray analysis, were selected for validation by qRT-PCR in the following 10 
samples: 4 BRCA1/2-mutation positive, 3 control, and in 3 HGSC samples. As a 
result, the genes showed similar expression patterns in the qRT-PCR validation as 
those in the original microarray, which further validates the microarray results as 
intended. Comparable patterns of expression were observed in five out of six genes 
in BRCA1/2-mutation-positive RRSO and HGSC samples. qRT-PCR analyses are 
summarized in Table 8. 
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Table 8.  Differentially expressed genes selected for validation by quantitative RT-PCR in 
BRCA1/2 RRSO, serous ovarian carcinoma and control samples. 
 
Gene Expression in 
BRCA1/2 ovarian 
and Fallopian tube 
samples (n=4)1 
Expression in 
serous ovarian 
carcinoma 
samples (n=3)1 
Expression in 
original array 
KLF4a 0.48 0.26 3.4x downregulation 
PLK3b 0.69 1.28 2.0x downregulation 
SIK1c 0.16 0.07 4.9x downregulation 
TDP2d 1.83 2.23 1.5x upregulation 
AQP9e 6.32 2.12 2.2x upregulation 
EGR3f 0.12 0.08 5.4x downregulation 
 
1 Samples from normal ovarian and Fallopian tube tissue from mutation-negative patients (n=4); in 
quantitative RT-PCR analyses relative expression levels of selected genes in the control samples was 
set to 1.00 to which gene expression in BRCA1/2 RRSO and serous ovarian cancer samples was then 
compared. 
a Kruppel-like factor 4 
b Polo-like kinase 3 
c Salt-inducible kinase 1 
d Tyrosyl DNA phosphodiesterase-2 
e Aqua-glyceroporins 9 
f Early growth response 3. 
GO=gene ontology; RRSO= Risk-reducing salpingo-oophorectomy 
5.1.3 Gene ontology enrichment analysis 
To identify biological processes in which the identified differentially expressed genes 
are involved, GO enrichment analysis was performed. A significant p-value was 
observed for ten different GO terms, and these are summarized in Figure 9. In 
addition, ten enriched biological processes were identified when one hundred 
overlapping differentially expressed genes were analyzed from ovarian and Fallopian 
tube versus control samples and Fallopian tube versus control samples (Figure 9). 
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Figure 9.  Enriched biological processes in differentially expressed genes shared between ovarian 
and Fallopian tube versus control samples and Fallopian tube versus control samples. 
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5.2 PARP expression (II) 
5.2.1 PARP concentration by ELISA pharmacodynamic assay  
In 51 out of 57 study tumors, PARP levels were measurable (89%) and ranged 
between 0.67- 1024.68 pg/ml. The median and mean values were 203 and 311.1 (SD 
292.1) pg/ml. Corresponding to the median value, the high PARP activity cut-off 
level was set to 203 pg/ml.  
As a main result, we found that a high PARP concentration was associated with 
platinum sensitivity in the entire study cohort (p=0.022), and this result was 
prominent in the high-grade subgroup (p=0.017). However, low levels of PARP 
concentration were associated with NACT (p=0.014).  
5.2.2 PARP-1 immunohistochemistry 
Fifty-six representative tumor blocks were available for PARP-1 staining analyses. 
Half (or 28) of the samples showed low/moderate PARP nuclear staining. In turn, 
another half showed strong staining. PARP concentration determined by 
pharmacodynamic assay was not associated with IHC PARP-1 staining. Low PARP-
1 IHC staining was associated with normalized serum CA12-5 levels after three 
cycles of platinum-based chemotherapy (p=0.027).   
5.2.3 Survival analyses 
Longer PFS was associated with a high PARP concentration when compared to a 
low concentration (32 vs 14 months, respectively, log-rank p=0.009; Figure 10a). A 
low PARP concentration was associated with an increased risk of recurrence both in 
univariate (HR 2.4; 95% CI 1.204-4.797) and multivariate analyses using Cox 
regression. There was no association with increased risk of death (HR 1.12; 95% CI 
0.455-2.764).  
Additionally, a trend for the association of longer PFS with low PARP-1 by IHC 
was detected (32 vs 15 months, log-rank p=0.061; Figure 10b). However, low PARP-
1 IHC was not associated with decreased risk of recurrence in multivariate Cox 
regression analysis. There was also no association with low PARP-1 IHC staining 
and overall survival (HR 0.724; 95% CI 0.307-1.708). 
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Figure 10. a. Kaplan-Meier analysis of progression-free survival (PFS) according to median level of 
PARP concentration (log-rank p =0.009). The cut-off level for high PARP concentration 
was set to 203 pg/ml (median value of PARP concentration). Vertical lines represent 
censored patients. 
b. Kaplan-Meier analysis of progression-free survival (PFS) according to PARP-1 
immunohistochemistry staining (log-rank p =0.061). Vertical lines represent censored 
patients. 
 
5.3 Gene expression analyses (III) 
5.3.1 Microarray analysis of a subgroup of HGSC patient samples based 
on platinum sensitivity and PARP activity 
To evaluate gene expression in HGSC samples targeting the genes possibly 
associated with chemoresistance, a subgroup of samples with platinum sensitivity 
and high PARP activity (defined in the analyses of study II) was compared to samples 
with platinum resistance and low PARP activity (n=12). The genome-wide 
microarray analysis revealed a total of 3,001 differentially expressed genes between 
the two comparison groups when a log fold change cut-off of 2 was implemented. 
Altogether, 1463 downregulated genes and 1538 upregulated genes were identified. 
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5.3.2 Differential expression of ROR2 and GREB1 
Fourteen differentially expressed mRNAs identified in the microarray analysis 
(ROR2, CAST, ATP6V1D, GUCY1A3, TMOD1, MYCN, DLK1, PLEKHG4B, 
GREB1, B4GALNT4, SLC35F3, PTCH2, TNNC1, BNC1) were selected for 
validation by qRT-PCR in the original cohort of 53 ovarian cancer patients. qRT-
PCR validation confirmed two differentially expressed genes: ROR2 and GREB1. 
These two genes were differentially expressed in high PARP/platinum-sensitive vs 
low PARP/platinum-resistant group of EOC samples (for ROR2 p=0.02 and for 
GREB1 p=0.002). In high PARP/platinum-sensitive tumor samples, ROR2 was 
downregulated, and GREB1 was upregulated.   
5.3.3 Analyses of ROR2 signaling pathway 
To further investigate ROR2 expression in the setting of low PARP 
activity/platinum-resistance, the protein expression levels of Wnt5a (ROR1 and 
ROR2 ligand), ROR1 and ROR2 were examined by Western blot in a subcohort of 
samples (n=30) that were chemonaïve (only cases with PDS were included). In the 
low PARP/platinum-resistant subgroup, Wnt5a, the ROR1 and ROR2 proteins had 
higher expression levels. In addition, downstream signaling mediators such as 
pSTAT3 (Y705) and NF-kB were also upregulated in the tumor samples with 
platinum resistance. 
5.3.4 ROR2 and GREB1 expression in cisplatin-resistant cell line model 
The A2780 and cisplatin-resistant A2780cis ovarian cancer cell lines were chosen to 
further investigate the expression levels of ROR2 and GREB1. Cisplatin resistance 
of A2780cis cells compared to that of A2780 parental cells was confirmed by CTG 
assay. ROR2 mRNA upregulation in the platinum-resistant A2780cis cell line 
compared to the platinum-sensitive A2780 cell line was observed (p=0.0046; Figure 
11). In addition, GREB1 mRNA levels were downregulated in A2780cis relative to 
A2780 parental cells (p=0.0012; Figure 11). 
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Figure 11. ROR2 and GREB1 mRNA expression in platinum sensitive and resistant cell lines. 
 
5.3.5 Survival analyses with respect to GREB1 and ROR expression 
Association of GREB1 expression with patient survival was analyzed in the original 
cohort of 53 ovarian cancer patients. High GREB1 expression was associated with 
longer PFS (p = 0.019 in log-rank test; Figure 12). Furthermore, a database search 
was performed in the online Kaplan-Meier plotter database. The online database 
included data from 1465 ovarian cancer patients and showed a similar result, with 
high GREB1 expression associating with a longer PFS (log-rank p=0.014). ROR2 
expression levels had no association with patient survival in the original patient 
cohort. Additionally, no overall or progression-free survival data were available in 
the online Oncomine or Kaplan-Meier plotter databases with respect to ROR1/2 
expression in EOC.  
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Figure 12. Progression free survival according to median level of GREB1 concentration (log rank p= 
0.019). Vertical lines represent censored patients. 
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6 DISCUSSION 
6.1 BRCA-mutated RRSO cohort vs healthy women (I) 
 
Genome-wide investigations in BRCA1/2 mutation carriers from RRSO samples 
remain scarce (Tone et al., 2008;  George et al., 2011; Press et al., 2010). BRCA 
mutation carriers’ RRSO histopathology reports have been published, underlining 
the importance of timely procedures in terms of preventing OC (Lee et al., 2017) 
(Zakhour et al., 2016). Investigation of the Fallopian tube tissue from BRCA 
mutation carriers might reveal insight into the early phases of tumor development. 
This was the hypothesis for the first study in this dissertation.  
To investigate the early pathogenetic events in EOC development, the genome-
wide gene expression levels in RRSO samples derived from BRCA1/2 mutation 
carriers were studied and compared to those of healthy controls. The microarray 
assay yielded a variety of differentially expressed genes, which were then evaluated 
based on their presence in one or more GO categories, and six genes were then 
chosen for further validation: KLF4, PLK3, SIK1, TDP2, AQP9, and EGR3. The 
validation was carried out in HGSC samples that were selected for their positive 
BRCAness phenotype (Konstantinopoulos et al., 2010).  
In detail, the validation results were comparable to the initial microarray 
expression of all other genes except PLK3. This suggests that KLF4, SIK1, TDP2, 
AQP9, and EGR3 may play roles in ovarian carcinogenesis. The PLK3 expression 
discrepancy suggests that perhaps it is not involved in the early pathogenesis of OC, 
although either overexpression or downregulation of PLK proteins occurs 
frequently in various cancer types (prostate, breast, leukemia, lung) (Maniswami et 
al., 2018; Archambault et al., 2015).  
TDP2 was found to be upregulated in the microarray assay and validation analysis. 
TDP2 is a DNA-repairing phosphodiesterase that acts by excising topoisomerase II- 
and potentially also topoisomerase III-DNA adducts. It is also involved in signal 
transduction (under the former names of TTRAP or EAPII) (Pommier et al., 
2014). Additionally, TDP2 suppresses chromosome translocations from DSBs 
introduced during gene transcription (Gómez-Herreros et al., 2017). The regulation 
 82 
of TDP2 activity by posttranslational modifications in DNA repair remains unclear 
(Bian et al., 2016). It has not been previously associated with ovarian cancer.  
Furthermore, EGR3 (early growth response 3) regulates signal transduction, cell 
growth, and proliferation (Patwardhan et al., 1991) (Blok et al., 1995). In our study, 
EGR3 was the second most downregulated gene in the expression array and 
concordantly was also downregulated in HGSC samples, suggesting a potential role 
as a tumor suppressor, a finding not published previously. A cancer association has 
been made in other tumor types: cutaneous squamous cell carcinoma (Wei et al., 
2018), leukemia (R. Li et al., 2017) and nonsmall-cell lung cancer, among others 
(Chien et al., 2017). The mechanism of EGR3 function in tumor development is 
through the JAK-STAT signaling pathway, affecting the expression of SOCS3 
(suppressor of cytokine signaling 3, also downregulated in our array), a negative 
regulator in this pathway. Its aberrant function is possibly associated with tumor 
growth (Inagaki-Ohara et al., 2013).  
Another validated gene was KLF4, a gene belonging to the Krüppel-like factors 
(KLFs), which are a family of DNA-binding transcriptional factors linked by a triple 
zinc finger DNA-binding domain modulating diverse and essential functions in 
multiple cellular processes, including differentiation, proliferation, migration, 
pluripotency and inflammation (Tetreault et al., 2013; Jiang et al., 2008). KLF4 can 
both activate and repress transcription, depending on the contents of target 
promoters (Zhang et al., 2000), and additionally, KLF4 functions as an oncogene or 
a tumor suppressor depending on the type of cancer: in intestinal epithelium it acts 
as a suppressor, and in skin, larynx and breast, it acts an oncogene (Evans and Liu, 
2008). It has also been discovered that PARP1 is a KLF4-interacting partner: in 
cancer and stem cells PARP1 recruits KLF4 to activate telomerase expression and 
stem cell pluripotency, indicating a positive regulatory role (Hsieh et al., 2017). 
It has been previously shown that that KLF4 functions as a tumor suppressor 
gene in OC by inhibiting TGF	-induced epithelial-to-mesenchymal transition (Chen 
et al., 2014). Epithelial-to-mesenchymal transition greatly facilitates the spread 
of cancer cells and is characterized by the loss of epithelial markers and the 
acquisition of mesenchymal markers, thus making the cells more migratory and 
invasive (Zhang et al., 2018). KLF4 depletion modulates OC cells towards being 
more migratory and invasive. KLF4 has also been hypothesized being a driver in 
cisplatin resistance in the setting of EOC cell line model (Lund et al., 2017). 
However, a result stating the opposite has also been published – in another OC cell 
line model, KLF4 expression was found to enhance the efficacy of chemotherapy 
drugs and the authors proposed that inducing KLF4 expression with APTO-253 
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might be a novel therapeutic strategy for treating OC (Wang et al., 2017). Further 
studies are needed to clarify the role of KLF4 in EOC. 
The SIK1 gene was also downregulated. The salt-inducible kinases (SIKs) 
represent a subfamily of AMP-activated protein kinase (AMPK) family kinases; the 
major biological role of these kinases is to control gene expression in response to 
extracellular cues that increase intracellular levels of cAMP (Wein et al., 2018). In 
terms of carcinogenesis, reduced SIK1 expression is correlated with poor prognosis 
in two large human breast cancer datasets (Shaw, 2009). SIK1 suppresses metastasis 
p53-dependently (Cheng et al., 2009). SIK1 also has been suggested to act as a novel 
biomarker and therapeutic target for lung cancer (Yang et al., 2018). In OC, SIK1, 
which is also known as MSK/SIK/SNF1LK, has been shown to be downregulated 
and its expression regulated by miR-141 (Chen et al., 2016). In another study, 
enhancement of LKB1-SIK1 suppressed the growth and aggressiveness of clinical 
sample OC cells, leading to an inhibition of metastatic potential (Hong et al., 2018). 
The findings published previously and presented here strongly suggest a role in OC, 
although more detailed understanding is impossible without further investigations. 
AQP9 belongs to the aquaporins, which are transmembrane water channel 
proteins involved in transport of fluid, transcellular water movement and cell 
migration (Ribatti et al., 2014). In this study, AQP9 was upregulated. AQP9 has 
previously been associated with several cancers, such as hepatocellular (through 
FOXO1 expression upregulation) and prostate cancer (through ERK pathway) (Li 
et al., 2016; Q. Chen et al., 2016). According to previous data, aquaporin expression 
in tumor cells and vessels facilitates tumor growth and spread, suggesting a 
possibility for an antitumor therapy (Verkman et al., 2008). In OC, previous studies 
have demonstrated that there is significantly higher AQP7 and AQP9 protein 
expression in malignant and borderline tumors than in benign tumor and 
normal ovarian tissue (Yang et al., 2011). Additionally, in this study, the 
AQP9 expression level was positively and significantly correlated with tumor grade 
and histological type. Other aquaporins from the AQP family members have been 
associated with varied prognostic properties and drug sensitivity regulation in OC 
(Chen et al., 2015; Chetry et al., 2018).  
The study aimed to uncover genes possibly involved in the early pathogenesis of 
EOC. Some of the genes found to be associated with ovarian cancer have been 
indicated previously, such as AQP9, SIK1 and KLF4. TDP2 and EGR3 have not 
been previously associated with OC and thus represent a novel finding. It would be 
of interest to further investigate these genes in OC cell line models, as well as larger 
cohorts of OC patient-derived samples. Previous RRSO studies in BRCA mutation 
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carriers have also revealed interesting genes possibly associated with OC, although 
the results are somewhat conflicting. A study from 2008 found DAB2 and SKIL 
were differentially expressed (Tone et al., 2008), whereas a study from 2010 found 
CDKN1C and EFEMP1 were differentially expressed (Press et al., 2010). Another 
RRSO study revealed 440 differentially expressed genes and abrogated pathways 
(George et al., 2011). None of the results in this study overlap with these previous 
findings, indicating the heterogeneity of different alterations involved. The 
differences in the studies may be due to several factors such as the use of different 
microarray method, methodological differences related to sample collection as well 
as the sample cohort size. Thus, the importance of validation in larger sample 
collections is underlined in order to separate meaningful findings from random 
occurrences. However, the genes described in the study presented here might indeed 
have a role in the pathogenesis of EOC and thus serve as interesting targets for 
future studies.  
6.2 PARP in HGSC (II) 
As mentioned in the Review of the Literature, the treatment of OC has been changed 
in recent years by the introduction of PARP inhibitors. PARPi is an effective targeted 
treatment with broadening indications and is transforming the care of HGSC 
patients. 
Because PARPi have been proven to be especially efficient in platinum-sensitive, 
BRCA-mutated or otherwise HRD disease, the current study was designed to 
evaluate PARP protein in paraffin-embedded blocks and, more importantly, to 
measure the activity of PARP in OC tissue in correlation with platinum sensitivity. 
As a result, platinum sensitivity was associated with high PARP concentration in the 
entire study cohort and especially in the high-grade subgroup. With regard to 
survival, a high PARP concentration was associated with longer PFS and low PARP 
with an increased risk of recurrence. These are novel results not previously described 
in an EOC setting. To my knowledge, PARP activity has not been measured by 
pharmacodynamic assay in an OC setting from patient samples. 
Platinum sensitivity serves as a marker for the BRCAness profile, and although 
BRCA mutation status was not available for the patients participating in this study, 
it can be argued that the patients with platinum sensitivity and favorable prognosis 
befit the BRCAness profile (Tan et al., 2008). This was considered when interpreting 
the results. The high-grade and platinum-sensitive subgroup association with PARP 
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activity is in line with this theory as well as the difference in progression-free survival 
between high PARP expression vs low PARP. 
Interestingly, in this study, low PARP was associated with NACT, which may be 
the result of NACT affecting tumors by exploiting PARP. A possible explanation 
may also be NACT’s effect on tumor biology, inducing alterations leading to 
diminished PARP activity. Both remain speculations, as there were no sequential 
samples available for NACT-treated patients.  
In previous studies, the preferential use of repair mechanisms in the absence of 
HR often leads to DNA alterations, including deletions of genetic material (Lord and 
Ashworth, 2017), and through these alterations, NACT’s negative effect on platinum 
response has been proposed (Sato and Itamochi, 2014). In an in vitro study, platinum 
resistance was common after NACT (Matsuo et al., 2010). In a retrospective study 
involving 341 patients, it was found that NACT may increase the risk of platinum 
resistance in stage IIIC and IV EOC (Luo et al., 2016). It must be stated, however, 
that prospective data on the matter are currently unavailable. Some biomarkers have 
been proposed: tumor necrosis factor -induced protein 8 (TNFAIP8) may be 
involved via autophagy-related proteins (J. Wang et al., 2018). In another 
study, NACT and subsequent relapse and resistance were associated with the highest 
basal expression of HGF and c-Met, mediated by mir-193a-5p (Mariani et al., 2014), 
proposing that inhibitors of this pathway may improve the efficacy of NACT. The 
effect of NACT on tumor biology remains an interesting target for research. 
In terms of ICH findings, PARP ICH and PARP activity did not correlate. PARP-
1 has been assessed by IHC in an OC setting and has been found to be 
overexpressed, possibly enhancing angiogenesis by upregulating VEGF (W. Wei et 
al., 2016). On the other hand, a study from 2017 found no correlation between PARP 
IHC staining and the outcome (Hjortkjær et al., 2017). PARP expression 
measurement attempts have been made with different modalities, with a recent study 
incorporating radiotracer [18F]FluorThanatrace ([18F]FTT) as a marker 
of PARP expression in vitro to show the correlation of PARP-1 expression with 
response to PARPi treatment (Sander Effron et al., 2017). The result would need to 
be tested in patients’ samples but is certainly promising. In clinical samples, PARP-
1 overexpression was found in clear-cell and endometrioid carcinomas associating 
with early recurrence and worse OS (Barreta et al., 2018). These results are the 
opposite of the results presented in this study, although it must be noted that the 
focus of the current study was HGSC, which may in part explain the inconsistency. 
Due to poor reproducibility among other studies (no clear evidence related to 
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prognosis and effect on treatment), to date, PARP-1 expression is not routinely 
tested in the setting of OC. 
The current study clarified that PARP IHC does not provide a clinical tool for 
assessment of PARP activity. PARP activity measured in fresh frozen tumor samples 
provides a more precise result in terms of PARP activity but is difficult and costly to 
obtain. The study described here did give new insight into interactions between 
platinum sensitivity, favorable prognosis and PARP activity.  
6.3 Expression analysis in HGSC (III) 
Acquired chemoresistance and its underlying mechanisms are discussed in detail in 
chapter 2.3.4 of this thesis. Keen efforts on the front of database research have been 
made to provide additional insight into chemoresistance in OC, in addition to basic 
mechanism and pathway-orientated research. Among others, dataset analysis has 
been deployed with the TCGA OC dataset, which was imputed with patient tumor 
responses to over 100 different drugs and of these, five drugs (ABT-888, BIBW2992, 
gefitinib, AZD6244 and lenalidomide) identified as potentially improving the clinical 
outcome of chemoresistant OC (Wang et al., 2017). These large-scale genomic 
database studies do enhance the understanding of basic molecular events in the 
tumorigenesis and chemoresistance of OC (Krzystyniak et al., 2016). However, this 
approach needs more elaborate testing and validation in vivo. 
Although multiple mechanisms and approaches have been investigated, specific 
targeted treatment has not yet been introduced to clinical practice. There is also no 
prognostic marker available for chemoresistance testing that could be used in clinical 
work and patient assessment in order to avoid needless therapy.  
To investigate some of the molecular mechanisms involved in OC 
chemoresistance, gene expression analysis of HGSC patient samples was assessed by 
microarray, qRT-PCR and Western blotting and OC cell line analyses. The sample 
cohorts were retrospective and specifically selected, taking into consideration also 
the results from study II involving PARP activity and platinum sensitivity. 
Specifically, the aim was to select groups representing on one hand a platinum-
sensitive, high PARP activity, favorable prognosis group befitting the BRCAness 
profile and on the other hand, a low PARP activity, platinum-resistant, poor 
prognosis group. In addition, two other groups were formed – one with high PARP 
activity and platinum-resistant patients and the other with low PARP activity and 
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platinum sensitivity. These selections were made to maximize the data to be 
extracted from a relatively small sample size with special interest in chemoresistance. 
As a result, ROR2 was found to be downregulated in the microarray and 
validation analyses, and the results were further underlined by protein expression 
profiling. In addition, the levels of ROR2 (and STAT3, NF-kB and Wnt5a that are 
parts of the affected pathway) were increased in OC A2780cis cells in comparison 
to the parental cell line, A2780.  
ROR2 is a receptor that is part of the noncanonical Wnt pathway (Katoh, 2005). 
Wnt signals either stabilize 	-catenin in the nucleus (canonical/	-catenin-dependent) 
or elicit alternative routes of intracellular signaling independent of 	-catenin 
stabilization (noncanonical/	-catenin-independent) (Roarty et al., 2017; Angers and 
Moon, 2009). Regulation of organized cellular movements, cell shape and the 
orientation of proper cell polarity are all transduced through noncanonical Wnt 
signals (van Amerongen, 2012). The Wnt pathway has been carefully studied and its 
parts identified (Klaus and Birchmeier, 2008). Wnt signaling and the role of ROR2 
have been investigated in cancer and found to be present in several cancers as well 
as other diseases (Sumithra et al., 2016). More specifically, hereditary 
colorectal cancer, exudative vitreoretinopathy, bone diseases, and intellectual 
disability syndrome can be caused by germline mutations in Wnt signaling molecules 
(Katoh and Katoh, 2017). In OC, ROR2 has been shown to have a role in stromal 
activation and metastasis development through cell adhesion and migration 
mechanisms (Henry et al., 2017). ROR2 has also been demonstrated to play a role in 
chemoresistance by altering cell migration and invasion mechanisms (Henry et al., 
2016). In the same study, it was proposed that ROR knockdown could sensitize OC 
cells to cisplatin and thus provide an option for treatment. This result, however, 
needs to be validated in other models to further investigate its attractiveness.  
In the current study, ROR2 gene expression was upregulated in platinum-resistant 
samples. The results are in concordance with previous results suggesting that this 
pathway could be involved in platinum resistance development. There is prior 
evidence that Wnt5a is involved in chemotherapy resistance in bladder and breast 
cancers (Cao et al., 2018; Zeng et al., 2016), although through differently mediated 
mechanisms that do not involve ROR receptors. There is also evidence that parts of 
the pathway, namely, STAT3, have a role in chemoresistance development in the 
OC setting. To be more specific, STAT3 is hyperactivated in OC spheroids, and 
targeting STAT3 in combination with paclitaxel reduces peritoneal seeding and 
prolongs survival in a murine model of OC. (Chen et al., 2017). The active role of 
the Wnt pathway in OC has thus been established, and a possibility for targeted 
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treatment has been underlined (Arend et al., 2013); our results offer further support 
to these prior investigations. 
GREB1 was upregulated in the microarray data in the high PARP and platinum-
sensitive patient group, and the result was validated by qRT-PCR. High expression 
of GREB1 was associated with better survival (longer PFS). 
GREB1 is a chromatin-bound ER coactivator and is essential for ER-mediated 
transcription by stabilizing interactions between ER and additional cofactors 
(Mohammed et al., 2013). GREB1 was identified in a breast cancer cell line MCF7 
as a hormone-responsive gene (Ghosh et al., 2000). In BC, the role of GREB1 has 
been investigated (Cheng et al., 2018). GREB1 has been shown to be upregulated in 
breast cancer tissues, and the high expression level of GREB1 has been associated 
with the high grade and TNM stage of breast cancer (Ding et al., 2018). 
In the OC setting, data have suggested that 86% of EOCs are ER-positive (Shen 
et al., 2017). Furthermore, estrogen can stimulate the proliferation of ER-positive 
OC cell lines (Langdon et al., 1994). GREB1 was expressed in 75–85% of EOC cells 
in OC tissue microarray analysis (Hodgkinson et al., 2018). It has been demonstrated 
in a transgenic mouse model of poorly differentiated EOC that exogenous E2 
accelerates ovarian tumor initiation by causing precancerous lesions in the ovarian 
surface epithelium (Laviolette et al., 2010). Additionally, GREB1 has been identified 
in this setting, again in a mouse model, as a moderator in this reaction, and the 
knockdown of GREB1 decreased their proliferation rate in vitro and increased 
survival time in mice engrafted with the cells (Laviolette et al., 2014). In our study, 
that finding is supported in EOC tumor samples with regard to better survival and 
upregulation of GREB1 in the platinum-sensitive and high PARP patient group that 
has a more favorable prognosis. Further investigations into hormone receptors and 
their regulation in association with GREB1 are warranted to uncover potential 
targets for therapeutics. 
The aim of this study was to identify candidate genes and their respective 
molecular pathways involved in the pathogenesis and chemoresistance of HGSC. 
This is a subject extensively researched in the setting of OC, and although promising 
avenues of research have been opened up, a targeted treatment in clinical practice 
remains elusive to date. The results of this study investigating Wnt5a and ROR2 
expression and their association with the development of platinum resistance do 
provide some additional insight into this field of research. Importantly, since ROR1 
and ROR2 silencing restores the chemosensitivity of platinum-resistant OC cells 
(Henry et al., 2016), ROR might have the potential to influence and overturn that 
effect as a therapeutic agent. In addition, GREB1 expression was for the first time 
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described in EOC tumor samples with an effect on survival. These findings provide 
possibilities for future investigations in terms of possible treatment options. 
6.4 Limitations and advantages 
There are some limitations to the research depicted in this thesis. In detail, the first 
publication unarguably has a small sample size. However, it must be pointed out that 
BRCA-mutation positive RRSO samples are difficult to collect. Although genetic 
testing for BRCA 1/2 mutations has been available since 1996, only recently has 
more vigorous testing of BRCA mutations has been deployed in clinical work. 
Regardless, the mutations are quite rare, even if tested more often and that impacts 
significantly the speed and effectiveness of sample collection. 
To further discuss the limitations, it must be noted that the BRCA status of the 
control samples is unverified, although it is very unlikely they harbor the mutation. 
In addition, tissue microdissection was not undertaken at the time of sample 
collection, and the results are thus limited in terms of cell collection precision. 
However, it must be noted that while physical cell separation techniques (i.e., 
microdissection) can enhance the sample collection and results derived, they are also 
costly, labor-intensive and might limit investigation of interactions between different 
cell types (Liebner et al., 2014). RNA extraction was performed from tissue 
containing both stromal and epithelial ovarian cells, doubtless impacting the results. 
To discuss the techniques used, the microarray technique has been useful for 
assigning functions to previously annotated genes as well as for grouping genes into 
pathways (DeRisi et al., 1996). Concerns over the reliability of the technology have 
been raised, since contradictory results have been published using same RNA 
samples but different platforms (MAQC Consortium et al., 2006). This issue has 
been addressed in the ovarian cancer setting, and microarray quality control analysis 
has been performed. It demonstrated that 40% of the microarray files were false-
negative and that 70% of the significantly expressed genes were correlated in separate 
analyses (Villegas-Ruiz et al., 2016). To address this, the Bioconductor package was 
used to ensure quality control (Kauffmann et al., 2009).  
As an advantage, bioinformatics tools were used to group the large amount of 
data provided by microarray assay and thus the information retrieval possibilities 
were maximized. Furthermore, the patient cohort in the first study benefitted from 
harboring clearly identified BRCA mutations. In addition, it must be emphasized 
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that the study was designed as a hypothesis-generating exploration, serving as a 
means to provide candidates for further studies.  
The second study in this thesis has a prospective sample cohort, which is an 
advantage. Ideally, for the second study, the BRCA or HRD status for the study 
patients would have been tested, and the lack of these data is a limitation. However, 
in view of the relatively substantial study cohort, the costs would have been 
unreasonable at the time the study was carried out.  
In addition, the fresh frozen sample collection was done without intraoperative 
tissue verification. Intraoperative assessment by an experienced gynecological 
oncologist to assess the presence of tumor tissue in a specimen was used in this 
study, and in some cases, intraoperative frozen sections supported the assessments. 
However, in terms of NACT, there were no sequential samples collected, and the 
results in terms of NACT and PARP activity are thus limited.  
In the third study, different techniques were deployed to the advantage of the 
results and their interpretation, namely, in addition to gene expression, protein 
expression was measured as well. OC cell line models were used to further underline 
the findings in the case of ROR2. The limitations include the lack of tumor tissue 
verification already discussed above. In addition, the carefully preselected study 
cohorts for microarray designed to provide information about chemoresistance also 
predispose to a bias. The PARP activity determined in study two was used to select 
the cohort in study three; however, the platinum sensitivity and more favorable 
BRCAness profile associated with high PARP activity may bear impact on the results 
the microarray yielded. It cannot thus be stressed enough that the results provided 
should be further validated in a larger sample cohort without specific preselection. 
Furthermore, the biological significance of the results in study III were not 
confirmed by employing mechanistic studies. 
Additionally, for GREB1 investigations, cell line work was not undertaken and 
remains a possible target for further investigations. However, GREB1 expression in 
OC tumor samples has been demonstrated for the first time as a novel finding, and 
the importance is further underlined by the association with survival. A more 
extensive study design might provide additional evidence in the future.  
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7 FUTURE PROSPECTS 
This research project provided many interesting prospects for further investigations. 
In detail, the comparison of the RRSO samples in BRCA mutated and healthy 
controls provided several genes that may be involved in the development of HGSC. 
A more detailed investigation into the details and pathways of these mechanisms in 
a larger sample size are warranted for several of the genes, namely, SIK1, KLF4 and 
EGR3 as most interesting candidates based on their expression and data derived 
from previous literature. In addition to investigating the network surrounding the 
genes, OC cell line model work could provide insight into the genes’ effects in vitro. 
Regarding the PARP protein, the results provided here illustrated the difficulty 
of measuring PARP in paraffin-embedded blocks. Activity in tumor cells is more 
reliable for measuring PARP activity but acquiring the material suitable for that poses 
a more difficult task. In this study, platinum sensitivity was used as a surrogate 
marker for the BRCAness profile, which has previously been associated with a 
response to PARPi treatment (Lord and Ashworth, 2016). In this study, the platinum 
sensitivity was associated with high PARP activity, and it could be hypothesized that 
it would predict the response to PARPi. However, the testing of this hypothesis 
would require large, randomized studies involving PARPi treatment.  
The results of the third study researching ROR2 were encouraging. ROR 
receptors are part of the Wnt pathway; recently, Wnt pathway inhibitors have shown 
great promise in cancer treatment and are currently under evaluation as a potential 
therapeutic in several cancers (Ahmed et al., 2019; Zhu et al., 2018; Flanagan et al., 
2017). A possible targeted therapy or a combination with chemotherapeutic agent 
might be a promising option in the setting of OC as well. Further detailing of the 
pathway and its affected components is certainly warranted. 
GREB1 is also an interesting gene, possibly bearing an influence on the 
modulation of EOC via hormonal interactions, and thus further studies might be of 
interest.  
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8 SUMMARY AND CONCLUSIONS 
This dissertation concentrated on the early pathogenesis of HGSC, as well as 
expression profiling at the gene and protein level, with special regard to treatment 
response. Specifically, it was revealed that:  
1. In BRCA1/2-mutation-positive RRSO samples compared to healthy controls, 
there were interesting differentially expressed genes revealed by microarray analysis. 
From these, selected genes were validated by qRT-PCR, demonstrating comparable 
expression patterns between BRCA1/2-mutation-positive RRSO and HGSC 
samples. Thus, this study revealed potential candidate genes for future research on 
EOC pathogenesis and targeted therapy. 
2. PARP expression in EOC tumor tissue was investigated by a PARP 
pharmacodynamic assay and PARP IHC staining. Interestingly, an association 
between high PARP activity and platinum sensitivity and longer PFS was observed, 
which is a novel finding. Furthermore, NACT seemed to be associated with low 
PARP activity. The IHC staining and pharmacodynamic assay PARP activity 
measurements did not associate. Based on the results, biologically significant PARP 
seems to be indicated by PARP pharmacodynamic assay rather than PARP IHC, 
which is, based on this study, not a clinically usable surrogate marker for PARP 
activity.  
3. As a novel result, ROR2 and GREB1 were associated with treatment response in 
HGSC. Furthermore, the Wnt5a/ROR2 pathway is potentially actionable in the 
possible modulation of chemoresistance. A combination of ROR antagonists and 
chemotherapeutic agents may be an investigation-worthy option in the future.  
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Microarray Analysis of Differentially Expressed
Genes in Ovarian and Fallopian Tube Epithelium
From Risk-Reducing Salpingo-Oophorectomies
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Mutations in the BRCA1 and BRCA2 genes confer an increased lifetime risk for breast and ovarian cancer. Ovarian cancer
risk can be decreased by risk-reducing salpingo-oophorectomy (RRSO). Studies on RRSO material have altered the para-
digm of serous ovarian cancer pathogenesis. The purpose of this study was to identify candidate genes possibly involved in
the pathogenesis of serous ovarian cancer by carrying out a microarray analysis of differentially expressed genes in BRCA1/
2- mutation positive ovarian and fallopian tube epithelium derived from RRSO surgery. Freshly frozen ovarian and fallopian
tube samples from nine BRCA1/2 mutation carriers scheduled for RRSO were prospectively collected together with ﬁve
mutation-negative control patients undergoing salpingo-oophorectomy for benign indications. Microarray analysis of
genome-wide gene expression was performed on ovarian and fallopian tube samples from the BRCA1/2 and control
patients. The validation of microarray data was performed by quantitative real-time polymerase chain reaction (qRT-PCR)
in selected cases of RRSO samples and also in high grade serous carcinoma samples collected from patients with a BRCA
phenotype. From 22,733 genes, 454 transcripts were identiﬁed that were differentially expressed in BRCA1/2 mutation car-
riers when compared with controls, pooling all ovarian and fallopian tube samples together. Of these, 299 genes were stat-
istically signiﬁcantly downregulated and 155 genes upregulated. Differentially expressed genes in BRCA1/2 samples reported
here might be involved in serous ovarian carcinogenesis and provide interesting targets for further studies. VC 2015 Wiley
Periodicals, Inc.
INTRODUCTION
Germ-line mutations of the BRCA1/2 genes are
associated with an increased susceptibility for
breast and ovarian cancer (Nelson et al., 2005).
Risk-reducing salpingo-oophorectomy (RRSO) has
been shown to minimize the risk of ovarian and
fallopian tube cancer and also to substantially
lower the risk of developing breast cancer among
BRCA1/2 mutation carriers (Kauff and Barakat,
2007). Data derived from RRSO studies have pro-
foundly altered the insights of early pathogenesis
of epithelial serous ovarian cancer, or the concept
of distal fallopian tube epithelium, instead of ovar-
ian surface epithelium (OSE), being the original
site of early pathogenetic process in high grade
serous ovarian cancer (Crum, 2009; Jarboe et al.,
2009).
Epithelial ovarian cancer (EOC) is the most
important cause of mortality among gynecological
cancers (Kurman and Shih, 2011), and more than
half of the EOCs are of high-grade serous (HGSC)
type (Hannibal et al., 2012). Individualized ther-
apy is warranted as EOC is a heterogeneous dis-
ease (McCluggage, 2011). Therefore, both
identiﬁcation of speciﬁc targets for treatment and
improvement of early diagnostics remain a true
challenge (Trinh et al., 2011).
Recent microarray technology and bioinfor-
matics have been able to identify oncogenic cellu-
lar signaling pathways based on speciﬁc gene
signatures in various cancers (Bild et al., 2006;
Dressman et al., 2007; Gatza et al., 2010). Several
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microarray studies have been able to identify gene
expression proﬁles associating with prognosis of
HGSC (Konstantinopoulos et al., 2010; Kang et al.,
2012; Yoshihara et al., 2012; Verhaak et al., 2013).
Interestingly, gene expression array studies have
been able to identify speciﬁc expression proﬁles also
in BRCA1- and BRCA2-mutation positive ovarian
cancers and these proﬁles are suggestive of a divi-
sion of sporadic ovarian cancers in “BRCA1-like”
and “BRCA2-like” tumors (Jazaeri et al., 2002). It
has also been indicated that among ovarian cancer
patients, BRCA2 mutation carriers with no BRCA1
deﬁciency have improved survival, illustrating differ-
ences in these subgroups (Yang et al., 2011). More-
over, a speciﬁc BRCAness expression proﬁle was
found in a subgroup of sporadic ovarian cancer with
other defects in homologous recombination and
hence also responsive to the promising PARP-
inhibitor therapy (Konstantinopoulos et al., 2010).
The purpose of this study was to combine the
potential of prospective RRSO specimens derived
from BRCA1/2 mutation carriers possibly harboring
early pathogenetic events in EOC development
and microarray technology providing high through-
put screening of genome-wide gene expression.
Therefore we have prospectively collected RNA
from both ovarian and fallopian tube samples from
BRCA1/2 mutation carriers scheduled for RRSO in
order to identify differentially expressed genes
potentially involved in early pathogenesis of EOC
or as candidates of targeted therapy.
MATERIALS AND METHODS
The study was carried out in the University of
Tampere and Tampere University Hospital
(TAUH), Tampere, Finland. Local Ethics Com-
mittee approved the study protocol.
Tissue Samples
The prospective study cohort consisted of nine
BRCA1/2 mutation carriers undergoing RRSO and
ﬁve control patients with no BRCA1/2 mutation
undergoing salpingo-oophorectomy for benign indi-
cations. The mean age of BRCA1/2 mutation car-
riers at the time of RRSO surgery was 55 years.
Seven out of nine (78%) mutation carriers had been
diagnosed with breast cancer. Five control patients
had no personal or family history of gynecological
malignancy and were scheduled for adnexal surgery
for benign reasons, for example, benign cyst unilat-
erally, in which case the tissue sample was taken
from the macroscopically healthy-looking ovary or
fallopian tube. The mean age of control patients at
the time of surgery was 47 years.
Both fallopian tube and ovarian samples were
collected from each BRCA1/2 mutation carrier,
resulting in eighteen mutation positive adnexal
samples. Both fallopian tube and ovarian control
samples were collected from one control patient
while either an ovarian or a fallopian tube sample
was available from four control patients, respec-
tively, resulting in six adnexal control samples. The
macroscopic and morphological ﬁndings were later
conﬁrmed by an experienced pathologist as part of
routine diagnostics at the TAUH Department of
Pathology. There were no occult tumors or prema-
lignant lesions detected in BRCA-mutation positive
RRSO samples. In addition, three samples of tumor
tissue were obtained from patients with sporadic
ovarian cancer undergoing surgery in TAUH.
These HGSC ovarian cancer cases were selected
for qRT-PCR validation assay based on their
BRCAness phenotype reﬂecting speciﬁc phenotypic
characteristics and molecular defects of sporadic
ovarian cancers shared with cancers linked to BRCA
germ-line mutation (Tan et al., 2008).
Approximately, 0.5 3 0.5 3 0.5 cm sized tissue
samples of distal fallopian tube and ovarian surface
were collected from the surgery specimens and
were immediately snap-frozen with liquid nitrogen
and stored in 270C for further analyses. Written
informed consent was obtained from all study par-
ticipants. The characteristics of study patients and
samples are summarized in Table 1.
RNA Isolation
Approximately 30 mg of unprocessed tissue
(i.e., containing both epithelium and underlying
stromal tissue) was homogenized (TissueRupter,
Qiagen, Venlo, The Netherlands) and total RNA
was then automatically extracted using the QIA-
cube instrument with RNeasy Fibrous Tissue
Mini Kit (Qiagen) according to the manufacturer’s
instructions. The RNA concentration and quality
was analyzed using the Agilent 2100 Bioanalyzer
RNA 6000 Nano LabChip (Agilent Technologies,
Palo Alto, CA) prior to microarray analysis. Sam-
ples with RNA concentration minimum of 100 ng/
ll and RNA integrity number (RIN) value above
eight were used for gene expression analysis.
Finally, high quality RNA was available from nine
BRCA1/2-mutation positive ovarian and eight
BRCA1/2-mutation positive fallopian tube samples
and from three control ovarian and three control
fallopian tube samples (Table 1).
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Gene Expression Array
One hundred nanogram of total RNA was used in
analyses of gene expression. The Ambion WT
Expression Kit was used to generate puriﬁed sense-
strand cDNA (with incorporated 20-Deoxyuridine,
50-Triphosphate, dUTP). Fifteen ug of cRNA was
used for single-stranded cDNA-synthesis (sscDNA).
DNA was labeled by terminal deoxynucleotidyl
transferase (TdT) with the AffymetrixVR proprietary
DNA Labeling Reagent that is covalently linked to
biotin using the Affymetrix GeneChip WT Termi-
nal Labeling Kit (Affymetrix, Santa Clara, CA). A
total of 5.5 mg of sscDNA was fragmented and
hybridized to the GeneChip array (Affymetrix
Human Gene 1.0 ST Array) in cartridge format dur-
ing 17-h incubation at 45C. Immediately following
hybridization, the array was washed and stained
with streptavidin phycoerythrin conjugate using an
automated protocol on the GeneChipVR Fluidics
Station 450, followed by scanning on a GeneChipVR
Scanner (Affymetrix Human Gene 1.0 ST Array).
Data Analysis
All ovarian and fallopian tube samples were
patient matched. GeneChipVR signal intensity data
were processed with robust multiarray analysis
using remapped gene annotations from the Brainar-
ray Custom CDF ﬁles (HuGene10stv1_Hs_ENSG,
v.14.1.0) (Gentleman et al., 2004). Additional gene
information was extracted from EnsEMBL using
BioMart and matching was done via EnsEMBL
gene names. Analysis was implemented in R using
the simpleaffy, limma, BioMart, and qvalue pack-
ages of the Bioconductor project (Storey and Tib-
shirani, 2003; Gentleman et al., 2004; Smyth, 2004;
Durinck et al., 2005; Wilson and Miller, 2005). The
signiﬁcance of differential expression was assessed
using the empirical Bayes moderated paired t-statis-
tics followed by P-value adjustment with FDR
(false discovery rate) approach (Smyth, 2004).
Arrays were quality weighted before statistical test-
ing (Ritchie et al., 2006). Genes with FDR cor-
rected P-values 0.05 were considered as
differentially expressed. Quality of the data was
assessed by checking quality values. Data were
visualized by hierarchical clustering (HC) and prin-
cipal component analysis (PCA). Data visualization
was done in MatlabVR (R2012b). Gene expression
data have been loaded into the GEO website
(http://www.ncbi.nlm.nih.gov/geo/).
Quantitative Real-Time PCR
The validation of microarray data was performed
by qRT-PCR as previously described (Balacescu
TABLE 1. Characteristics of Study and Control Patients
Patient
No.
Mutation
carriera
BRCA1
mutation
BRCA2
mutation
Ovarian
sample
Fallopian
tube
sample
Age at
surgery
(years)
History of
breast
cancer
Ovarian
tumor
tissue available
History of
ovarian cancer
1 Yes – 8327T>G Yes Yesb 70 Yes No No
2c Yes – 8327T>G Yes Yes 45 Yes No No
3 Yes 5214C>T – Yes Yes 47 Yes No No
4d Yes – 9118-2A>G Yes Yes 48 No No No
5 Yes – 7480C>T Yes Yes 51 Yes No No
6 Yes nt3744 – Yes Yes 43 No No No
7 Yes 3640G>T – Yes Yes 49 Yes No No
8 Yes 5214C>T – Yes Yes 67 Yes No No
9 Yes – 7480C>T Yes Yes 74 Yes No No
10 No – – Yes No 13 No No No
11 No – – Yes No 38 No No No
12 No – – Yes Yes 49 No No No
13 No – – No Yes 51 No No No
14 No – – No Yes 86 No No No
15 No – – No No 56 No Yes Yes
16 No – – No No 55 No Yes Yes
17 No – – No No 78 No Yes Yes
aPatients number 10–14 (controls) have not been tested for BRCA1/2 mutation but have no personal or family history of ovarian or breast cancer
and are therefore classiﬁed as mutation-negative. Patients 15–17 have distinct BRCAness phenotype, but have not been tested for BRCA1/2 muta-
tion. Macroscopically, normal ovarian and fallopian tube samples derived from patients 1–14 were included in the microarray and high-grade serous
ovarian cancer samples derived from patients 15–17 were included only in the qRT-PCR validation assay.
bRNA sample with RIN value <8 and therefore omitted from microarray analysis.
cPatient number 2 is the daughter of patient number 1.
dPatient number 4 has undergone prophylactic mastectomy.
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et al., 2014). The expression of six differently
expressed genes was analyzed in the following 10
samples: four BRCA1/2-mutation positive, three
control, and in three HGSC samples.
Total RNA of 385 ng was used in cDNA synthesis
using DyNAmo cDNA Synthesis Kit (Thermo-
Fisher Scientiﬁc, MA) according to the manufac-
turer’s instructions. The primer-probe pairs for the
selected genes were designed using Roche’s Univer-
sal Probe Library Assay Design Center and ACTB
was chosen as the reference gene. The detailed
description of primer and probe sequences are avail-
able on request. Synthesized cDNA was diluted
1:50 prior to qPCR analyses, which were performed
using LightCycler 480 Instrument II thermal cycler
(Roche Applied Science, Pentzberg, Germany) with
hydrolysis probes from Universal ProbeLibrary Set
(Human) and Universal ProbeLibrary Human
ACTB Gene Assay (Roche Applied Science). The
speciﬁc thermocycling conditions are available on
request. Negative controls (H2O and negative
reverse transcriptase control) were included in the
assays. All samples were tested in triplicate and fell
within the standard curve. Fold change in expres-
sion was calculated using the following formula
[Gene of interestSample]/[Reference GeneSample])/
([Gene of interestControl]/[Reference GeneControl].
Gene Ontology Enrichment Analysis
Gene ontology (GO) enrichment analysis was
performed using the GO Slim ontology (Davey
et al., 2011), GO human annotation ﬁles (ver. 6/11/
2013), and experimentally validated interactions
(EXP, IDA and IPI). Hypergeometric testing with
Bonferroni correction was used to test the signiﬁ-
cance of the enrichment. The signiﬁcance level
threshold was set to 0.05. GO analysis was per-
formed in MatlabVR (R2012b) using the Bioinfor-
matics ToolboxVR functions to handle the GO
structure.
RESULTS
Expression Array
From 22,733 genes, 454 transcripts were identi-
ﬁed as differentially expressed in BRCA1/2 muta-
tion carriers when statistically compared with
controls (all ovarian and fallopian tube samples
were pooled together). Of these, 299 genes were
signiﬁcantly downregulated and 155 genes upregu-
lated. The 20 most downregulated and upregu-
lated genes are presented in Tables 2 and 3 and
the complete list of the 454 differentially
expressed genes or transcripts is available as sup-
plemental data (Supporting Information Tables 1
and 2). When only BRCA1/2-mutation positive fal-
lopian tube samples were compared with controls,
altogether 148 transcripts were differentially
expressed. Of these, 34 genes were upregulated
(Supporting Information Table 3) and 114 were
downregulated (Supporting Information Table 4).
Twenty genes were coincidentally upregulated
TABLE 2. The 20 Most Upregulated Genes in BRCA1/2 Ovarian and Fallopian Tube RRSO Samples
Gene id Gene name Gene description Fold increase P-value
ENSG00000201164 U4 U4 small nuclear RNA 3.21 0.011
ENSG00000001461 NIPAL3 NIPA-like domain containing 3 family member 2.65 0.027
ENSG00000103569 AQP9 Aquaporin 9 2.22 0.046
ENSG00000181690 PLAG1 Pleiomorphic adenoma gene 1 2.10 0.028
ENSG00000212829 RPS26P3 Ribosomal protein S26 pseudogene 3 2.09 0.046
ENSG00000221886 C5orf54 Chromosome 5 open reading frame 54 2.08 0.014
ENSG00000162753 SLC9A11 Solute carrier family 9, member 11 1.99 0.035
ENSG00000151882 CCL28 Chemokine (C-C motif) ligand 28 1.85 0.008
ENSG00000170421 KRT8 Keratin 8 1.84 0.049
ENSG00000197128 ZNF772 Zinc ﬁnger protein 772 1.77 0.007
ENSG00000167840 ZNF232 Zinc ﬁnger protein 232 1.73 0.005
ENSG00000143891 GALM Galactose mutarotase 1.71 0.031
ENSG00000252690 SCARNA15 Small Cajal body-speciﬁc RNA 1 1.69 0.046
ENSG00000196981 WDR5B WD repeat domain 5B 1.66 0.010
ENSG00000181631 P2RY13 Purinergic receptor P2Y, G-protein coupled, 13 1.66 0.015
ENSG00000144115 THNSL2 Threonine synthase-like 2 (S. Cerevisiae) 1.65 0.0104
ENSG00000170629 DPY19L2P Dpy-19-like 2 pseudogene 2 (C. elegans) 1.65 0.015
ENSG00000199980 Y_RNA Y RNA 1.63 0.046
ENSG00000162777 DENND2D DENN/MADD, a signaling protein that has multiple functions 1.62 0.041
ENSG00000140563 MCTP2 Multiple C2 domains, transmembrane 2 1.57 0.046
RRSO, Risk-reducing salpingo-oophorectomy.
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TABLE 3. The 20 Most Downregulated Genes in BRCA1/2 Ovarian and Fallopian Tube RRSO Samples
Gene id Gene name Gene description
Fold
decrease P-value
ENSG00000125740 FOSB FBJ murine osteosarcoma viral oncogene homolog B 7.31 0.002
ENSG00000179388 EGR3 Early growth response 3 5.43 0.003
ENSG00000119508 NR4A3 Nuclear receptor subfamily 4, group A, member 3 5.00 0.003
ENSG00000142178 SIK1 Salt-inducible kinase1 4.93 0.001
ENSG00000081041 CXCL2 Chemokine (C-X-C motif) ligand 2 4.87 0.003
ENSG00000158859 ADAMTS4 ADAM metallopeptidase with thrombospondin type 1 motif 4.85 0.0008
ENSG00000184557 SOCS3 Suppressor of cytokine signaling 3 4.58 0.0004
ENSG00000153234 NR4A2 NR4A2 nuclear receptor subfamily 4, group A, member 2 4.50 0.012
ENSG00000128016 ZFP36 Zinc ﬁnger protein 36 4.14 0.003
ENSG00000144655 CSRNP1 Cysteine-serine-rich nuclear protein 1 4.09 0.001
ENSG00000142871 CYR61 Cysteine-rich, angiogenic inducer, 61 4.09 0.039
ENSG00000205364 MT1M Metallothionein 1M 4.02 0.013
ENSG00000123358 NR4A1 A member of nuclear receptor family, involved in cell death 3.98 0.005
ENSG00000059804 SLC2A3 Solute carrier family 2 3.89 0.001
ENSG00000130844 ZNF331 Zinc ﬁnger protein 33 3.86 0.005
ENSG00000205362 MT1A Metallothionein 1A 3.84 0.005
ENSG00000069849 ATP1B3 ATPase, Na1/K1 transporting, beta 3 polypeptide 3.83 0.003
ENSG00000113070 HBEGF Heparin-binding EGF-like growth factor 3.72 0.003
ENSG00000136826 KLF4 Kruppel-like factor 4 3.60 0.0004
ENSG00000186594 MIR22HG MIR22 host gene 3.55 0.005
RRSO, Risk-reducing salpingo-oophorectomy.
TABLE 4. Validation of Selected Differently Expressed Genes by Quantitative RT-PCR in BRCA1/2 RRSO, Controla
and High-Grade Serous Ovarian Carcinoma Samples
Gene
Rationale for
selection
Expression in
original array
BRCA1/2
RRSO vs. control
ovarian and
fallopian
tube samples
Expression in
BRCA1/2 ovarian
and fallopian tube
samples (n5 4)a
Gene expression
concordance
BRCA1/2 RRSO vs.
control ovarian
and fallopian
tube samples
Expression in
high-grade
serous
ovarian
carcinoma
(n5 3)a
Gene expression
concordance that
is. similar
patterns of expression
BRCA1/2 RRSO vs.
HGSC samples
KLF4b Presence in four
GO categories
3.43 downregulation 0.48 Yes 0.26 Yes
PLKc Presence in three
GO categories
2.03 downregulation 0.69 Yes 1.28 No
SIK1d Presence in one GO
category and foruth
most downregulated
gene in array
4.93 downreulation 0.16 Yes 0.07 Yes
TDP2e Presence in two GO
categories
1.53 upregulation 1.83 Yes 2.23 Yes
AQP9f Third most
upregulated gene
in array
2.23 upregulation 6.32 Yes 2.12 Yes
EGR3g Presence in one GO
category and second
most downregulated
gene in array
5.43 downregulation 0.12 Yes 0.08 Yes
GO, gene ontology; RRSO, Risk-reducing salpingo-oophorectomy.
aSamples from normal ovarian and fallopian tube tissue from mutation-negative patients (n5 4); in quantitative RT-PCR analyses relative expression
levels of selected genes in the control samples was set to 1.00 to which gene expression in BRCA1/2 RRSO and serous ovarian cancer samples
was then compared.
bKruppel-like factor 4.
cPolo-like kinase 3.
dSalt-inducible kinase 1.
eTyrosyl DNA phosphodiesterase-2.
fAqua-glyceroporins 9.
gEarly growth response 3.
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and 80 downregulated when ovarian and fallopian
tube samples were analyzed together or when the
analyses were restricted only to fallopian tube
samples. These overlapping differentially
expressed genes are presented in Supporting
Information Tables 5 and 6.
The global gene expression patterns were ana-
lyzed using PCA, which showed that ovarian and
fallopian tube samples were separated from each
other and that BRCA1/2-mutation positive samples
mostly grouped together regardless of personal
history of breast cancer (Fig. 1). To highlight the
differences in gene expression, a supervised HC
was performed on the set of differentially
expressed genes. Expression proﬁles of BRCA1/2-
mutation positive and control samples forming
separate clusters are shown in Figure 2.
qRT-PCR
Six differentially expressed genes in microarray
analysis were selected for validation by qRT-PCR.
All the genes selected for qRT-PCR validation
showed similar expression pattern as the original
microarray where BRCA1/2-mutation positive
RRSO samples were compared with control fallo-
pian tube and ovarian samples. Five out of six
genes showed comparable pattern of expression in
BRCA1/2-mutation positive RRSO and HGSC
samples. The summary of the qRT-PCR analyses
is shown in Table 4.
GO Enrichment Analysis
GO enrichment analysis was performed to iden-
tify biological processes in which the identiﬁed
differentially expressed genes are involved. Nine
different GO terms showed a signiﬁcant P-value
and are summarized in Figure 3 and Table 5. Ten
enriched biological processes in overlapping one
hundred differentially expressed genes in ovarian
and fallopian tube versus control samples and fal-
lopian tube versus control samples were identiﬁed
Figure 1. Scatterplot showing location of control, BRCA1 and
BRCA2 ovarian and fallopian tube samples along the ﬁrst two principal
components (PC1 and PC2). Ovarian samples are represented by
squares and fallopian tube samples by dots. Black color corresponds to
control samples (i.e., mutation-negative samples), bright and dark red
corresponds to samples from BRCA1 mutation carriers with or without
a personal history of breast cancer (BC), respectively. Cyan and blue
color corresponds to samples from BRCA2 mutation carriers with or
without a personal history of breast cancer, respectively. Samples from
study and control patients are numbered as in Table 1. [Color ﬁgure
can be viewed in the online issue, which is available at wileyonlineli-
brary.com.]
TABLE 5. Enriched Biological Process Gene Ontology Categories for Differentially Expressed Genes in BRCA1/2 Ovarian and Fal-
lopian Tube RRSO Samples
GO Term P-value Counts (D.E./BG) Deﬁnition
GO:0008219 3.32e-08 28/369 Cell death
GO:0009058 1.68e-07 58/1195 Biosynthetic process
GO:0006950 7.08e-07 33/550 Response to stress
GO:0048646 1.70e-05 9/77 Anatomical structure formation
involved in morphogenesis
GO:0007165 2.36e-05 42/906 Signal transduction
GO:0034641 2.80e-05 55/1311 Cellular nitrogen compound
metabolic process
GO:0006412 9.37e-05 8/76 Translation
GO:0040007 1.50e-04 9/99 Growth
GO:0008283 2.13e-04 17/283 Cell proliferation
Total D.E. 443
Total Genes 18181
Unique Gene Names 16697
D.E., differentially expressed genes; D.E./BG, differentially expressed genes/background gene pool; GO, gene ontology; RRSO, Risk-reducing sal-
pingo-oophorectomy.
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Figure 3. Pie chart showing relative proportions of enriched biological process GO categories
for differentially expressed genes in BRCA1/2 ovarian and fallopian tube RRSO samples. [Color
ﬁgure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
Figure 2. Heatmap of differentially expressed genes between BRCA
1/2 ovarian and fallopian tube RRSO (n5 17; column sample numbers
1–9) and control samples (n5 6; column sample numbers 10–14),
obtained from unsupervised hierarchical clustering. The color indicates
the level of mRNA expression: red—higher level of expression;
green—lower level of expression; black—no expression changes. Each
row represents a gene. Fallopian tube samples are referred as ft and
ovarian samples as ov. Samples from study and control patients are
numbered as in Table 1. [Color ﬁgure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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and they are summarized in Supporting Informa-
tion Figure 1.
DISCUSSION
We have studied the genome-wide gene expres-
sion levels in RRSO samples derived from
BRCA1/2 mutation carriers. Several reports on
RRSO-derived specimens have been published,
where histological and morphological analysis of
parafﬁn-embedded archival samples has revealed
interesting data on the site of initial ovarian carci-
nogenesis (Crum et al., 2007; Kurman and Shih,
2010).
There are only few studies on genome-wide
gene expression levels in RRSO samples derived
from BRCA1/2 mutation carriers and data pre-
sented here provide a potentially valuable addition
to the few previous studies (Tone et al., 2008;
Press et al., 2010; George et al., 2011). Here, gene
expression proﬁling by supervised HC or PCA
showed distinct clustering of samples according to
either tissue of origin or to BRCA1/2-mutation sta-
tus. Our microarray analysis revealed a number of
differentially expressed genes in BRCA1/2 samples
compared with controls. Downregulation of gene
expression was more pronounced both in the
amount (up to sevenfold decrease) and in the
number of genes than upregulation (up to three-
fold increase). GO enrichment analysis was used
to identify cellular and biological processes for dif-
ferentially expressed genes in the array. GO
enrichment analysis is widely recognized as the
premier tool for the organization and functional
annotation of extensive microarray data (Lovering
et al., 2008).
The six following differentially expressed genes
were chosen for qRT-PCR validation because of
their presence in one or more GO category or top
rank in the list of most up- or downregulated
genes: KLF4, PLK3, SIK1, TDP2, AQP9, and
EGR3. qRT-PCR results were in accordance with
the microarray ﬁndings in all instances. In addi-
tion, gene expression of selected genes was com-
pared between BRCA1/2 RRSO and HGSC
ovarian cancer samples by qRT-PCR. HGSC sam-
ples were selected for their positive BRCAness
phenotype, which has been associated with a spe-
ciﬁc gene expression proﬁle predictive of response
to chemotherapy (Konstantinopoulos et al., 2010).
Moreover, speciﬁcally BRCA1-mutation seems to
associate with deﬁned gene expression proﬁle in
HGSC ovarian tumors distinct from BRCA2-posi-
tive or wild-type ovarian cancers (George et al.,
2013). Despite of BRCA2-mutation positive RRSO
samples included in our study, HGSC samples
showing BRCAness phenotype were regarded as
the most suitable reference material available. In
the qRT-PCR assay comparing BRCA1/2 RRSO
samples with HGSC samples, all but the PLK3
gene showed comparable pattern of expression,
suggesting that KLF4, SIK1, TDP2, AQP9, and
EGR3 may play a role in ovarian carcinogenesis or
at least serve as interesting candidates for future
studies. The discrepancy in PLK3 expression may
have several explanations. First, PLK3 might not
be important in ovarian cancer pathogenesis and
differential expression of PLK3 in BRCA RRSO
samples in our microarray might be associated
with some other features than inherited cancer
predisposition of BRCA mutation carriers. Second,
early and late events in cancer development might
not be parallel and could at least partially explain
the discordance in PLK3 expression pattern in
qRT-PCR validation assay, where BRCA-mutation
positive macroscopically normal RRSO samples
were compared with advanced stage HGSC sam-
ples. In fact, either overexpression or downregula-
tion of PLK proteins occurs frequently in various
cancer types (Pellegrino et al., 2010), and recent
data have emphasized the relevance of PLK3 in
angiogenesis in tumor development (Xu et al.,
2012).
Speciﬁcally, previous studies have shown that
KLF4 is a key transcriptional regulator and is sug-
gested to play a role in several malignancies, func-
tioning as a potential tumor suppressor (Yori et al.,
2011; Cui et al., 2013; Tetreault et al., 2013).
There are only few reports on KLF4 and EOC but
one previous report showed downregulation of
KLF4 in ovarian cancer (Yoon and Roh, 2012). Our
ﬁndings therefore are in line with previous data
regarding KLF4 and warrant further investigation
on the role of KLF4 in ovarian carcinogenesis.
Here, KLF4 was present in four GO categories,
such as cellular nitrogen compound metabolic pro-
cess, cell death, anatomical structure formation,
and biosynthetic process. Moreover, there is evi-
dence of KLF4 regulating both JAK-STAT and
NOTCH signaling pathways, alterations of which
affect various cellular functions, such as inﬂamma-
tion, cell growth, and angiogenesis (Aittom€aki and
Pesu, 2014; Hale et al., 2014).
EGR3, the early growth response three, is a
transcription factor regulating signal transduction,
cell growth, and proliferation (Patwardhan et al.,
1991). In our study, EGR3 was the second most
downregulated gene in the expression array and
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was also downregulated in HGSC samples, sug-
gesting that it is a potential tumor suppressor in
ovarian cancer. EGR3 was present in anatomical
structure formation category in GO analysis. Inter-
estingly, EGR3 has not been previously associated
with ovarian cancer, but its overexpression has
been shown in nonrelapsing prostate cancer and
decreased expression in gastric cancer has been
associated with poor prognosis (Liao et al., 2013;
Pio et al., 2013). Moreover, EGR3 has been shown
to regulate the expression of SOCS3 (suppressor
of cytokine signaling three, also downregulated in
our array), also a negative regulator of JAK-STAT
signaling pathway, aberrant function of which is
possibly associated with tumor growth (Inagaki-
Ohara et al., 2013). Taken together, its role in the
EOC pathogenesis should be target of future
investigation.
Another downregulated gene was SIK1, which is
the fourth most downregulated gene in our expres-
sion array and also downregulated in HGSC samples.
According to previous data, Salt-inducible kinases are
a family of related serine-threonine kinases and
involved, for example, in liver glucose homeostasis,
steroidogenesis, and adipogenesis (Yong Kim et al.,
2013). In our GO analysis, SIK1 was present in signal
transduction category in accordance with its multiple
roles. In terms of carcinogenesis, SIK1 has been
shown to suppress metastasis in a TP53-dependent
manner (Cheng et al., 2009) and to regulate E-
cadherin expression affecting intercellular junction
stability (Eneling et al., 2012). To our knowledge
SIK1 has not been previously linked to ovarian can-
cer. In the light of our microarray analysis and previ-
ously published data, SIK1 provides an interesting
target for future ovarian cancer studies.
Two upregulated genes validated by qRT-
PCR were AQP9 and TDP2. AQP9 belongs to
aquaporins, which are integral transmembrane
water channel proteins involved in transcellular
water movement, transport of ﬂuid, and cell
migration (Ribatti et al., 2014). AQP9 has been
associated with several cancers, such as lung,
prostate, brain, and ovarian cancer (Yang et al.,
2011; Fossdal et al., 2012; Hwang et al., 2012;
Wang et al., 2014). According to previous data,
aquaporin expression in tumor cells and vessels
facilitates tumor growth and spread, suggesting
aquaporin inhibition as a novel antitumor therapy
(Verkman et al., 2008). AQP9 was the third
most upregulated gene in array and also upregu-
lated in ovarian cancer tissue, suggesting that
AQP9 serves as promising target for further
investigation.
TDP2 is a phosphodiesterase that prevents
DNA breaks induced by aberrant topoisomerase II
activity (Gao et al., 2014). It has not been previ-
ously associated with ovarian cancer, but it has
been shown to act as an oncogenic agent, and
some data also suggest it has a role in chemoresist-
ance (Li et al., 2011). Here, TDP2 was upregulated
in BRCA1/2 mutation carriers and ovarian cancer
tissue. It was involved in two GO categories:
response to stress and cellular nitrogen compound
metabolic process. Our ﬁndings suggest that TDP2
may have a role in EOC pathogenesis, warranting
further investigations. It could be speculated that
impaired BRCA1/2 function in DNA repair by
homologous recombination (Li and Heyer, 2008)
could also lead to upregulation of TDP2 and that it
therefore serves as an interesting target for further
studies, especially in regard to EOC treatment.
Our ﬁndings are mostly in accordance with pre-
vious data on gene expression in BRCA-mutation
positive RRSO specimens despite certain distinct
differences in study materials (Tone et al., 2008;
Press et al., 2010; George et al., 2011). Previous
reports have mainly focused on BRCA1-mutation
samples (Press et al., 2010; George et al., 2011)
and exclusively on fallopian tube epithelium
selected by laser capture microdissection (Tone
et al., 2008; Press et al., 2010; George et al., 2011).
Regardless of the current understanding of fallo-
pian tube as origin of progenitor cells of HGSC,
we aimed at analyzing gene expression from both
ovarian and fallopian tube samples. This was par-
tially based on recent in vivo animal data suggest-
ing that ovaries may, in fact, interact with fallopian
tube in the invasive process by providing a favor-
able hormonal environment for development of
advanced disease (Perets et al., 2013). Our study
protocol did not include laser capture microdissec-
tion, partly due to lack of premalignant lesions in
RRSO specimens. In addition, we did not want to
rule out the effect of possible interaction between
stromal and epithelial tissue. In fact, ovarian epi-
thelial cell interplay with the immune system with
regard to folliculogenesis has been established
long ago (Bukovsky et al., 1995), and such an
interplay is possibly present also in HGSC (Mar-
tins Filho et al., 2014). Regardless of these differ-
ences, many of the differentially expressed genes
reported here have also been implicated previ-
ously, like aquaporins, Kruppel-like transcription
factors (KLFs), interleukins, and suppressor of
cytokine signaling genes (e.g., SOCS3), emphasiz-
ing the possible relevance of the differentially
expressed genes and involved cellular pathways
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revealed by microarray technology (Tone et al.,
2008; Press et al., 2010; George et al., 2011).
When gene expression was studied separately
only in BRCA1/2-mutation positive fallopian tubes
in comparison with controls, KLF4, SIK1, and
AQP9 were all differentially expressed and EGR3
was at the limit of signiﬁcant downregulation
(P5 0.05). In the light of the fallopian tube theory
in EOC pathogenesis, this subgroup analysis may
emphasize the signiﬁcance of differential gene
expression in the case of these genes. TDP2, how-
ever, was not signiﬁcantly expressed in this sub-
group analysis, but the quite small sample size has
to be taken into account. Small, but possibly bio-
logically relevant differences in gene expression
can escape notice, a fact that applies also for the
whole array study even with all ovarian and fallo-
pian tube samples analyzed together.
There are limitations to our study. As already
brieﬂy discussed above, the number of mutation
positive and control samples was limited, but it is
important to note that the array used in the study
determined the total number of samples studied.
In addition, due to rarity of germ-line BRCA1/2
mutations (Edlich et al., 2005), collection of con-
siderable number of patients is challenging. How-
ever, the aim of this study was to screen for
differences in global gene expression in a well-
deﬁned patient population of BRCA1/2-mutation
carriers serving as a starting point for more
detailed future studies. Some of the differences in
gene expression can be explained by BRCA1/2-
mutation carriers being older than the control
patients. In addition, some of the mutation carriers
were of rather high age at time of the RRSO sur-
gery and they might not serve as ideal study
patients of predisposition for ovarian cancer at
young age. However, as BRCA mutations are
associated with an increased life-time risk of ovar-
ian cancer and these patients also had a personal
history of breast cancer, indicative of actualized
personal cancer predisposition, they were included
in the study. In addition, archival parafﬁn-
embedded RRSO samples of BRCA1/2-mutation
positive patients in the present study have been
previously studied for TP53 nuclear immunoreac-
tivity, which was shown to be signiﬁcantly higher
compared with control adnexal samples, further
justifying the inclusion of all BRCA-mutation posi-
tive samples in the present study (Staff et al.,
2014).
In conclusion, we present microarray data of dif-
ferentially expressed genes in BRCA1/2-mutation
positive RRSO samples. Selected genes were vali-
dated by qRT-PCR showing comparable expres-
sion patterns between BRCA1/2-mutation positive
RRSO and HGSC samples, suggesting that micro-
array analysis was able to reveal potential candi-
date genes for future research on EOC
pathogenesis and targeted therapy.
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Abstract Targeting Poly (ADP-ribose) polymerase 1 (PARP-
1) involved in base excision repair (BER) has been shown to
be a clinically effective treatment strategy in epithelial ovarian
cancer (EOC) defective in homologous recombination (HR).
The aim of this study was to evaluate fresh EOC tumor tissue
in regard to PAR (Poly (ADP-ribose)) concentration as a sur-
rogate marker for PARP activity and PARP protein expression
in archival samples by immunohistochemistry (IHC). The
prospective study cohort consisted of 57 fresh tumor samples
derived from patients undergoing primary (n=38) or interval
debulking surgery (n= 19) for EOC and parallel archival
paraffin-embedded tumor samples. PARP activity in fresh fro-
zen tumor tissue was assessed by an enzymatic chemilumines-
cence assay and PARP protein expression in paraffin-
embedded tumor tissue by IHC. No correlation was detected
between PARP enzyme activity and PARP staining by IHC
(p=0.82). High PARP activity was associated with platinum
sensitivity both in the entire study cohort (p=0.022) and in the
high-grade subgroup (p=0.017). High PARP activity was also
associated with improved progression-free survival (PFS) (32
vs 14 months, log-rank p=0.009). However, PARP immuno-
staining pattern was not predictive of patient survival. In con-
clusion, we present a novel finding of high PARP activity
associated with platinum sensitivity and improved PFS in
EOC. There was no association between PARP IHC and phar-
macodynamic assay, and the correlation of PARP IHC with
clinico-pathological characteristics and patient survival was
poor. Pharmacodynamic assay rather than IHC seems to re-
flect better biologically significant PARP.
Keywords PARP . Epithelial ovarian cancer . BRCA .
Platinum sensitivity . IHC
Introduction
Epithelial ovarian cancer (EOC) is a heterogeneous disease
with distinct epidemiological, phenotypical, and molecular
subtypes including high-grade serous carcinoma (HGSC),
low-grade serous, mucinous, endometrioid, and clear cell car-
cinoma [1]. Genetically complex and unstable HGSC is the
most prevalent histotype and responsible for the highest mor-
tality associated with EOC [1].
Cytoreductive surgery followed by platinum-taxane based
combination chemotherapy is the cornerstone of the treatment
of EOC [2]. Although initial response rates to chemotherapy
are high, majority of patients will relapse, leading ultimately
to the development of chemoresistance [3]. Therefore,
unraveling the molecular mechanisms leading to platinum re-
sistance constitutes a true challenge in current EOC research.
There is emerging evidence that sufficiently functional DNA
repair and intact homologous recombination are major determi-
nants of platinum resistance [4, 5]. The detailed analysis of EOC
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by TCGA network has revealed a homologous recombination
defect (HRd) in approximately 50 % of HGSC cases [6]. HRd
notonlyresults fromgerm-lineorsomaticmutationsorepigenetic
silencingofBRCA1/2genesbut also fromdefects invariousother
genes such as EMSY, RAD51C, ATR, ATM, PTEN, and genes in
Fanconi anemia (FA) pathway [7]. Compatible with the possible
association betweenHR status and response to platinum therapy,
BRCA1/2mutationcarriers respondbetter toplatinum-basedche-
motherapy [8] and have an improved 5-year overall survival as
compared to sporadic cases [9, 10]. BRCAness profile has been
suggested to identify a specific phenotype of sporadic high-grade
OC with responsiveness to platinum therapy and improved out-
come comparable toBRCA1/2 germ-linemutation carriers [11].
In the setting of defective HR, inhibition of a second DNA
repair pathway such as base excision repair (BER), results in
synthetic lethality [12]. Poly (ADP-ribose) polymerase 1
(PARP-1) has been identified as a key enzyme involved in
BER [13, 14]. The observation of synthetic lethality was
followed by development of PARP inhibitors [12, 15], which
were originally designed to potentiate the tumor-killing activ-
ity of ionizing radiation and genotoxic agents, such as temo-
zolomide (TMZ) and topotecan [16]. PARP inhibition has
been shown to be an effective treatment strategy in various
malignant tumor types, especially EOC, derived from BRCA1/
2 germ-line mutation carriers [17, 18]. Recently olaparib, a
potent PARP inhibitor, was found to provide a significant
progression-free survival (PFS) benefit over placebo as a
maintenance therapy in platinum-sensitive recurrent BRCA1/
2-mutation positive HGSC [19, 20].
In addition to BRCA1/2 mutations, deficiency in other HR
genes may also cause sensitivity to PARP inhibitors [6, 21]. In
fact, the clinical efficacy of olaparib, albeit to a lesser degree,
was seen also in wild-type (i.e., non-BRCA1/2 mutation)
platinum-sensitive OC [20]. The sensitivity of HRd cells to
PARP inhibitors exceeds that of any other class of compounds
by at least one order of magnitude, suggesting that other func-
tions of PARP may also underlie the strong synthetic lethal
interaction observed [22]. Identification of aberrant DNA re-
pair pathways in other histological subtypes of OC and com-
bination of PARP inhibitors with other biologic agents will
likely increase the number of patients benefiting from PARP
inhibitors [23]. In fact, a recent study suggests HRd to be a
common event not only in serous but also in non-serous OC
subtypes highlighting the potential activity of PARP inhibition
beyond BRCAness and HGSC subtype [24].
To our knowledge, no data regarding PARP activity in fresh
EOCtumor tissueareavailableatpresent. InclinicalOC, thereare
previousdata regardingPARP1mRNAexpressionbymicroarray
technology [25, 26] and PARP protein content by immunohisto-
chemistry [26–28]. However, the available data concerning clin-
ical correlations of PARP IHC are contradictory [25, 29].
Therefore, the aimof this studywas to analyze bothPARconcen-
tration as an indirectmeasurement ofPARPactivity in freshEOC
tumor tissuebyapharmacodynamicassay [30]andPARPprotein
expression fromparallel paraffin-embedded archival tumor sam-
ples by IHC. Both PARP activity and PARP immunostaining
pattern were correlated with clinico-pathological characteristics
and response to chemotherapy.
Patients and methods
The study was carried out at the University of Tampere and
Tampere University Hospital (TAUH), Tampere, Finland. The
study protocol was approved by the Ethics Committee of TAUH
(Identification code ETL-R11137, September 13, 2011).
Study cohort and tissue samples
The prospective study cohort consisted of 100 consecutive
women providing an informed consent and scheduled either
for primary or interval debulking surgery for suspected or
histologically verified ovarian cancer at TAUH in 2012–
2013. Fresh samples from tumor tissue were collected from
each enrolled patient at surgery. Two samples sized
0.5×0.5×0.5 cm were chosen at the operation room from
the surgery specimens and were immediately snap-frozen with
liquid nitrogen and stored in −70 °C for further analyses. In
the cases of interval debulking surgery, fresh tumor samples
were taken from the macroscopically visible residual tumor.
The morphological and histological findings from the corre-
sponding archival surgical tumor specimens were assessed by
experienced pathologists as part of routine diagnostics at the
Department of Pathology of TAUH. Only samples from pa-
tients with histologically verified primary epithelial ovarian
malignancy were included in the final study cohort for further
analyses of PAR concentration. Thus, the final study cohort
consisted of 57 women with fresh samples from primary ep-
ithelial ovarian cancer.
Clinical characteristics
Clinical and pathological data, including age at diagnosis, date
of primary or interval surgery, FIGO stage, grade, and histo-
logical tumor type were collected from the patient records.
Clinical data included patient’s height, weight, history of
breast cancer, systemic hormone replacement therapy
(HRT), and smoking. Stage was confirmed by a thorough
review of the operative and pathology reports. In addition,
data regarding chemotherapy were obtained as follows: num-
ber of treatment cycles, platinum sensitivity defined as no
recurrence within 12 months after the completion of first-
line platinum-based chemotherapy, use of neoadjuvant che-
motherapy (NACT), and CA12-5 level before, during, and
after chemotherapy. Follow-up data were collected from
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medical records by documenting the time of recurrence or the
last follow-up visit or death, respectively.
The mean age of the patients was 66 years (SD 9.3). Most
tumors were high-grade (70 %) with serous (84 %) histology.
The median follow-up time was 31 months (range 2–
50 months). The main clinico-pathological characteristics of
study patients are summarized in Table 1.
Assessment of PAR concentration
For the measurement of PAR (Poly (ADP-ribose)) concentra-
tion in tumor tissue, the HT PARP in vivo Pharmacodynamic
Assay II by Trevigen (Gaithersburg, MD, USA) was used. In
response to DNA damage, as a result of its enzymatic activity,
PARP-1, the main isoform of PARP family, catalyzes the
NAD+-dependent addition of PAR onto itself and adjacent
nuclear proteins [25]. Therefore, the measurement of PAR
concentration can be regarded as an indirect measurement of
PARP-1 activity.
The pharmacodynamic assay was run according to the in-
structions by the manufacturer. Briefly, approximately 10 mg
of frozen tissue sample was minced in lysis buffer, homoge-
nized with vortex, and sonicated three times in 10 s cycles
with 23 % amplitude (Sonics, Vibra-Cell, Newtown, CT,
USA). Sodium dodecyl sulfate (SDS) was added to the lysates
to the final concentration of 1.0 %, and samples were incubat-
ed at 100 °C for 5 min. After centrifugation, supernatants were
collected and protein concentration was measured with BCA
protein assay kit (Thermo Fisher Scientific, MA, USA). Equal
amounts of protein lysates were analyzed in duplicates with
ELISA assay according to the manufacturer’s instructions,
and PAR concentrations were quantified based on chemilumi-
nescent signal measurement (Luminoskan Ascent, Thermo
Fisher Scientific, MA, USA). Initially, 3 and 10 μg protein
lysates were tested in parallel, and values with 3 μg of the total
protein were found to allocate better to the PAR standard
curve (detection range 10–1000 pg/ml). Samples were run in
duplicates and averaged to achieve the final concentration. In
addition, commercial protein lysate controls with
predetermined PAR concentrations were included in the assay.
Immunohistochemistry
Immunohistochemistry (IHC) was used to evaluate the PARP-
1 protein expression. The archival representative ovarian can-
cer samples were derived from the Department of Pathology at
Tampere University Hospital. The tumor sample blocks were
cut into 3–4 μm thick sections using a standard microtome.
For IHC staining, the slides were then deparaffinized,
rehydrated in graded ethanol, and subsequently pretreated
with a PT-Module (Lab Vision, Fremont, CA) at 98 °C for
15 min in 0.05 M TrisHCl buffer, pH 9.0 containing 0.001 M
EDTA. The primary PARP-1 antibody (anti-PARP-1, Cat# sc-
8007; Santa Cruz Biotechnology, Dallas, TX) at a dilution of
1:5000 was visualized with a PowerVision + polymer kit
(Leica Biosystems Newcastle Ltd., Newcastle, UK) and di-
aminobenzidine as chromogen (DABImmPact, Vectorlabs,
Burlingame, CA). The tissue sections were counterstained
with hematoxylin (Mayer’s hematoxylin, Oy FF-Chemicals
Ab, Haukipudas, Finland), dehydrated, cleared, and mounted.
Staining protocols were carried out with Autostainer 480 (Lab
Vision, CA, USA) automated immunostainer. Placenta was
used as a positive tissue control for PARP-1 staining.
Positive and negative (primary antibody omitted) controls
were included in each staining batch.
Table 1 Characteristics of study patients
Characteristic
Patients in study, n 57
Age at surgery, years (SD) 66 (9.3)
BMI, mean (SD) 26.8 (6.2)
Median follow-up, months (range) 31 (2–50)
Ca 125 before treatment, median (range) 490.5 (25–4728)
FIGO stage, n (%)
Stage 1 5 (9)
Stage 2 3 (5)
Stage 3 34 (60)
Stage 4 15 (26)
Histology, n (%)
Serous 48 (84)
Endometroid 4 (7)
Mucinous 3 (5)
Carcinosarcoma 1 (2)
Other 1 (2)
Grade, n (%)
Grade 1 and 2 15 (29)
Grade 3 36 (71)
Prior HRT, n (%) 20 (35)
Residual tumor, n (%)
<1 cm 35 (62)
>1 cm 22 (38)
Response to platinum therapya, n (%)
Sensitive 28 (49)
Resistant 13 (21)
Partial sensitive 12 (20)
Neoadjuvant therapy, n (%) 19 (35)
Recurrence 37 (65)
Death 21 (37)
FIGO International Federation of Gynecology, HRT hormone replace-
ment therapy
a Sensitive: recurrence >12 months after completion of platinum-based
first-line therapy. Resistant: recurrence ≤6 months after completion of
platinum-based first-line therapy. Partially sensitive: recurrence 6–
12 months after completion of platinum-based first-line therapy
Tumor Biol. (2016) 37:11991–11999 11993
Immunostained sections were analyzed with Olympus
System Microscope BX43. The assessment of PARP-1 stain-
ing was performed blinded in regard to the clinico-
pathological information of the patients and PAR concentra-
tion by pharmacodynamic assay. In all tissue samples, PARP-
1 nuclear staining intensity was scored semiquantitatively as
low (negative or weak nuclear staining), intermediate (more
pronounced or focally more intensive nuclear staining com-
pared to low staining pattern), or strong (intensive uniform
nuclear staining). The slides were independently scored by
two different researchers, who were blinded to the patient
medical history. For the statistical analysis, low and interme-
diate nuclear staining was combined as low PARP-1 staining
and strong nuclear staining as high PARP-1 staining.
Statistical analyses
The clinico-pathological associations with variation in levels
of PAR concentration and PARP-1 staining pattern were sta-
tistically evaluated. The comparison of the groups was made
using the Student’s t test, Mann-Whitney U test, and Fisher’s
exact test where appropriate. The Kaplan-Meier and Cox re-
gression analyses were used to estimate the survival rates from
the date of surgery (primary debulked patients) or from the
date of the first dose of neoadjuvant therapy until the date of
the event of interest. For progression-free and overall survival
(PFS, OS), the event of interest was a recurrence or death,
whichever occurred first. Patients alive at the last follow-up
without a recurrence were censored at the last follow-up date.
Version 22 of IBM SPSS statistics software (IBM Inc.,
Armonk, NY, USA) was used in statistical analyses. A p value
less than 0.05 was considered significant.
Results
PAR concentration by ELISA pharmacodynamics assay
PAR concentration was available (i.e., PAR levels were mea-
surable) from 51 out of 57 study patients (89 %). In fresh OC
tumor tissue, PAR concentration levels ranged between 0.67
and 1024.68 pg/ml, with median and mean values of 203 and
311.1 (SD 292.1) pg/ml, respectively (Table 2). The cut-off
level for high PARP activity was set to 203 pg/ml correspond-
ing to median value.
Platinum sensitivity associated with high PAR concentra-
tion in the entire study cohort (p=0.022; Fig. 1) and especially
in the high-grade (i.e., grade 3) subgroup (p=0.017). In turn,
NACT associated with low levels of PAR (p=0.014). The
associations of levels of PAR concentration with clinico-
pathological characteristics are summarized in Table 2.
In Kaplan-Meier analyses, high PAR concentrationwas asso-
ciatedwith longer PFS than low concentration (32 vs 14months,
respectively, log-rank p=0.009; Fig. 2). In Cox regression, low
PAR concentration was associated with an increased risk of re-
currence both in univariate (HR 2.4; 95 % CI 1.204–4.797) and
Table 2 Level of PAR concentration by ELISA pharmacodynamics
assay in correlation with clinico-pathological characteristics
Characteristic No. of
patients
Median level of PAR
concentration
in pg/ml (IQR), n= 51
p valuea
51 203 (398.1)
PARP staining by IHC
Weak to moderate 24 197.7 (416.7) 0.82
Strong 26 196.3 (402.3)
Age at surgery
<Mean 26 289.2 (465.9) 0.13
>Mean 25 192.5 (348.7)
BMI
≤25 17 124.6 (426.3) 0.13
>25 33 243.5 (426.3)
Grade
1 and 2 15 279.1 (583.6) 0.12
3 36 163.4 (418.2)
Prior use of HRT
Yes 18 185.1 (280.6) 0.43
No 33 257.8 (430.8)
CA125 after 3 cycles of CT or C alone
Normal (≤35) 21 257.6 (478.2) 0.08
Abnormal (>35) 30 124.6 (391.0)
Platinum sensitivityb
Yes 26 312.6 (575.8) 0.022
No 22 117.6 (262.4)
Platinum sensitivityb in high-grade subgroup
Yes 16 404.7 (519.8) 0.017
No 19 81.4 (261.4)
NACT
Yes 16 87.1 (220.6) 0.01
No 35 292.5 (384.4)
Recurrencec
Yes 34 137.2 (388.7) 0.11
No 17 356.8 (450.6)
Deathc
Yes 19 243.5 (379.9) 0.59
No 32 176.1 (459.8)
IQR interquartile range, IHC immunohistochemistry, HRT hormone re-
placement therapy, CT carboplatin and taxane, C carboplatin, NACT neo-
adjuvant therapy
aNonparametric Mann-Whitney U test
b Sensitivity defined as relapse or event-free follow-up time >12 months
after completion of platinum-based first-line therapy
cMedian duration of follow-up time in the study cohort was 31 months
(range 2–50)
11994 Tumor Biol. (2016) 37:11991–11999
multivariate analyses (Table 3), but not with increased risk of
death (HR 1.12; 95%CI 0.455–2.764).
PARP-1 immunohistochemistry
Representative tumor blocks were available from 56 patients.
Half (or 28) of the tumors showed low/moderate PARP
nuclear staining, while another half showed strong staining
(Fig. 3). IHC PARP-1 staining pattern was not associated with
PAR concentration by pharmacodynamic assay (Tables 2 and
4). A low PARP-1 immunohistochemistry staining associated
significantly with normalized serum CA12-5 levels after three
cycles of platinum-based chemotherapy (p=0.027). The asso-
ciations of PARP-1 IHC with clinico-pathological character-
istics are summarized in Table 4.
In Kaplan-Meier analyses, a trend for association between
low PARP-1 by IHC and longer PFS was detected (32 vs
15 months, log-rank p=0.061; Fig. 4). However, in multivar-
iate Cox regression analysis, low PARP-1 IHC was not asso-
ciated with decreased risk of recurrence (Table 3). There was
also no association with low PARP-1 IHC staining and overall
survival (HR 0.724; 95 % CI 0.307–1.708).
Discussion
We report here an evaluation of PAR concentration as a sur-
rogatemarker for PARP enzyme activity in a prospective EOC
patient cohort and PARP-1 IHC staining results of parallel
archival tumor samples. Although there are previous data re-
garding PARP1 gene expression [25] and PARP protein con-
tent by microarray technology and IHC in EOC [25, 27], to
our knowledge, this is the first report of PARP enzyme activity
measurement using fresh tumor samples from EOC patients in
comparison with PARP-1 immunostaining pattern in corre-
sponding archival tumor samples. The methodology used for
measuring PARP activity (or PAR concentration) from cellu-
lar extracts is based on chemiluminescence and has previously
been validated [30] and reported in a cohort of clinical breast
cancer specimens [31]. PAR is the product of catalytic activity
of PARP-1 enzyme and therefore measurement of PAR
Fig. 1 Box plot diagram of PAR concentration levels according to
platinum sensitivity (p= 0.022), Mann-Whitney U test; horizontal lines
represent median levels of PAR concentration. Outlier is marked with a
circle
Fig. 2 Kaplan-Meier analysis of progression-free survival (PFS) accord-
ing to median level of PAR concentration (log-rank p = 0.009). The cut-
off level for high PAR concentration was set to 203 pg/ml (median value
of PAR concentration). Vertical lines represent censored patients
Table 3 Risk factors for ovarian cancer progression in multivariate
Cox regression analysis
Characteristic HR 95 % CI p value
Low PAR concentrationa 2.521 1.132–5.615 0.024
Age at surgery (<mean) 0.993 0.946–1.042 0.769
Low PARP stainingb 0.582 0.277–1.224 0.154
Primary surgery vs NACT 0.399 0.156–1.019 0.055
Low gradec 0.470 0.180–1.222 0.121
Local diseased 0.482 0.059–3.932 0.495
Non-optimal surgery 3.740 1.472–9.501 0.006
NACT neoadjuvant therapy, HR hazard ratio
a Cut-off point for low versus high PAR concentration, 203 pg/ml (median
value of PAR concentration)
b Immunohistochemistry staining
c Grade 1 and 2 vs 3
d Stage I–II vs III–IV
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product can be regarded as an indirect measurement of PARP-
1 enzyme activity [25].
In the present study, high PARP activity in fresh frozen
tumor tissue was associated with platinum sensitivity, which
is generally accepted as a surrogate marker for HRd or
BRCAness [5]. Moreover, the association between high
PARP activity and platinum sensitivity was even stronger in
the high-grade subgroup. Both platinum sensitivity and
HGSC in EOC have been considered as phenotypic character-
istics of BRCAness profile, further implying the possible as-
sociation between HRd and high PARP activity [11].
Although in clinical setting high PARP activity has not been
shown to predict response to PARP inhibitor therapy in OC
[32], in mouse tumor models the current assay methodology
has provided a valid biomarker for PARP inhibition [33].
Currently BRCA mutation status is considered as the primary
biomarker for prediction of response to PARP inhibition, al-
though it has been shown in a randomized clinical trial that
also wild-type OC patients (i.e., non-BRCA1/2 mutated) ben-
efit from PARP inhibition with olaparib [20]. Functional tests
that assess HR deficiency have been intensively studied in
both ovarian cancer and triple-negative breast cancer [34,
35]. A HRd score based on patterns of genomic loss of het-
erozygosity has also been proposed to identify patients with
HRd regardless of its etiology [36].
According to our results, high PARP activity was further
translated into longer PFS, and low PARP activity was
Fig. 3 Examples of PARP-1 immunohistochemistry staining in ovarian
cancer tumor tissue. a Weak or moderate nuclear staining. b Strong nu-
clear staining
Table 4 PARP immunohistochemistry (IHC) staining and its correla-
tion with clinico-pathological characteristics
Characteristic PARP IHC
weak to
moderate
staining, n= 28
PARP IHC
strong
staining,
n= 28
p valuea
PAR concentrationb, n
Lowb 12 12 1.00
Highb 13 13
Age at surgery, mean (SD) 65.96 (8.0) 66.46 (10.3) 0.841c
BMI, mean (SD) 26.24 (5.8) 27.15 (6.4) 0.583c
Grade, n
1 and 2 9 7 0.768
3 19 21
Prior use of HRT, n
Yes 16 10 1.000
No 18 10
CA12-5 after 3 cycles of CT or C alone, n
Normal (≤35) 16 7 0.027
Abnormal (>35) 11 19
Platinum sensitivityd, n
Yes 17 12 0.275
No 10 14
Recurrencee, n
Yes 14 21 0.097
No 14 7
NACT, n
Yes 7 12 0.259
No 21 16
Deathe, n
Yes 10 11 1.000
No 18 17
NACT neoadjuvant therapy, HRT hormone replacement therapy, CT
carboplatin and taxane, C carboplatin
a Fisher’s exact test for categorical characteristics (excluding age and
BMI)
b Cut-off point for low versus high PAR concentration, 203 pg/ml (medi-
an value of PAR concentration)
c Student’s t test for continuous variables showing normal distribution
(age and BMI)
d Platinum sensitivity defined as relapse or event-free follow-up time
>12 months after completion of platinum-based first-line therapy
eMedian duration of follow-up time in the study cohort was 31 months
(range 2–50)
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associated with early recurrence. In addition, the effect of
PARP activity on PFS was found to be independent of tumor
grade, stage, given NACT, or age of the patients. In our study,
PARP activity and PARP-1 protein expression by IHC did not
show any association. This discrepancy is somewhat difficult
to explain, but it seems possible that a static assay like IHC is
not optimal for evaluation of a dynamic repair mechanism of
DNA single-strand breaks. Previous studies addressing
PARP-1 expression in clinical OC material by IHC methods
have reported contradictory findings and they also partly dif-
fer from the results presented here [27, 37]. High PARP-1
expression by IHC has been previously associated with com-
plete response to initial chemotherapy but not with improved
PFS [37]. On the other hand, weak PARP-1 staining by IHC
has been associated with improved PFS and even OS [27]. In
our data, there was also a trend for association between low
PARP-1 by IHC and longer PFS and a significant association
with a surrogate marker for platinum sensitivity, i.e., normal-
ized CA12-5 level after three cycles of platinum-based che-
motherapy. It is noteworthy that comparisons between these
previous studies mentioned should, however, be made with
caution since it is possible that the conflicting results are due
to different methods used. For example, the previous IHC
studies have used different primary PARP-1 antibodies with
different scoring systems [27, 37]. It has also been suggested
that the IHC assay used for PARP-1 determination detects not
only functionally active PARP-1 but also inactive, auto-
modified PARP-1 [31], and this could also explain inferiority
of IHC methodology compared to enzymatic pharmacody-
namic assay used in our study. Nevertheless, the optimal
methodology to evaluate tumoral PARP-1 activity in clinical
OC should be addressed in future studies [38, 39].
Another finding in the present study involves low PARP
activity in samples obtained after NACT. Theoretically,
NACT can lead to a low PARP activity in two ways. First,
after platinum therapy, HRd tumors are dependent on BER
and thus exploit PARP, decreasing its concentration. Second,
NACTmay induce activemolecular changes in tumors, which
are thereafter reflected as low PARP activity. The latter expla-
nation is intriguing since several studies have suggested that
NACT may induce platinum resistance [40]. However, it is
somewhat challenging to interpret the finding of lower PARP
activity after NACT, as we did not obtain sequential samples
from patients before and after NACT, but all samples available
are post-NACT. It is possible that the patients not eligible for
upfront surgery and consequently, selected for NACT are a
priori patients with worse prognosis. It is, however, worth
mentioning that in a recent EOC study intratumoral PARP-1
expression by IHC was reduced after chemotherapy [26]. In
that study, not only unmatched chemo-naïve and chemo-
treated tumor samples were used but also nine PARP-1 posi-
tive cases with matched tumor samples before and after che-
motherapy were included [26]. In our study, there was no
association between NACTand PARP-1 IHC staining, but this
may of course be due to a smaller sample size in our study or
to differences in the antibodies used. In our study, we used an
antibody recognizing highly conserved PARP-1 C-terminus
containing the catalytic domain [41] instead of N-terminal
domain [26]. As discussed before, the weakness of PARP-1
IHC seems to associate with its dependency on researcher-
related methodological factors such as the antibody used,
staining protocol and data analysis. Altogether, this prelimi-
nary finding warrants validation in a large cohort of sequential
tumor samples obtained before and after NACT. If NACT
truly affects PARP-1 protein expression or its enzymatic ac-
tivity, it provides a relevant target for future research consid-
ering that PARP inhibitors are now used in the maintenance
therapy of recurrent and heavily chemo-treated OC patients.
There are limitations to our study. First, the study cohort
included a relatively small number of patients. This is due to
the laborious and expensive collection of a prospective snap-
frozen fresh tumor material as opposed to collection of, e.g.,
retrospective archival material. Despite this, we feel that our
study cohort was comprehensive enough to be able to detect
an association of PARP activity with response to chemother-
apy, the outcome of our primary interest. Second, the fresh
tissue samples for PARP analyses were not selected based on
microscopic investigation but rather on a gross examination,
which may have led to inclusion of non-tumor tissue in the
analyses. Third, the genetic characterization (e.g., BRCA sta-
tus) of the study cohort was not included. Our main scope,
however, was to analyze PARP activity in fresh tumor tissue
of EOC patients regardless of their BRCA1/2 status.
Fig. 4 Kaplan-Meier analysis of progression-free survival (PFS) accord-
ing to PARP-1 immunohistochemistry staining (log-rank p = 0.061).
Vertical lines represent censored patients
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In conclusion, we present the data of PARP pharmacody-
namic assay and PARP IHC staining in EOC tumor tissue. We
found an association between high PARP activity and plati-
num sensitivity and longer PFS, which is a novel finding. In
addition, NACT seemed to be associated with low PARP ac-
tivity. The IHC staining and pharmacodynamic assay findings
did not associate, and PARP pharmacodynamic assay rather
than PARP IHC seems to reflect better biologically significant
PARP. Therefore, PARP pharmacodynamic assay may better
identify patients with likely HRd tumors possibly benefiting
from PARP inhibitors compared to PARP IHC.
Acknowledgments We sincerely thankMrs. Sari Toivola for her excel-
lent assistance in laboratory.
Supported by Finnish Cancer Society, Tampere Medical Society,
Finnish Medical Society, The Academy of Finland, the Sigrid Juselius
Foundation, the Tampere Tuberculosis Foundation, Competitive
Research Funding of the Tampere University Hospital (Grants 9N056,
9S040, and 9S051), the Doctoral Programme in Biomedicine and
Biotechnology, University of Tampere, and the Cultural Foundation of
Finland.
Compliance with ethical standards The study was carried out at the
University of Tampere and Tampere University Hospital (TAUH), Tampere,
Finland. The study protocol was approved by the Ethics Committee of
TAUH (Identification code ETL-R11137, September 13, 2011).
Conflicts of interest None
References
1. George SHL, Shaw P. BRCA and early events in the development
of serous ovarian cancer. Front Oncol. 2014;4:5.
2. Sonoda Y. Management of early ovarian cancer. Oncology.
2004;18:343–56. discussion 358, 361-2.
3. Piccart MJ, Lamb H, Vermorken JB. Current and future potential
roles of the platinum drugs in the treatment of ovarian cancer. Ann
Oncol. 2001;12:1195–203.
4. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role
of DNA repair pathways. Clin Cancer Res. 2008;14:1291–5.
5. Wiedemeyer WR, Beach JA, Karlan BY. Reversing platinum resis-
tance in high-grade serous ovarian carcinoma: targeting BRCA and
the homologous recombination system. Front Oncol. 2014;4:34.
6. Cancer Genome Atlas Research Network. Integrated genomic anal-
yses of ovarian carcinoma. Nature. 2011;474:609–15.
7. Cerbinskaite A, Mukhopadhyay A, Plummer ER, Curtin NJ,
Edmondson RJ. Defective homologous recombination in human
cancers. Cancer Treat Rev. 2012;38:89–100.
8. Tan DS, Rothermundt C, Thomas K, et al. BBRCAness^ syndrome
in ovarian cancer: a case-control study describing the clinical fea-
tures and outcome of patients with epithelial ovarian cancer associ-
ated with BRCA1 and BRCA2 mutations. J Clin Oncol. 2008;26:
5530–6.
9. Bolton KL, Chenevix-Trench G, Goh C et al.; EMBRACE;
kConFab Investigators; Cancer GenomeAtlas Research Network.
Association between BRCA1 and BRCA2mutations and survival in
women with invasive epithelial ovarian cancer. JAMA. 2012;307:
382–90.
10. Vencken PM, Kriege M, Hoogwerf D, et al. Chemosensitivity and
outcome of BRCA1- and BRCA2-associated ovarian cancer pa-
tients after first-line chemotherapy compared with sporadic ovarian
cancer patients. Ann Oncol. 2011;22:1346–52.
11. Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T,
Fountzilas E, Francoeur N, et al. Gene expression profile of
BRCAness that correlates with responsiveness to chemotherapy
and with outcome in patients with epithelial ovarian cancer. J Clin
Oncol. 2010;28:3555–61.
12. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair
defect in BRCA mutant cells as a therapeutic strategy. Nature.
2005;434(7035):917–21.
13. Parsons JL, Dianova II, Allinson SL, Dianov GL. Poly(ADP-ri-
bose) polymerase-1 protects excessive DNA strand breaks from
deterioration during repair in human cell extracts. FEBS J.
2005;272(8):2012–2.
14. Veuger SJ, Curtin NJ, Smith GC, Durkacz BW. Effects of novel
inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-
dependent protein kinase on enzyme activities and DNA repair.
Oncogene. 2004;23:7322–9.
15. Metzger MJ, Stoddard BL, Monnat Jr RJ. PARP-mediated repair,
homologous recombination, and back-up non-homologous end
joining-like repair of single-strand nicks. DNA Repair. 2013;2:529.
16. Shen Y, Aoyagi-ScharberM,WangB. Trapping PARP. J Pharmacol
Exp Ther. 2015;353(3):446–57. doi:10.1124/jpet.114.222448.
17. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose)
polymerase in tumors fromBRCAmutation carriers. N Engl JMed.
2009;361:123–34.
18. AudehMW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose)
polymerase inhibitorx olaparib in patients with BRCA1 or BRCA2
mutations and recurrent ovarian cancer: a proof-of-concept trial.
Lancet. 2010;376:245–51.
19. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance
therapy in platinum-sensitive relapsed ovarian cancer. N Engl J
Med. 2012;366:1382–92.
20. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance
therapy in patients with platinum-sensitive relapsed serous ovarian
cancer: a preplanned retrospective analysis of outcomes by BRCA
status in a randomized phase 2 trial. Lancet Oncol. 2014;15:852–
61.
21. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of
DNA damage by homologous recombination and sensitivity to
poly(ADP- ribose) polymerase inhibition. Cancer Res. 2006;66:
8109–15.
22. Gottipati P, Vischioni B, Schultz N, et al. Poly(ADP-ribose) poly-
merase is hyperactivated in homologous recombination-defective
cells. Cancer Res. 2010;70(13):5389–98.
23. Liu JF, Konstantinopoulos PA, Matulonis UA. PARP inhibitors in
ovarian cancer: current status and future promise. Gynecol Oncol.
2014;133(2):362–9.
24. Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic
mutations in homologous recombination genes predict platinum
response and survival in ovarian, fallopian tube, and peritoneal
carcinomas. Clin Cancer Res. 2014;20:764–75.
25. Ossovskaya V, Koo IC, Kaldjian EP, Alvares C, Sherman BM.
Upregulation of Poly(ADP-Ribose) polymerase-1 (PARP1) in
triple-negative breast cancer and other primary human tumor types.
Genes Cancer. 2010;1:812–2.
26. Marques M, BeauchampMC, Fleury H, Laskov I, Qiang S, Pelmus
M, et al. Chemotherapy reduces PARP1 in cancers of the ovary:
implications for future clinical trials involving PARP inhibitors.
BMC Med. 2015;13:217.
27. Gan A, Green AR, Nolan CC, Martin S, Deen S. Poly(adenosine
diphosphate-ribose) polymerase expression in BRCA-proficient
ovarian high-grade serous carcinoma; association with patient sur-
vival. Hum Pathol. 2013;44:1638–47.
11998 Tumor Biol. (2016) 37:11991–11999
28. Denkert C, Sinn BV, Issa Y, Maria Müller B, Maisch A, Untch M, et
al. Prediction of response to neoadjuvant chemotherapy: new bio-
marker approaches and concepts. Breast Care. 2011;6(4):265–72.
29. Garg K, Levine DA, Olvera N, Dao F, BisognaM, Secord AA, et al.
BRCA1 immunohistochemistry in a molecularly characterized co-
hort of ovarian carcinomas. Am J Surg Pathol. 2013;37:138–46.
30. Kinders RJ, Hollingshead M, Khin S, Rubinstein L, Tomaszewski
JE, Doroshow JH, et al. Preclinical modeling of a phase 0 clinical
trial: qualification of a pharmacodynamic assay of poly(ADP-ri-
bose) polymerase in tumor biopsies of mouse xenografts. Clin
Cancer Res. 2008;14:6877–85.
31. Jacot W, Thezenas S, Senal R, et al. BRCA1 promoter hypermethy-
lation, 53BP1 protein expression and PARP-1 activity as bio-
markers of DNA repair deficit in breast cancer. BMC Cancer.
2013;13:523.
32. Burgess M, Puhalla S. BRCA 1/2-mutation related and sporadic
breast and ovarian cancers: more alike than different. Front
Oncol. 2014;4:19.
33. Liu X, Palma J, Kinders R, Shi Y, et al. An enzyme-linked immu-
nosorbent poly(ADP-ribose) polymerase biomarker assay for clin-
ical trials of PARP inhibitors. Anal Biochem. 2008;381:240–7.
34. Naipal KA, Verkaik NS, Ameziane N, et al. Functional ex vivo
assay to select homologous recombination-deficient breast tumors
for PARP inhibitor treatment. Clin Cancer Res. 2014;20:4816–26.
35. Shah MM, Dobbin ZC, Nowsheen S, Wielgos M, Katre AA,
Alvarez RD, et al. An ex vivo assay of XRT-induced Rad51 foci
formation predicts response to PARP-inhibition in ovarian cancer.
Gynecol Oncol. 2014;134:331–7.
36. Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS,Meyer
LA, et al. Patterns of genomic loss of heterozygosity predict homol-
ogous recombination repair defects in epithelial ovarian cancer. Br J
Cancer. 2012;107(10):1776–82.
37. Godoy H,Mhawech-Fauceglia P, Beck A,Miller A, Lele S, Odunsi
K. Expression of poly (adenosine diphosphate-ribose) polymerase
and p53 in epithelial ovarian cancer and their role in prognosis and
disease outcome. Int J Gynecol Pathol. 2011;30:139–44.
38. von Minckwitz G, Muller BM, Loibl S, Budczies J, Hanusch C,
Darb-Esfahani S, et al. Cytoplasmic poly(adenosine diphosphate-
ribose) polymerase expression is predictive and prognostic in pa-
tients with breast cancer treated with neoadjuvant chemotherapy. J
Clin Oncol. 2011;29:2150–7.
39. Rojo F, Garcia-Parra J, Zazo S, Tusquets I, Ferrer-Lozano J,
Menendez S, et al. Nuclear PARP-1 protein overexpression is as-
sociated with poor overall survival in early breast cancer. Ann
Oncol. 2012;23:1156–64.
40. Sato S, Itamochi H. Neoadjuvant chemotherapy in advanced ovar-
ian cancer: latest results and place in therapy. Ther AdvMed Oncol.
2014;6:293–304.
41. Muthurajan UM, Hepler MR, Hieb AR, Clark NJ, Kramer M, Yao
T, et al. Automodification switches PARP-1 function from chroma-
tin architectural protein to histone chaperone. Proc Natl Acad Sci U
S A. 2014;111:12752–7.
Tumor Biol. (2016) 37:11991–11999 11999

PUBLICATION 
III 
Expression analysis of platinum sensitive and resistant epithelial ovarian cancer patient samples 
reveals new biomarkers for targeted therapies 
 
Veskimäe K, Scaravilli M, Ungureanu, D, Karvonen H, Niininen W, Jaatinen S, Nykter M, Isola J, 
Mäenpää J, Visakorpi T and Staff S. 
 equal contribution 
Transl Oncol. 2018 Oct;11(5):1160-1170.  
 
Publication reprinted with the permission of the copyright holders.  
 



Expression Analysis of Platinum
Sensitive and Resistant Epithelial
Ovarian Cancer Patient Samples
Reveals New Candidates for
Targeted Therapies1
K Veskimäe*,2, M Scaravilli†,‡, 2, W Niininen†,‡,
H Karvonen†,‡, S Jaatinen†,‡, M Nykter†,‡,
T Visakorpi†,‡, §, J Mäenpää*,‡, D Ungureanu†,‡ and
S Staff*,†
*Department of Obstetrics and Gynecology, Tampere
University Hospital, Tampere, Finland; †BioMediTech
Institute, University of Tampere, Tampere, Finland.; ‡Faculty
of Medicine and Life Sciences, University of Tampere,
Tampere, Finland; §Fimlab Laboratories, Tampere University
Hospital, Tampere, Finland
Abstract
Ovarian cancer has the highest mortality rate of all gynecologic malignancies. Identification of new biomarkers is
highly needed due to its late diagnosis and high recurrence rate. The objective of this study was to identify
mechanisms of therapy resistance and potential biomarkers by analyzing mRNA and protein expression from
samples derived from patients with platinum-sensitive and -resistant ovarian cancer (total cohort n = 53). The data
revealed new candidates for targeted therapies, such as GREB1 and ROR2. We showed that the development of
platinum resistance correlated with upregulation of ROR2, whereas GREB1 was downregulated. Moreover, we
demonstrated that high levels of ROR2 in platinum-resistant samples were associated with upregulation of Wnt5a,
STAT3 and NF-kB levels, suggesting that a crosstalk between the non-canonical Wnt5a-ROR2 and STAT3/NF-kB
signaling pathways. Upregulation of ROR2, Wnt5a, STAT3 and NF-kB was further detected in a platinum-resistant
cell-line model. The results of the present study provided insight into molecular mechanisms associated with
platinum resistance that could be further investigated to improve treatment strategies in this clinically challenging
gynecological cancer.
Translational Oncology (2018) 11, 1160–1170
Introduction
Epithelial ovarian cancer (EOC) accounts for the majority of
mortality from gynecological cancers, with diagnosis often at a late
stage. Currently, the golden standard of treatment is primary
debulking surgery (PDS) followed by platinum-based chemotherapy
[1]. Although most patients initially respond to chemotherapy, cancer
cells will eventually develop resistance leading to relapse [2]. Despite
intensive efforts to improve targeted therapy in EOC, the five-year
survival rate is still only 30% for advanced disease [3]. Therefore,
increased knowledge about mechanisms of platinum resistance in
EOC treatment is needed in search for cure.
Genetically complex and unstable high-grade serous ovarian cancer
subtype (HGSC), accounting for approximately 50–70% of EOC,
represents the most aggressive histological subtype [4]. A large-scale
integrated genomic data analysis for HGSC identified TP53
mutations in almost 96% of tumors. Recurrent somatic mutations
were found in nine other genes including NF1, BRCA1, BRCA2,
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RB1 and CDK12, as well as DNA copy number aberrations and
promoter methylation events, indicating biological and molecular
heterogeneity that should be considered when developing novel
therapeutic strategies [5].
While only 10%–15% of ovarian cancer patients carry BRCA1 or
BRCA2 mutations in their germline, ∼50% of ovarian cancers exhibit
a defect in the homologous recombination (HR) repair of DNA [6].
PARP-1 enzyme became an attractive target for chemotherapeutics
for its crucial function in single-strand breaks (SSBs) DNA repair
mechanism through base excision repair (BER) pathway [7]. The
concept of synthetic lethality has been used in genetic studies to
determine functional interactions and compensation among genes for
decades and has also been exploited in the development of PARP
(Poly (ADP-ribose) polymerase) inhibitors [8]. The responsiveness to
platinum and PARP inhibitors associates with so called BRCAness
profile showing independent prognostic value [9,10].
The chemotherapy resistance can arise due to multiple mecha-
nisms, such as drug target alteration, re-activation or amplification of
the oncogenic pathway, activation of parallel pathways, increased
DNA damage tolerance/repair, and deregulation of growth factor
receptors among others [11]. Deregulation of apoptosis and altered
phosphorylation (intracellular signaling), as well as metabolic
pathways represent the two main biological processes responsible
for oncogene-mediated drug resistance in ovarian cancer [12]. In this
context, activation of PI3K/AKT cell survival pathway plays a pivotal
role with NF-kB and STAT3 as the main mediations of these
intracellular events. On the other hand, tumor suppressor genes such
as BRCA1, BRCA2, MLH1 and p21 contribute to ovarian cancer
drug resistance via alterations in the DNA damage and repair
mechanisms, whereas RASSF1, TP53 and TP73 impair the apoptotic
machinery for the same outcome [13]. Epithelial-to-mesenchymal
transition (EMT) has also been implicated in HGSC invasiveness and
chemoresistance, and in vitro studies using ovarian cancer cell lines
have shown that more aggressive, mesenchymal-type cells are more
resistant to cisplatin treatment [14]. An important signaling cascade
involved in EMT is the Wnt signaling, with increasing evidence
suggesting that β-catenin-independent pathway via Wnt5a/ROR1/
ROR2 has a critical role in EMT and chemoresistance [15–18].
Consequently, therapies targeting these pathways may offer means to
overcome drug resistance.
Active and also productive research in the field of cancer therapy has led
to an improved understanding of the molecular mechanisms, providing
insight into the development of cancer. This new data has led to the
development of new treatment options for cancer patients, including
targeted therapies and associated biomarker tests that can select which
patients are most likely to respond [19]. The aim of this study was to
identify candidate genes and their molecular pathways involved in the
pathogenesis of ovarian cancer associating with platinum resistance.
Overcoming the paucity of obtaining large collection of tumor samples
available for molecular profiling, we investigated differences in mRNA
and protein expression between ovarian cancer samples derived from two
clinically and molecularly distinct patient cohorts namely high PARP/
platinum-sensitive and low PARP/platinum-resistant HGSC cohorts.
This comparison aimed at distinction of two cohorts with extremely
different clinical behavior. Finally, this analysis led to identification of
GREB1 and ROR2 that showed significant differential expression profile
between the two groups. Our data suggest new predictive biomarkers for
ovarian cancer drug resistance development warranting further
investigations.
Materials and Methods
Study Cohort and Tissue Samples
The study was carried out at the University of Tampere and
Tampere University Hospital (TAUH), Tampere, Finland. The study
protocol was approved by the Ethics Committee of TAUH
(identification code ETL-R11137).
The microarray study cohort consisted of 12 HGSC patients who
participated in a prospective study addressing PARP enzyme activity
in fresh ovarian cancer tumor samples [20]. The selection of this
patient subcohort was based on PARP values (high PARP/low PARP,
cut off 203 pg/ml, which corresponded to the median value of PARP)
and platinum sensitivity/resistance (treatment response), with no
differences in respect of age and FIGO (International Federation of
Gynecology). Platinum sensitivity was defined as no recurrence
within 12 months after the completion of first-line platinum-based
chemotherapy. Patient characteristics are presented in Table 1.
The validation cohort of the microarray data consisted of all the
patients (n = 53) that participated in the previous prospective study
[20]. The median follow-up time of patients was 31 months. The
validation cohort is described in Table 2.
For further investigation of ROR2 in EOC, a retrospective
subcohort was chosen from the study cohorts described above
consisting of a subgroup of patients who had not received NACT
(neoadjuvant chemotherapy) and were divided in two categories
based on treatment response, i.e. either platinum-sensitive or
platinum-resistant (Table 3).
The tumor tissue samples were collected at surgery, two samples
approximately 0.5 cm were chosen at the operation room from
macroscopically visible tumor and were snap-frozen with liquid
nitrogen and stored in −70 °C. The findings from the corresponding
archival surgical tumor specimens were assessed by experienced
pathologists as part of routine diagnostics at the Department of
Pathology at TAUH.
Table 1. Characteristics of the Study Patients in the Microarray Cohort (n = 12)
Characteristic Platinum Sensitive * n (%) Platinum Resistant * n (%)
All 6 6
PDS † 5 2
NACT ‡ 1 4
PARP § low 0 6
PARP § high 6 0
Age
mean (SD) 65 62
median (range) 63 (46–78) 62 (55–79)
Grade 3 ¶ 6 (100%) 6 (100%)
Stage #
FIGO st I 0 0
FIGO st II 0 0
FIGO st III and IV 6 6
Histology
serous 6 (100%) 6 (100%)
PFS ** (months) 28 3.5
* Sensitivity defined as relapse or event-free intervalN 12 months after completion of platinum based 1st
line therapy.
† PDS - primary debulking surgery.
‡ NACT - neoadjuvant therapy.
§ PARP - PARP activity in fresh frozen tumor tissue was assessed by an enzymatic chemiluminescense
assay in a previous study [20]; the cut-off level for high PARP activity was set to 203 pg/ml corresponding to
median value.
¶ Grade – Grade 3 represents high grade tumors.
# FIGO - International Federation of Gynecology.
** PFS - progression free survival.
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mRNA Microarray
Total RNA from ovarian cancer fresh frozen samples was extracted
using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), according to the
manufacturer's protocol. The quality and integrity of the RNA was
assessed using Fragment Analyzer parallel capillary electrophoresis
(Advanced Analytical Technologies, Ankeny, IA, USA). The RNA was
subsequently labeled and hybridized using the Agilent gene expression
microarray kit (Agilent Technologies, Santa Clara, CA, USA), according
to the manufacturer's instruction. Briefly, the RNA from the clinical
samples was labeled with Cy3 fluorochrome and subsequently co-
hybridized withCy5 labeled Xpress Ref TMHumanUniversal Reference
Total RNA (SuperArray Bio-science Corporation) as a control. The
hybridization was carried out for 21 hours on Agilent 4X44K human
gene expression array slides. The slides were subsequently scanned on an
Agilent C scanner and raw data were extracted using the Agilent Feature
Extraction software ver. 11.0.1.1 and quantile normalized. A fold-change
cutoff of 2 was used to determine differential mRNA expression as well as
q-value and signal intensity.
qRT-PCR
Putatively differentially expressed genes (ROR2, CAST, ATP6V1D,
GUCY1A3, TMOD1, MYCN, DLK1, PLEKHG4B, GREB1,
B4GALNT4, SLC35F3, PTCH2, TNNC1, BNC1) were selected
from the array results based on fold change, q-value, signal intensity
and literature data and were validated by quantitative real-time
polymerase chain reaction (qRT-PCR). Total RNA from ovarian
cancer fresh frozen tumor samples were extracted with TRIzol as
described above and were reverse transcribed using random hexamere
primers and MultiScribe reverse transcriptase (Thermo Fischer
Scientific, Waltham, MA, USA). Quantitative Real Time PCR was
performed using Maxima SYBR Green/ROX qPCR Master Mix
(Thermo Fischer Scientific) on a BioRad CFX96 ™ Real-Time PCR
Detection System (BioRad Laboratories, Hercules, CA, USA). Each
sample was run in duplicate and expression values were normalized
against the TATA-binding protein (TBP). The primer sequences for
the two validated genes are as follows:
Western blotting
Frozen tumor pieces were thawed, washed 2X with cold PBS and
pestered to lyse in lysis buffer (50 mMTris–HCl pH 7.5, 10% glycerol,
150 mM NaCl, 1 mM EDTA, 1% Triton-x-100, 50 mM NaF)
supplementedwith protease and phosphatase inhibitor cocktails (Bimake,
Houston, TX, USA). Lysates were mixed with 4X Laemmli loading
buffer and subjected to SDS-PAGE gel electrophoresis and Western
blotting. The primary antibodies used were as following: pAkt S473
(#4060), pMEK1/2 S217/221 (#9121), NF-κB p65 (#6956), pPI3K
p85 Y458/p55 Y199 (#4228), PI3K p85α (#13666), Rac-1 (#4651),
pSTAT3 Y705 (#9145), STAT3 (#9139), Wnt5a/b (#2530) (Cell
Signaling Technology, Danvers, MA, USA); Akt (#sc-5298), Bcl-2 (#sc-
7382), MEK1/2 (#sc-6250), β-tubulin (#sc-166,729) (Santa Cruz,
Dallas, TX, USA); ROR1 6D4 (Dr. Riddel lab, ref. Balakrishana et al.
2016); ROR2 (#565550, BD Biosciences, San Jose, CA, USA).
Secondary antibodies: IRDye® 800CW Donkey anti-Mouse IgG, or
IRDye® 680RDDonkey anti-Rabbit IgG (LI-COR, Lincoln, NE, USA).
Blots were scanned and quantified using Odyssey CLx and Image Studio
Table 2. Characteristics of the Study Patients in the Validation Cohort (n = 53)
Characteristic
Patients in study, n 53
Age at surgery, yrs. (SD) 66 (9.3)
BMI, mean (SD) 26.8 (6.2)
Median follow-up, months (range) 31 (2–50)
Ca 125 level (kU/L) before treatment, median (range) 523 (30–4728)
FIGO * Stage, n (%)
Stage 1 2 (3,7%)
Stage 2 3 (5,6%)
Stage 3 34 (64,3%)
Stage 4 14 (26,4%)
Histology, n (%)
Serous 46 (86,8)
Endometroid 4 (7,6%)
Papillar 2 (3,7%)
Mucinous 0 (0%)
Carcinosarcoma 0 (0%)
Transitional cell 1 (1,9%)
Grade †, n (%)
Grade 1 and 2 10 (18%)
Grade 3 43 (82%)
Sensitivity to platinum therapy ‡, n (%)
Sensitive 25 (47,2%)
Resistant 15 (28,3%)
Partial sensitive 13 (24,5%)
Neoadjuvant therapy, n (%) 19 (36%)
Recurrence 36 (68%)
Death 22 (42%)
* FIGO = International Federation of Gynecology.
† Grade – Grade 3 represents high grade tumors, Grade 1 and 2 low grade tumors.
‡ Sensitive: Recurrence N12 months after completion of platinum-based 1st line therapy; Resistant:
Recurrence ≤6 months after completion of platinum-based 1st line therapy; Partially sensitive: Recurrence 6–
12 months after completion of platinum-based 1st line therapy.
Table 3. Characteristics of the study patients in the ROR investigation subcohort (n = 30)
Characteristic
Patients in study, n 30
Age at surgery, yrs mean (SD) 66 (9.3)
Median follow-up, months (range) 31 (2–50)
FIGO * Stage, n (%)
Stage 1 2 (6,7%)
Stage 2 4 (14%)
Stage 3 17 (56%)
Stage 4 7(23,3%)
Histology, n (%)
Serous 22(73,3%)
Endometroid 2 (6,7%)
Papillar 2 (6,7%)
Mucinous 2 (6,7%)
Carcinosarcoma 1 (3,3%)
Transitional cell 1 (3,3%)
Grade †, n (%)
Grade 1 and 2 8 (26,7%)
Grade 3 22 (73,3%)
Response to platinum therapy ‡, n (%)
Sensitive 20 (66,7%)
Resistant 10 (33,3%)
Recurrence 20 (66,7%)
Death 9 (30%)
* FIGO = International Federation of Gynecology.
† Grade – Grade 3 represents high grade tumors, Grade 1 and 2 low grade tumors.
‡ Sensitivity defined as relapse or event-free follow up timeN 12 months after completion of platinum
based 1st line therapy.
GREB1 fw 5’ATGGGAAATTCTTACGCTGGAC
GREB1 rev 5’CACTCGGCTACCACCTTCT
ROR2 fw 5’GTGCGGTGGCTAAAGAATGAT
ROR2 rev 5’ATTCGCAGTCGTGAACCATATT
TBP fw 5’GAATATAATCCCAAGCGGTTTG
TBP rev 5’ACTTCACATCACAGCTCCCC
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software (LI-COR). Protein quantification was normalized to β-tubulin
expression level for each sample.
Cell Culture
A2780 and A2780cis cells were purchased from Merck & Company
Inc. (Kenilworth, NJ, USA) and cultured according to manufacturer's
recommendations. The A2780 line was maintained in medium
containing 1 μM cisplatin (Selleckchem, Munich, Germany). The
cisplatin EC50 response of A2780 and A2780cis cells was validated by
incubating cells with increasing concentration of cisplatin for 3 days and
cell viability was determined using CellTiterGlo (CTG) Assay (Promega,
USA) according to manufacturer's instructions.
qRT-PCR of the Ovarian Cancer Cell Lines
RNA was collected from A2780 and A2780cis using TRI Reagent®
(Molecular Research Center Inc. Cincinnati, OH, USA) according to
the manufacturer's protocol. qRT-PCR was performed as described
for the ovarian cancer clinical samples. Each cell line was run in 4
replicates and the expression of ROR2 and GREB1 was normalized
against TBP.
Statistical Analysis
The statistical analysis of mRNA microarray data was implemented
in R using packages limma and preprocessCore of Bioconductor
project [21–23]. Data was quantile normalized and probe sets were
summarized by choosing the probes with the highest average
expression [22]. Using limma approach, differential expression was
identified between patients who had low PARP value and were
platinum resistant, and patients who had high PARP value and were
platinum sensitive [23]. P-values were obtained by the empirical
Bayes moderated t-test. A fold-change cutoff of 2 was used to
determine differential mRNA expression. The results were
Table 4. The 50 Most Upregulated mRNAs in High PARP and Platinum Sensitive OC Patient Samples in Comparison to low PARP and Platinum Resistant Samples.
Gene name Gene description log2-fold change p-value q-value
COLEC11 collectin subfamily member 11 3.68E+ 00 1.29E-02 0.2588936
MYCN MYCN proto-oncogene. bHLH transcription factor 3.61E+ 00 2.74E-04 0.1050305
ESM1 endothelial cell specific molecule 1 3.18E+ 00 1.64E-04 0.1028588
IGF1R insulin like growth factor 1 receptor 3.08E+ 00 5.29E-03 0.211962
TNNC1 troponin C1. slow skeletal and cardiac type 3.04E+ 00 1.25E-05 0.0472319
LGSN lengsin. Lens protein with glutamine synthetase domain 3.02E+ 00 1.25E-02 0.2588936
LOC100134423 uncharacterized LOC100134423 2.97E+ 00 2.71E-04 0.1050305
DLK1 delta like non-canonical Notch ligand 1 2.89E+ 00 4.17E-03 0.2013983
CRYGC crystallin gamma C 2.86E+ 00 2.37E-03 0.1822358
A_33_P3286709 NA 2.82E+ 00 9.15E-05 0.0864965
PLEKHG4B pleckstrin homology and RhoGEF domain containing G4B 2.82E+ 00 1.17E-03 0.1525447
TSPAN8 tetraspanin 8 2.78E+ 00 2.99E-02 0.3064189
ENPP6 ectonucleotide pyrophosphatase/phosphodiesterase 6 2.73E+ 00 1.20E-02 0.2563874
FLJ30901 uncharacterized protein FLJ30901 2.60E+ 00 3.26E-04 0.1050305
PROM1 prominin 1 2.59E+ 00 3.02E-02 0.3079072
COL22A1 collagen type XXII alpha 1 chain 2.58E+ 00 2.64E-03 0.1844765
KIAA1324 KIAA1324 2.58E+ 00 5.48E-04 0.1261184
PTCH2 patched 2 2.57E+ 00 1.93E-05 0.0472319
SLC35F3 solute carrier family 35 member F3 2.54E+ 00 3.87E-05 0.0596903
GABRG3 gamma-aminobutyric acid type A receptor gamma3 subunit 2.51E+ 00 4.50E-05 0.0628517
LOC613266 uncharacterized LOC613266 2.50E+ 00 4.89E-02 0.3485897
LCE1E late cornified envelope 1E 2.49E+ 00 2.28E-04 0.1050305
B4GALNT4 beta-1.4-N-acetyl-galactosaminyltransferase 4 2.49E+ 00 1.24E-05 0.0472319
STC2 stanniocalcin 2 2.48E+ 00 2.86E-04 0.1050305
FOXL2NB FOXL2 neighbor 2.48E+ 00 1.04E-01 0.4447586
AK124496 NA 2.47E+ 00 2.78E-02 0.3020977
CU677518 NA 2.47E+ 00 2.82E-06 0.0275612
NM_130777 NA 2.45E+ 00 1.10E-02 0.2525629
NR_102701 NA 2.43E+ 00 2.11E-03 0.1762016
NSG1 neuronal vesicle trafficking associated 1 2.43E+ 00 1.05E-03 0.1525447
STAR steroidogenic acute regulatory protein 2.41E+ 00 5.08E-03 0.2110634
MCTS2P malignant T-cell amplified sequence 2. pseudogene 2.40E+ 00 5.43E-03 0.2134259
TRABD2A TraB domain containing 2A 2.36E+ 00 4.89E-03 0.2078187
DEPTOR DEP domain containing MTOR interacting protein 2.35E+ 00 4.70E-04 0.125416
CLEC4GP1 C-type lectin domain family 4 member G pseudogene 1 2.35E+ 00 4.56E-03 0.2021535
LINC01405 long intergenic non-protein coding RNA 1405 2.33E+ 00 6.95E-04 0.1391319
COL2A1 collagen type II alpha 1 chain 2.32E+ 00 1.82E-02 0.2816697
HS6ST2 heparan sulfate 6-O-sulfotransferase 2 2.31E+ 00 2.15E-02 0.2871745
PRAME preferentially expressed antigen in melanoma 2.30E+ 00 4.32E-05 0.0628517
LINC02398 long intergenic non-protein coding RNA 2398 2.29E+ 00 1.08E-05 0.0472319
GJB7 gap junction protein beta 7 2.29E+ 00 3.18E-02 0.3122712
PLCXD3 phosphatidylinositol specific phospholipase C X domain containing 3 2.28E+ 00 6.03E-02 0.3707384
ERVI-1 endogenous retrovirus group I member 1 2.27E+ 00 1.28E-02 0.2588936
ZNF556 zinc finger protein 556 2.27E+ 00 1.46E-06 0.0213888
NTS neurotensin 2.26E+ 00 6.56E-02 0.3828556
BU963192 NA 2.25E+ 00 7.17E-05 0.0751488
GMNC geminin coiled-coil domain containing 2.24E+ 00 1.52E-02 0.2689731
A_33_P3274001 NA 2.24E+ 00 9.36E-05 0.0864965
CRYGD crystallin gamma D 2.24E+ 00 2.58E-02 0.2964626
GREB1 growth regulation by estrogen in breast cancer 1 2.22E+ 00 1.22E-03 0.1542519
mRNAs selected for further validation are shown in bold.
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interpreted by principal component analysis [24] and hierarchical
clustering.
qRT-PCR data were analyzed using the Student's t-test and
Mann–Whitney U test where appropriate. The Kaplan–Meier
regression analyses were used to estimate the survival rates from the
date of surgery (primary debulked patients) or from the date of the
first dose of neoadjuvant therapy until the date of the event of
interest. For progression-free survival (PFS), the event of interest was
a recurrence or death, whichever occurred first. Patients alive at the
last follow-up without a recurrence were censored at the last follow-up
date. Statistical analysis was performed using GraphPad Prism 6
software for Windows (GraphPad Software Inc., La Jolla, CA, USA).
A p-value less than 0.05 was considered significant.
Oncomine (https://www.oncomine.org/resource/login.html) and
Kaplan–Meier plotter (http://kmplot.com/analysis/index.php?p=
service&cancer=ovar) databases were searched for gene expression
and survival data.
Results
Microarray Analysis of HGSC Patient Samples
In order to identify differentially expressed genes between ovarian
cancer samples with platinum-sensitivity with high PARP levels and
samples with platinum resistance with low PARP levels (n = 12),
gene expression microarray was performed on total RNA isolated
from the freshly frozen tumor samples. The analysis of gene
expression showed a total of 3001 differentially expressed genes
between the two comparison groups when a log fold change cutoff 2
was implemented. In this comparison, 1463 genes were downregu-
lated and 1538 genes were upregulated. 50 most upregulated and 50
Table 5. The 50 Most Downregulated mRNAs in High PARP and Platinum Sensitive OC Patient Samples in Comparison to Low PARP and Platinum Resistant Samples
Gene Name Gene Description Log2-Fold Change p-Value q-Value
EFEMP1 EGF containing fibulin extracellular matrix protein 1 −3.85E+ 00 1.50E-03 0.1587368
FAP fibroblast activation protein alpha −3.66E+ 00 9.07E-04 0.1525447
TMOD1 tropomodulin 1 −3.41E+ 00 2.92E-08 0.0008577
BNC1 basonuclin 1 −3.36E+ 00 2.74E-04 0.1050305
ENST00000453673 NA −3.22E+ 00 2.22E-02 0.2877726
ENST00000411475 NA −3.18E+ 00 2.30E-02 0.2898232
SCRG1 stimulator of chondrogenesis 1 −3.18E+ 00 1.64E-03 0.1627023
PTGFR prostaglandin F receptor −3.04E+ 00 1.05E-03 0.1525447
POSTN periostin −3.01E+ 00 1.10E-02 0.2525629
ENST00000390237 NA −2.97E+ 00 1.54E-02 0.2695379
BF175071 NA −2.92E+ 00 5.12E-02 0.3538495
GUCY1A3 guanylate cyclase 1 soluble subunit alpha −2.89E+ 00 5.68E-05 0.0723946
ENST00000390628 NA −2.87E+ 00 4.44E-03 0.2021325
CXCL13 C-X-C motif chemokine ligand 13 −2.87E+ 00 1.02E-02 0.2487313
ACKR4 atypical chemokine receptor 4 −2.86E+ 00 9.73E-05 0.0864965
IGLL5 immunoglobulin lambda like polypeptide 5 −2.86E+ 00 3.46E-02 0.318167
AREG amphiregulin −2.83E+ 00 1.43E-02 0.2670241
A_33_P3251412 NA −2.81E+ 00 1.46E-02 0.2682963
FYB1 FYN binding protein 1 −2.79E+ 00 2.51E-03 0.1843078
CD38 CD38 molecule −2.78E+ 00 1.54E-03 0.1587368
ENST00000468879 NA −2.77E+ 00 4.36E-02 0.3380632
ENST00000390252 NA −2.73E+ 00 1.49E-02 0.2682963
JCHAIN joining chain of multimeric IgA and IgM −2.70E+ 00 6.61E-03 0.2195342
ENST00000390547 NA −2.69E+ 00 5.85E-03 0.2163421
MEDAG mesenteric estrogen dependent adipogenesis −2.69E+ 00 4.49E-02 0.3403785
CNR1 cannabinoid receptor 1 −2.68E+ 00 9.85E-03 0.2471112
PRRX1 paired related homeobox 1 −2.68E+ 00 7.45E-04 0.1427284
NR4A3 nuclear receptor subfamily 4 group A member 3 −2.67E+ 00 2.00E-02 0.2850432
CH25H cholesterol 25-hydroxylase −2.65E+ 00 2.21E-03 0.1762175
AB363267 NA −2.65E+ 00 4.23E-02 0.3347815
ENST00000426099 NA −2.63E+ 00 4.11E-02 0.331398
CCL18 C-C motif chemokine ligand 18 −2.57E+ 00 1.16E-04 0.0898927
THBS2 thrombospondin 2 −2.57E+ 00 3.91E-02 0.327707
ENST00000410078 NA −2.56E+ 00 5.30E-02 0.3580372
BCHE butyrylcholinesterase −2.55E+ 00 1.00E-02 0.2471753
ATP6V1D ATPase H+ transporting V1 subunit D −2.55E+ 00 1.54E-04 0.1028588
ENST00000390323 NA −2.55E+ 00 2.42E-02 0.2937808
CCR2 C-C motif chemokine receptor 2 −2.54E+ 00 9.37E-03 0.24523
ENST00000479981 NA −2.54E+ 00 9.43E-03 0.24523
CAST calpastatin −2.54E+ 00 1.02E-03 0.1525447
ASPN asporin −2.52E+ 00 2.94E-02 0.3049408
HBB hemoglobin subunit beta −2.52E+ 00 2.08E-02 0.2862875
ENST00000390247 NA −2.51E+ 00 2.16E-02 0.2871745
SULF1 sulfatase 1 −2.50E+ 00 1.80E-02 0.2805948
EPYC epiphycan −2.49E+ 00 1.28E-02 0.2588936
FGFBP1 fibroblast growth factor binding protein 1 −2.49E+ 00 1.03E-02 0.2499163
LRRC15 leucine rich repeat containing 15 −2.48E+ 00 4.14E-02 0.3321649
DOCK11 dedicator of cytokinesis 11 −2.45E+ 00 5.13E-04 0.1261184
OOEP oocyte expressed protein −2.45E+ 00 4.23E-03 0.2013983
ROR2 receptor tyrosine kinase like orphan receptor 2 −1.84E+ 00 2.83E-05 0.0506967
mRNAs selected for further validation are shown in bold.
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most downregulated genes are summarized in Tables 4 and 5,
respectively. The comparison of patient groups according to PARP
levels and treatment responses are shown in Figure 1, a-b.
GREB1 and ROR2 are Significantly Differentially Expressed
inOvarianCancer Tumor Samples Based on PlatinumSensitivity
and PARP Levels
Fourteen differentially expressed mRNAs (namely: ROR2, CAST,
ATP6V1D, GUCY1A3, TMOD1, MYCN, DLK1, PLEKHG4B,
GREB1, B4GALNT4, SLC35F3, PTCH2, TNNC1, BNC1) from the
microarray analysis were selected for validation by qRT-PCR in the
cohort of 53 ovarian cancer patients, based on fold change, q-value,
signal intensity and previous literature (Table 2). Two genes, namely
ROR2 and GREB1, were significantly differentially expressed in high
PARP/platinum-sensitive vs. low PARP/platinum-resistant groups
(P = .02 and 0.002, respectively) (Figure 2, a-b). ROR2 was
downregulated in microarray data in high PARP/platinum-sensitive
tumor samples and the same result was obtained by qRT-PCR
analysis in the validation cohort (n = 53). A trend towards statistically
significant difference between the platinum sensitive and resistant
groups regardless of PARP levels was observed (P = .058) (Figure 2a).
The comparisons described above were based on treatment response
as a significant clinical feature and issue of interest. In addition,
previously determined PARP levels were taken into account to further
investigate tumors from the BRCAness profile point of view. The
platinum sensitive and high PARP level cohort is considered a group
of better prognosis befitting with the BRCAness profile, whereas the
platinum resistant and low PARP level a group with poorer prognosis.
On the other hand, GREB1 was upregulated in microarray data in
high PARP/platinum-sensitive tumor samples, and this result was
validated by qRT-PCR (Figure 2b). Furthermore, GREB1 also
showed a trend of overexpression in platinum sensitive samples,
regardless of PARP level (P = .26).
GREB1 Expression Defines Platinum Sensitivity and Correlates
with Longer PFS in Ovarian Cancer
Furthermore, we investigated whether GREB1 expression affects
PFS in ovarian cancer patients (n = 53). High GREB1 expression was
significantly associated with longer PFS as shown in Figure 2c (P =
.019 in log-rank test). In Kaplan–Meier database search, which
included 1465 ovarian cancer patients, a similar result was shown
associating high GREB1 expression with better PFS (P = 0,014 in
log-rank test), as shown in Figure 2d. In addition to Kaplan–Meier
plotter database and Oncomine (website links are reported in
statistical analysis section) were searched for the ROR2 and GREB1
genes. No similar results in expression correlation were found,
however, no similar study settings were found (HGSC, treatment
response comparison).
High ROR2 Expression in LowPARP/Platinum Resistant
Ovarian Cancer Samples Correlated with HigherWnt5a, STAT3
and NF-kB levels
Previous data have shown no association with ROR2 expression
and relapse-free survival [25] in ovarian cancer. However, ROR2 and
ROR1 expression is increased in cisplatin resistant A2780 cell line
compared to parental cells ([18]), and silencing their ligand Wnt5a in
serous adenocarcinoma OVCAR3 cell line had greater effect in
inhibiting cell migration and invasion than silencing either ROR
alone [25]. Since ROR2 was significantly upregulated in low PARP/
platinum-resistant patient samples in our microarray data, we decided
Figure 1. a. Scatterplot showing location of samples of high PARP and platinum sensitive and low PARP and platinum resistant in patients
along the first two principal components (PC1 and PC2). Platinum sensitive and high PARP level samples are represented by black and low
PARP and platinum resistant samples by purple dots.b. Unsupervised clustering of the clinical samples shows differential expression
patterns in patients with high PARP levels and platinum sensitivity compared to patients with low PARP levels and platinum resistant.
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to investigate the expression levels of Wnt5a, ROR1 and ROR2
proteins by Western blot in a subcohort of samples described in
Table 3. As shown in Figure 3a-b, higher expression levels of Wnt5a,
ROR1 and ROR2 proteins were found in low PARP/platinum-
resistant group compared to high PARP/platinum-sensitive group.
Moreover, upregulation of downstream signaling mediators such as
pSTAT3 (Y705) and NF-kB was also observed in tumor lysates from
low PARP/platinum resistant group. Noteworthy, patient samples
with high levels of ROR1 and ROR2 from low PARP/platinum-
resistant group showed higher pSTAT3 (Y705) levels (Figure 3a),
indicating that STAT3 could mediate signaling downstream ROR1
and ROR2. Database search (Oncomine, Kaplan–Meier plotter; website
links are reported in statistical analysis section) revealed no additional
information regardingROR in therapy response and ovarian cancer setting.
ROR2 and GREB1 Show Differential Expression in Cisplatin
Resistant Ovarian Cancer Cell Line Model
The human epithelial ovarian cancer cell line A2780 and its
cisplatin resistant model A2780cis were selected to investigate the
expression levels of ROR2 and GREB1. We confirmed the
chemoresistant phenotype of A2780cis cells compared to A2780
parental cells by CTG assay and found significant increase of EC50 to
cisplatin treatment for A2780cis cells (Figure 4a). The expression of
both ROR2 and GREB1 mRNA level was investigated in A2780 and
Figure 2. a. Expression of ROR2 and GREB1 in platinum sensitive (n = 38) vs resistant (n = 15) samples as well as high PARP level and
platinum sensitive (n = 17) vs low PARP level and platinum resistant (n = 14) samples according to qRT-PCR (P = .02 and 0.002
respectively). The graphs show mean ± SEM.b. Kaplan–Meier analysis of progression free survival (PFS) according to median level of
GREB 1 concentration (log rank P = .019). Vertical lines represent censored patients.c. Kaplan–Meier analysis of progression free survival
(PFS) according to median level of GREB 1 concentration (log-rank P = .014) from Kaplan–Meier plotter database.
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A2780cis cells (Figure 4b and c). We observed ROR2 mRNA
upregulation in platinum resistant cell line A2780cis compared to
platinum sensitive A2780 cells (P = .0046), as previously shown
([18]), whereas GREB1 mRNA level was downregulated in A2780cis
compared to A2780 parental cells (P = .0012). Furthermore,
A2780cis cells have increased protein expression levels of ROR2
and Wnt5a compared with the parental A2780 cells as shown by
Western blotting of cytoplasmic cell lysates (Figure 4d). In addition,
we detected higher nuclear expression levels for STAT3 and NF-kB
in chemoresistant A2780cis compared to parental A2780 cells
(Figure 4d). Thus, our microarray data from patient samples are
validated in chemoresistant ovarian cancer cell line and investigations
are ongoing to decipher the molecular mechanisms employed by
ROR2 and GREB1 for their differential expression associated with
cisplatin resistance.
Discussion
Due to its poor prognosis, identification of new therapeutic
approaches is highly needed in ovarian cancer. Although approxi-
mately 50% of HGSC tumors with HR defects may benefit from
PARP inhibitors, beyond this, identification of other commonly
deregulated pathways could provide opportunities for better
therapeutic interventions. As such, our goal was to examine gene
and protein expression in a HGSC tumor sample cohort defined by
response to platinum therapy and the level of PARP expression.
Patients were carefully stratified based on their PARP levels and
platinum responsiveness as previously indicated [20] and monitored
for relatively long time, up to 50 months to ensure a comprehensive
analysis of their disease progression.
Two functionally unrelated genes, GREB1 and ROR2 were
identified in our analysis as significantly differentially expressed
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Figure 3. Wnt5a/ROR2 expression is increased in lysates from platinum resistant tumors. A. Western blot analysis of lysates from
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between high PARP/platinum-sensitive and low PARP/platinum-
resistant groups.
While initially sequenced from brain tissue, human GREB1 is
highly expressed in normal and neoplastic ovarian tissue and in several
other hormone-responsive tissues such as breast, uterine and prostate
[26–29]. GREB1, along with CCND1 and MYC, are common
transcription targets for E2 (17β-estradiol)-mediated proliferative
responses, via ESR1 (estrogen receptor one) engagement [28].
Estrogen receptor positive (ESR1+,) breast cancers usually express
GREB1, whereas in ovarian cancer, its expression could be detected in
both, ESR1+ or estrogen receptor negative (ESR1−) tumors. ESR1-
independent expression of GREB1 may indicate the existence of
Figure 4. a. Cisplatin sensitivity testing of A2780 and A2780cis cell lines. Cells were incubated as five replicates for 3 days with increased
concentrations of cisplatin as indicated and cell-viability was measured by CTG assay. EC50 was calculated using Graph Prism software
and shown as approximate values.b. ROR2 mRNA expression in platinum sensitive and resistant cell lines A2780/A2780cis (P = .0046).
The graphs show mean ± SEM.c. GREB1 mRNA expression in platinum sensitive and resistant cell lines A2780/A2780cis (P = .0012.
The graphs show mean ± SEM.d. Protein expression levels for ROR2, Wnt5a, NF-kB and STAT3 in the cytoplasmic and nuclear cell
lysates of A2780 and A2780cis cell lines. Protein quantification was done using Oddyssey Licor software and normalized against the
loading control.
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other signaling pathways for estrogen-promoting growth in the
absence of E2 and/or ESR1, underlining differences in E2-
responsiveness between breast and ovarian cancer that play an
important role in response to antiestrogenic therapies [30]. GREB1
was upregulated in all EOC tumors and was suggested to have
potential biomarker role in ovarian cancer [29]. GREB1 was
upregulated in our microarray data in high PARP/platinum-
sensitive patients, and high GREB1 expression was associated with
longer PFS, suggesting a prognostic value for GREB1 in ovarian
cancer.
It has been demonstrated that GREB1 knockdown inhibits
proliferation of ovarian cancer cell lines and consequently, prolongs
survival in an orthotopic mouse model [28]. Also, hypomethylation at
specific CpG site associated with GREB1 has been associated with
longer PFS in ovarian cancer in a DNAmethylation study designed to
investigate epigenetic modifications [31]. Interestingly, loss of
GREB1 has been linked to tamoxifen resistance in breast cancer
due to loss of sensitivity to endocrine agents in general, underlining its
important role in endocrine resistance [32–33]. Although endocrine
therapy has overall limited efficacy in ovarian cancer patients, more
research is needed to assess whether GREB1 is associated with
antiestrogen sensitivity in this cancer. In view of this previous data,
our results are in accordance with these findings reaffirming the
understanding that GREB1 is highly expressed in high PARP/
platinum-sensitive patient group that has been associated with a
positive outcome befitting with the BRCAness profile [10]. Our data
show for the first time that GREB1 could have prognostic value in
ovarian cancer and warrants further investigation, especially associ-
ated with response to hormone-based therapy.
ROR2 belongs to the ROR receptor family (ROR1 and ROR2)
from the non-canonical Wnt pathway [17]. ROR1 and ROR2 form
heterodimers in response to Wnt5a, which leads to RhoA/Rac1
activation and increases migration and invasion properties of cancer
cells [34]. Recent studies have demonstrated that upregulation of
ROR2 and its ligand Wnt5a in EOC regulates EMT and correlates
with worse prognosis [35]. ROR1 and ROR2 regulate migration and
invasion of ovarian cancer cells and more importantly, their
expression was increased in platinum resistant A2780 ovarian cancer
cell line compared to parental cells ([18]). TCGA data analysis of over
500 ovarian tumor samples identified high expression of Wnt5a and
Wnt5a protein was found prevalent in ascites samples of ovarian
cancer patients [36]. In our study, ROR2 gene expression was
significantly upregulated in low PARP/platinum-resistant vs. high
PARP/platinum-sensitive patient samples. We also found higher
protein levels of ROR2, ROR1 and Wnt5a ligand in lysates of
platinum-resistant tumors (Figure 3, a-b), confirming our gene
expression analysis. Interestingly, higher expression levels of NF-κB
and pSTAT3 (Y705) proteins were also noted in platinum-resistant
tumor lysate with high ROR1 and ROR2 levels, indicating that
STAT3 could be downstream mediator of ROR signaling in ovarian
cancer. These results showing Wnt5a-ROR2 and STAT3/NF-kB
signaling pathway in clinical ovarian tumor samples are novel
findings. A direct link between ROR1 and STAT3 expression has
been demonstrated previously in leukemia, showing that STAT3
promoter harbors two ROR1 binding sites [37]. Moreover, previous
studies have shown that Wnt5a is involved in cancer multidrug
resistance (MDR)[36]. High Wnt5a expression levels in ovarian
cancer cell lines correlated with lower chemosensitivity to paclitaxel,
oxaliplatin, 5-fluorouracil, epirubicin and etoposide ([38,39].
Furthermore, upregulation of Wnt5a and ROR2 was detected in
colon cancer cells resistant to butyrate, a histone deacetylase inhibitor
(HDACi)[40], along with activation of AKT/PKB (protein kinase B)
signaling pathway. Wnt5a orchestrates multiple signaling networks
involved in chronic inflammation and carcinogenesis, and crosstalk
with STAT3 and NF-κB pathways have been previously documented
[41]. Thus, upregulation of Wnt5a, ROR1 and ROR2 signaling
pathways could be common mechanisms in ovarian cancer
chemoresistance and could serve as putative biomarkers. ROR1
targeted therapies have shown promising results in preclinical and
clinical models, with anti-ROR1 monoclonal antibody cirmtuzumab
being efficient not only in leukemia, but also in ovarian cancer [42],
indicative of high therapeutic potential for targeting these receptors.
Our mRNA expression data from patient samples were validated
using a cisplatin resistant cell line model A2780cis and we found that
upregulation of ROR2 at the mRNA and protein levels is associated
with cisplatin resistance. Moreover, GREB1 mRNA level was
downregulated in A2780cis compared to A2780 parental cells.
Furthermore, we observed higher expression levels for Wnt5a,
STAT3 and NF-kB proteins in chemoresistant A2780cis cells
compared to parental cells, in support of our results from patient
samples (Figure 3).
In conclusion, we found the expression of ROR2 and GREB1 to
be associated with treatment response in HGSC. The association
between Wnt5a/ROR2 expression and development of platinum
resistance reported herein suggests that the Wnt5a/ROR2 pathway is
potentially actionable for possible modulation of chemoresistance.
Because silencing ROR1 and ROR2 restores the chemosensitivity of
carboplatin-resistant ovarian cancer cells [18], a combination of ROR
antagonists and chemotherapeutic agents may offer a promising
treatment option. Also, our findings regarding GREB1 expression in
highPARP/platinum-sensitive patients should reinforce the interest in
this gene for future investigations.
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